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P R E P A G E 
(i) 
The idea of chemical contraception based on 
interference with the estrogen/progesterone balance 
critical for ovulation, was conceived by Pincus who 
introduced the contraceptive 'Pill' in 1956. Since 
then a number of hormonal preparations based on a com-
bined or sequential regimen of estrogen and progesterone 
have been introduced. With the extensive use of these 
hormonal preparations, their side effects are gradually 
getting known and it has been realized that these hor-
monal products will not be acceptable in the long run. 
The most serious and hazarduous side effect is the 
hormonal imbalance accompanied by a number of neurologi-
cal and endocrinological disorders, mainly associated 
with the estrogenic component of the pill. 
The idea of post-coital contraception as an 
alternative to the pill has probably much to commend, 
provided suitable post-coital contraceptive agents are 
discovered Ttfhieh while being as efficaceous as the 
present day hormonal contraceptives, are devoid of any 
short term or long term collateral effects. 
(ii) 
'Atypical' estrogens, which can interfere with 
the post-ovulatory events in the reproductive cycle, but 
have decreased estrogenic character, hold promise as post-
coital contraceptives. The first chapter of the present 
thesis is devoted to a review of triaryl-ethylenes, 
-ethanes 'atypical' estrogens as possible post-coital 
contraceptives. 
In a continued quest to develop suitable post-
coital contraceptive agent from among 'atypical' estrogens, 
a number of compounds incorporating triaryl-ethylene/-
ethane structural unit were tested in this Institute for 
their antifertility activity. Quite a few promising 
compounds have emerged from these studies. Among these 
centchroman, 3,4-trans-2,2-dimethyl-5-phenyl-4-[p-(P-
pyrrolidinoethoxy)]phenyl-7-methoxychroman has shown 
promise and is currently undergoing phase Il/lII clinical 
trial. 
Molecular basis of the action of centchroman in 
particular, and triaryl-ethylenes/-ethanes in general is 
largely unknown. However, there is sufficient evidence 
to suggest that the 'atypical' estrogenic character 
of these molecules mediated through their interaction 
with the estrogen receptor is responsible for their post-
(iii) 
coital contraceptive activity. The present study was 
undertaken to determine the structural specificity of 
centchroman in terms of the contribution of its 'sub-
structures' for its receptor binding relative to that of 
estradiol-17p and diphenyl- and triaryl-ethylenes and to 
establish a correlation between receptor interaction and 
biological activity of centchroman. Optical resolution 
of centchroman was undertaken in order to establish 
whether the biological activity would be associated with 
only one of the isomers. The syntheses of various 
centchroman analogs and isomers and its resolution into 
d and 1 isomers and their receptor interaction and biolo-
gical activity are described in second chapter of this 
thesis. 
A relatively recent development in the field of 
antifertility is the introduction of prostaglandins as 
possible luteolytic agents which can thus be used as 
abortifacients/antiimplantation agents. It has been 
observed that at the time of parturition, there is a 
tremendous increase in the levels of prostaglandins Ep 
and P2a i n ^ e amniotic fluid which cause frequent and 
strong contraction of the uterus, and thus help in the 
onset of labor. Based on this understanding it has been 
(iv) 
surmised that elevation of the endogenous prostaglandin 
levels by the administration of suitable prostaglandin 
metabolic inhibitors could be successfully used for 
fertility control -without posing the risk of hormone 
imbalance. Lerner erfc al have recently shown that certain 
triazolo[5,l*-a]isoindoles and isoquinolines block the 
prostaglandin metabolism and thus inhibit pregnancy. 
Based on this lead some N-(substituted benzylidine)amino-
dihydroisoindol-l,3-diones, -dihydroisoindoles and 1,2,3*4-
tetrahydroisoquinolines were considered of interest. The 
third chapter of this thesis deals with the synthesis and 
antifertility activity of these oompounds. 
CHAPTER 1 
TRIARYL-ETHYLENES AND -ETHANES 
AS ANTIFERTIHTY AGENTS: A REVIEW 
Introduction 
The lack of molecular specificity in the series 
of natural estrogens e.g. estrone (1), estradiol (2), 
estriol (2), equilenin (4), equilin (£) and in some 
degradation products derived from thosejjgossessing high 
estrogenic activity such as doisynolic acid (6) and 
allenoic acid (7) led Dodds and coworkers to examine 
how molecular modification of natural estrogen could be 
carried out without diminishing estrogenic activity. 
These studies culminated in 1958 in the discovery of 
estrogenically potent synthetic compounds viz. diethyl-
stilbesterol-^ (DES, 8), hexesterol'* (£) and dienesterol^ 
(10). These synthetic compounds were found to possess 
all the qualitative estrogenic properties of the natural 
estrogens, were cheap to produce and were orally active. 
They have been widely used in clinical practice . 
In studies of structure function relationship of 
these compounds, efforts have been made to correlate the 
estrogenic activity with their physical characteristics. 















crystallography'' , it was shown that in diethylstilbes-
terol alkyl groups sterically hinder the two "benzene rings 
to achieve coplanarity, thus causing the aromatic rings to 
rotate and acquire a staggered configuration giving thick-
9 
ness to the molecule, G-iacomello and Bianchi found by 
X-ray crystallography that the molecule of diethylstil-
besterol (in the active trans form) and of estrone were 
o o 
8.55 A long and 3.88 A wide (Pig. 1). 
These studies led to further structural changes 
being carried out in stilbene structure and it was found 
that an additional aryl group on the ethylene chain 
introduced some interesting biological features in these 
molecules, and triaryl-ethylenes (TAEs) emerged as an 
interesting class of compounds in this field. 
1. Triaryl-ethylenes and -ethanes 
Dodds et al10 and Robson et al11'12 found that the 
introduction of a phenyl ring at one of the carbon centres 
in diethylstilbesterol molecule gave a series of new 
potent estrogenic compounds with prolonged duration of 
action. As can be visualized from the structure (11), 
the tri aryl ethylenes have both pis,- and trans-stilbene 
units. Steric interaction between the cis phenyl groups 
would result in the rotation of the aromatic rings giving 
thickness to the molecule which appears to be an essential 
5 
feature for activity of stilbene type of molecules. The 
removal, of any of the three phenyl groups results into 
lowering or loss of activity ' . 
Triphenylethylenes are more active than trans-
stilbenes and have the same order of activity as a-methyl-
a'-propyl-stilbenes. Triphenylethylenes have a more 
prolonged action than stilbesterols. This is presumably 
due to their storage in the body fat and slow hydroxy-
lation of the aromatic rings in vivo. Thus the introduct-
ion of hydroxy groups resulted in the rise in estrogenic 
activity with conoommitant drop in the duration of action , 
whereas the presence of a group that would block hydroxy-
lation led to inactive compounds ' . 
In SAR studies a number of structural changes have 
been carried out in the triphenylethylene system to study 
the effect of change of substituents in the .three phenyl 
rings and elsewhere in the molecule. 
Replacement of the phenyl group by a 2-pyridyl or 
17 4-pyridyl group gave inactive compounds . Linking of the 
two phenyl groups at C-, as in 9-benzylidinofluorene result-
ed in compounds with weak estrogenic activity , possibly 
owing to the inability of the molecule to adopt the appro-
priate conformation which is critical for activity. 
Alkylation in the p_ position of 1-phenyl ring 
diminished estrogenic activity. Thus l-(p_-ethyl) phenyl-
6 
1,2-diphenylethylene has low activity , whereas 1,1-bis-
20 (p_-biphenyl)~2-phenylethylene is inactive . 
Shortly after the discovery of the estrogenic 
21 
activity of triphenylethylenes, Robson et al showed that 
2-chloro-l,l,2-triphenylethylene was more potent than the 
22 parent triphenylethylene. Barbier et al found that in 
2-halo compounds the order of effectiveness for estrogenic 
23 potency was chloride> bromide> iodide. Schueler 
suggested that the inductive effect of the halogen atom 
results in p_-hydrogen atom of 1-phenyl group, acquiring a 
fractional positive charge and hence some hydrogen bonding 
capacity. Clark , however, suggested that halogen atom 
helped in the in vivo hydroxylation at the p_ position. 
2-Ethyl-l,l,2-triphenylethylene is more active as 
25 
compared to the corresponding triphenylethylene , suggest-
ing that the steric effect of the ethyl group may bring 
about a closer resemblance to diethylstilbesterol and thus 
this increased activity. A similar steric effect is 
possible with the 2-halogen atom. 
Introduction of halogen groups into triphenyl-halo-
ethylene enhances the estrogenic potency; l,l,2-tris-(p_-
2fi bromo) phenyl-2-chloroethylene has high activity . It 
seems possible that the halogen radical in such compounds 
is replaced in vivo by hydroxy groups. 
7 
The importance of halogen atom at C2 becomes more 
apparent from the fact that whereas l,l-bis-(3--fluoro-4-
methoxy) phenyl-2-phenylethylene was inactive, 1,1-bis-
(3~fluoro-4-niethoxy) phenyl-2-chloro-2-phenylethylen,e was 
active at 10 ^g and had a prolonged action . G-rundy 
has extensively reviewed various substituted triphenyl-
ethylenes and their :. estrogenic activity. 
Introduction of OF- group at G2 in triphenyl-
29 
ethylenes gave active compounds. Middleton e_t al have 
synthesised a number of '2-(trifluoromethyl)-l,l,2-triphenyl-
ethylenes by the reaction of fluoroolefins or arylfluoro-
olefins with arylorgano-metallic reagents and studied their 
post-coital antifertility and uterotrophic potencies. The 
most potent compound of this series is trans-l-(p-methoxy) 
phenyl-2-trifluoromethyl-l,2-diphenylethylene (12_) which 
showed an ED™ of 0.013 mg/kg/day for both antifertility 
and the uterotrophic responses in female rats. 
12 
8 
Introduction of a nitrile group at Cp i n triphenyl-
30 
ethylene gave active compounds . Thus 2-cyano-l,l,2-
triphenylethylene (13_) was active at 0.1 mg/kg. Substi-
tution of methoxy groups in the p_ position of 0-,-phenyl 
rings enhanced the activity by 10 fold. l,l-Di-(p_-methoxy) 
phenyl-2-cyano-2-phenylethylene (14) was thus found to be 
active at 0.01 mg/kg. However, presence of a polar group 
at C2 does not always result in enhanced activity. 
Replacement of cyano group by a carboxy function at C2 in 
13_ resulted in decrease in activity, 2-carboxy-l,l,2-
triphenylethylene (]J5) was found to be active at 5.0 mg/kg. 
Introduction of methoxy group in the p_ position of 0-,-
phenyl rings as in IL6 again gave enhanced activity. 
R" 
R.-V/-^ R 
R R1 R'» A c t i v i t y i n 
mg/kg 
13. CN H H 0 . 1 
14. ON OMe OMe 0.01 
15. C02H H H 5.0 
16 C0~H OMe OMe 1 .0 
9 
Replacement of 1-phenyl by a thienyl residue yielded 
active compounds^ . l-3romo-l-aryl-2-(p_-methoxy) phenyl-2-





17 R = H 
18 R = 01 
Substitution of the ethylene moiety by a cyclopropyl 
ring or replacement of one carbon atom by a nitrogen atom 
32 
abolished the estrogenic activity . 
2, Triaryl-ethylenes. -ethanols and -ethanes 
carrying one or more basic centres 
Triaryl-ethylenes, -ethanols and -ethanes carrying 
a basic side chain have low order of estrogenic and anti-
gonadotrophic activities. These compounds instead possess 
strong antiestrogenic properties. Maximum antiestrogenic 
activity was observed when one of the three phenyl groups 
was substituted with methyl, methoxy or halogen, preferably 
33 34 
a chloro radical or when halogen was introducted at G7 yt , 
10 
Such antiestrogens may compete with endogenous 
estrogens for specific estrogen receptor sites and thus 
prevent them from expressing their full effect on primary-
estrogen sites. Some of these compounds may inhibit the 
expression of the estrogenic activity at one site hut not 
at the other. Such compounds may be termed 'atypical' 
estrogens. 
35 Palopoli e_t air-' synthesised and screened a series 
of aminoalkoxy-triphenyl-haloethylenes. Out of these 
compounds, l~[p_-(f3-diethylaminoethoxy) Jphenyl-2-chloro-l,2-
diphenylethylene dihydrogen citrate (1£, Clomiphene, MRL-41) 
was found to possess antigonadotrophic, estrogenic and anti-
estrogenic properties in rats . In immature rats, it also 
showed gonadotrophin stimulation effect in low doses, 
whereas it induced ovulatory type menses in anovulatory 
and amenorrheic women ' * . MRL-41 blocked the action 
of endogenous and exogenous steroidal or non-steroidal 
estrogens with.remarkable effectiveness in rats, mice, 
39 
rabbits and monkeys^ . In addition, in rats and rabbits 
it caused degeneration of the fertilized egg in the oviduct 
and thus prevented pregnancy. Whether this property of 
MRL-41 is a consequence of its antiestrogenic action or a 
separate effect is not clear. 










ethylene (20,, CN-55,945-27) to "be an t i zygo t i c . I t provided 
100 per cent p ro tec t ion against pregnancy in r a t s a t 25 \ig/ 
kg^" . This i s a t t r i b u t e d to i t s an t i e s t rogen ic p roper ty . 
The corresponding l-(p_~hydroxy) phenyl compound (21) i s 
equally act ive in r a t s and has been shown to exert i t s a n t i -
implantat ion effect through i t s an t i e s t rogen ic and/or l u t e o -
l y t i c act ion v ia LH-secretion. 
Harper and Walpole ~" ^ inves t iga ted the a n t i -
f e r t i l i t y a c t i v i t y of l~[p_-(p-dimethylaminoethoxy) jphenyl-
2~ethyl~l,2~diphenylethylene. Whereas the c is- isomer (22, 
IC,I 41699) was a potent estrogen in ra t and mouse t e s t s , 
and had no an t i e s t rogen ic a c t i v i t y , the t rans- isomer (2£, 
ICI 46474) was an a typ ica l estrogen and had weak es t rogenic 
a c t i v i t y but potent an t i e s t rogen ic and antigonadotrophic 
a c t i v i t i e s . 
The estrogen antagonis ts which include MER-25 
(24) , MRI-41 5 6 , 4 9"" 5 1 (1<2), CN-55,945-2741 (20) and ICI 
46474 (2J5) have been reported to exert a n t i f e r t i l i t y . 
a c t i v i t y in rodents and r a b b i t s . Several of these a n t i -
es t rogenic compounds were found to i n h i b i t ovum implanta t -
51 ion i n the monkey . These compounds could i n h i b i t 
f e r t i l i t y through t h e i r an t i e s t rogen ic a c t i v i t y exerted 
a t the l eve l of hypothalamus, p i t u i t a r y and ovary. Other 
poss ib le mode of ac t ions of these ant ies t rogens for t h e i r 
a n t i f e r t i l i t y ac t ion are t h e i r effect on ova t r a n s p o r t , 
13 
toxic action on blastocyst, interference with nidation or 
aborting the developing foetus. 
3» Gyclized triaryl-ethylenes and -ethanes 
(a) Benzylidine derivatives; It has been observed 
that bridging of the two aryl residues on the same carbon 
atom of the triarylethylene system lead to inactive 
compounds. However, Allen and coworkers ' have reported 
compounds of the type 25-28, where R is.an aryl group 




(b) 2,5-Diaryl-indenesi A series of compounds 
possessing antifertility activity have resulted by 
incorporating the triarylethylene system into a rigid 
framework. The observation that certain 2~phenyl~3-alkyl-
indenes (2£) are potent estrogens '^, led Lednicer 
56 57 
et al iJ to synthesise a series of basic ethers of 2,3-
diarylindenes (^ O) as the first group of cyclized triaryl-
ethylenes. Out of these compounds, 2-phenyl-3-[p.~(p-
pyrrolidinoethoxy)]phenyl-6-methoxyindene (^ 1, U-11555A) 
was found to be most active as an antiimplantation agent. 
Prom SAR studies of these compounds, it appears that the 
presence of a methoxy group at an appropriate position has 
a profound effect on the antifertility activity of the 
molecule. The position and the type of basic side chair-
also appears crucial, the basic ether side chain increases 
the receptor binding affinity of the ligand thus indicat-
ing the presence of a specific counter-ionic binding sub-
site in this region of the receptor. The order of 
preference of a basic chain is generally -OCHpCHpN J J> 
-OCH2CH2N(Et)2 >-0CH2CH2N(Me)2. The effect of the alkyl 
groups in the tertiary amino residue must be to impart the 
critical hydrophobicity to the molecule. 
15 
R O ^ ^ " 
20 R = R± = H 
21 R = Me, Hj = CH2CH2N 
(c) 2,5-Diaryl-benzofuranst The oxygen hetero-
cycle 2,3-diarylbenzofurans which are closely related to 
indenes were studied by G-rover et al . 2-Phenyl-3-[p_-(|3-
pyrrolidinoethoxy)]phenyl-6-methoxybenzofuran (^2_) showed 
antiimplantation activity in rats at 8 mg/kg. The corres-
ponding naphthofurans (22.) with a large planar area were 
found to be four times more active as antiimplantation 
agents. The tetramethylene compound (24.) also showed 
significant antifertility activity. Further ring enlarge-
ment of planar area of the molecule as in phenanthrofurans 




R = CH2GH2N 
(d) 2 , 3 - D i a r y l ~ i n d o l e s ; A s e r i e s of 2 , 3 - d i a r y l -
59 i n d o l e s was p repared by G-opalchari and I y e r and Ladquis t 
fin 
and Marsden . Out of t h e s e n i t r o g e n h e t e r o c y c i e s , 
2 -pheny l -3 - [p_ - (p -py r ro l id inoe thoxy) Jpheny l indo le (]56.) and 
t h e cor responding d ie thy laminoe thoxy d e r i v a t i v e (;T7) p r e -
ven ted i m p l a n t a t i o n i n r a t s a t 10 mg/kg. S u r p r i s i n g l y 
i n t r o d u c t i o n of a 6-methoxy group i n t h e s e compounds 
a b o l i s h e d t h e a c t i v i t y . 
16 R = CSH20H^ "N 
I I R = GH2GH2N('Bt)2 
17 
(e) 1,2-D_iaryl-3> 4~dihydronaphthalenes i The fact 
that appropriately substituted 2~phenyl-3,4-dihydro~ 
naphthalenes as well as l,2-diphenyl-3,4-dihydronaphtha-
lenes possess uterotrophic activity led Lednicer ejb al 
to study a series of basic ether derivatives of 1,2-diaryl-
3,4-dihydronaphthalene (3_8). In this series, l-[p_-(p-
pyrrolidinoethoxy)]phenyl-2-phenyl~6-methoxy-3,4~dihydro-
naphthalene (22., U-11,100) was found to possess anti-
fertility activity at 25 |ig/kg/day dose level. The same 
dose, however, doubled the uterine weight when given for 
10 days orally. 
It has been observed that both the parent prototype 
models (4Q. and 4.1) are active (MBD100 0.005 and 0.01 mg/kg/ 
day respectively) but are highly estrogenic in the uterine 
63 
weight assay . Replacement of 1-phenyl by 2- or 4-
pyridyl moiety did not affect the activity significantly. 
Further the observation that aniline derivative (^2_) 
induced a classical estrogen response, supported the earlier 
findings that simple incorporation of a basic group into an 
estrogen did not suffice for the design of an estrogen 
antagonist. Instead, for antagonistic activity, a t-amino-
alkoxy chain at p_ position of 1-phenyl residue appears 
important. The basic side chain at this position with 
appropriate length and size associates with the receptor 
in a specific manner leading to modulation of the activity. 
The importance of 6-methoxy group noted in the 







R = R± = H 
R = OMe, R 1 = 0CH2CH2N 
R = OMe, R 1 = H 
R = OMe, Rx = N ( 0 H 5 ) 2 
4i 
(f) 1 ,2-Diaryl - l ,2 ,3* 4- tetrahydronaphthalenes: 
Benoze et a l ' prepared a s e r i e s of c i s - 1 , 2 - d i a r y l -
1,2 ,3 ,4- te t rahydronaphthalenes and t h e i r bas ic e thers 
through c a t a l y t i c reduction of su i t ab l e 3 i4~dihydro- l ,2-
di'pkenylnaphthalenes. The corresponding t rans- isomers 
were obtained by Fr iedel Graft reac t ion between phenol 
and l-hydroxy-2-aryl-3*4-dihydronaphthalenes. The t r a n s -
isomers, in genera l , were found to be more potent u t e r o -
6 A t roph ies than the corresponding cis-isomers . The bas ic 
e thers especia l ly 4JL» 4.4. and 4JL also showed more marked 
u te ro t roph ic a c t i v i t y , though t h e i r dose-response curves 
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were r a t h e r f l a t as compared t o t h e cor responding p h e n o l s , 
which d i s t i n g u i s h e d them from n a t u r a l e s t r o g e n s . 
S u r p r i s i n g l y o i s - 1 , 2 - d i p h e n y l - l , 2 , 5 , 4 - t e t r a h y d r o -
naph tha l ene (4.6) was found to be more p o t e n t u t e r o t r o p h i c 
subs t ance (8 (ig/kg) than t h e cor responding t r a n s - i s o m e r 
(47 , 100 | i g /kg ) . F u r t h e r , i t i s i n t r i g u i n g t h a t 4.6 was 
found to be more p o t e n t than t h e hydroxy la t ed d e r i v a t i v e s 
48 and 4J2» which c o n t r a d i c t t h e s u g g e s t i o n made by 
Emmens t h a t t h e a romat ic compounds have t o be hydroxy-
l a t e d by h e p a t i c enzymes before they can e l i c i t e s t r o g e n i c 
a c t i v i t y . This apparen t anamoly may be due t o i n f a v o u r a b l e 
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The most active antiimplantation agent in this 
series was the basic phenolic ether, l-[£-(p~diethylamino-
ethoxy) ]phenyl-2-(p_-chloro) phenyl-1,2-trans-l,2.5,4-
tetrahydronaphthalene (<£>) which had BD,Q0 of 20 ^g/kg/day 
in rats. Similar to the dihydronaphthalene series, 
introduction of a 6-methoxy group had a potentiating effect 
on antifertility activity. Thus trans-l-fp-(g-diethylamino-
ethoxy)Jphenyl-2-phenyl-6~inethQxy~l, 2,3,4-tetrahydronaphtha-
lene (4^ ,) was five times more active as antifertility agent 
(ED 1 0Q, 0.1 mg/kg) than the corresponding 6-des methoxy 
compound. 
(g) g,4-Diary!- coumarins; Syntheses and biologi-
cal activity of 3>4~diarylQ0umarins has been investigated 
by various groups . Interestingly, it has been 
observed that some of th.3 neural coutth.::i.^.' such au 
5,0, and $1 and some of their basic ethers showed anti-
fertility activity, presumably due to their estrogenic 
activity. However, the activity was on the whole rather, 
low. R, 
'Or^ 
5 0 ^ = OAc, Ra c H, R^ a OMe 
Q \ - OAc, R2 = R, « H 
21 
(h) 3.4-Diaryl-chromenes and -chromans; The study 
of the 3>4-diaryl-chromenes and -chromans which are s t r u c t -
u r a l l y re la ted to l ,2 -d ia ry l -3»4-d ihydro- and 1 ,2 ,3 ,4 -
tetrahydronaphthalenes proved qui te i n t e r e s t i n g . The most 
ac t ive compound of the 3,4-diarylchromene s e r i e s was 3 -
phenyl-4-[p_-((3-pyrrolidinoethoxy) ]phenyl-7-methoxyehromene 
70 (52) which showed a n t i f e r t i l i t y a c t i v i t y a t 1#5 mg/kg 
s ing l e dose in r a t s . A considerable drop in a c t i v i t y was 
71 observed by Ray ejfc a l on the in t roduct ion of a lky l 
r a d i c a l s at Gp which was even more pronounced with bulkier 
s u b s t i t u e n t s . The unsubst i tu ted 3»4~diphenylchromene was 
a l so found to be a potent u t e ro t roph ic agent and showed 
s i g n i f i c a n t a c t i v i t y a t a dose of 80 p.g/kg. In t roduc t ion 
of a chloro group in the 3-phenyl, or a methoxy group in 
the 4-phenyl r ing reduced e s t r o g e n i c i t y . 
In the 3,4-diarylchromans, the trans-chromans were, 
i n general , found to be more ac t ive than the corresponding 
cis-chromans as a n t i f e r t i l i t y and es t rogenic agen t s . 
Whereas t rans-3-phenyl-4-[p-(p-pyrrol id inoethoxy)Jphenyl-
7-methoxychroman (£3_, ED1Q0, 0.25 mg/kg, r a t s ) was found 
to be four times as ac t ive as the cis, compound as a n t i -
f e r t i l i t y agent, in the 2 ,2-d ia lkyl s e r i e s , the c i s 
compounds were t o t a l l y i n a c t i v e . In the 2 ,2 -d i a lky l s e r i e s 
the most ac t ive compound was 3 j4 - t r ans -2 ,2 -d ime thy l -3 -
phenyl-4-[p_-(P*-pyrrolidinoethoxy) jphenyl-7-methoxy chroman 
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(5.i> Gentchroman), which showed antifertility activity at 
71 0.25 mg/kg . This compound is a weak estrogen, a potent 
antiestrogen and is currently undergoing clinical trials 
as a post-coital antifertility agent. 
52 52 R = R« = H 
54 R = R» = Me 
4. Miscellaneous compounds containing triaryl system 
72 
( i ) , 2,3•4-Triarylfurans: Dikshit et a l studied 
the a n t i f e r t i l i t y act ivi ty of 2 ,3 ,4- t r iarylfurans . While 
the triphenyl-dihydro and tetrahydro-furans were inact ive, 
the furans showed 'significant ac t iv i ty . They also 
exhibited estrogenic act iv i ty and the i r a n t i f e r t i l i t y 
ac t iv i ty appears to "be related to t he i r estrogenicity. 
Surprisingly, unlike other groups of non-steroidal a n t i -
f e r t i l i t y agents, 2,3-diphenyl-4-p_-hydroxyphenyl-furan was 
found to be more active than the corresponding (3-t-amino-
ethyl ether derivative. 
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( i i ) l-Phenyl-2~(6»phenethyl.) -1,2,3* 4-tetrahydro-
isoguinolines; Ant i fe r t i l i ty ac t iv i ty of 1 ,2 ,3 ,4- te t ra-
hydroisoquinolines has been investigated by Rolf Paul 
73 et a l . (+) l-Phenyl-2-(p-phenethyl)-1,2,3,4-tetrahydro-
isoquinoline hydrochloride (££.) was found to be active in 
female r a t s . On resolving th is compound, the a n t i f e r t i l i t y 
ac t iv i ty and estrogenicity were found to reside in the (-) 
form alone. SAB. studies with th i s compound showed that 
the presence of a hydroxy group in the aromatic portion-
of the isoquinoline nucleus reduced the a n t i f e r t i l i t y 
ac t iv i ty but without al ter ing the estrogenicity. The 
presence of a 6-methoxy group (J2J5) increased the a n t i -
f e r t i l i t y ac t iv i ty . 
The introduction of a pyrrolidinoethoxy chain at 
the p_ position of 1-phenyl ring enhanced the antif e r t i l i t y 
ac t iv i ty considerably and the compound (£2) exhibited an 
impeded estrogenic behaviour. 
A methyl or ethyl substituent at the p-position 
of the p-phenethyl chain enhanced the a n t i f e r t i l i t y 
ac t iv i ty with a simultaneous increase in estrogenicity. 
An introduction of a phenyl or pyrrolidinoethoxy group on 
the aromatic part of the isoquinoline ring as in £8 and £2. 
reduced the ac t iv i ty . 
l~[p.-(p-Pyrrolidinoethoxy) ]phenyl-2-((3-methyl) 
phenethyl-l,2,3,4-tetrahydroisoquinoline (60_) was found to 
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be t h e most a c t i v e compound i n t h i s s e r i e s . I t showed 
c h a r a c t e r i s t i c f e a t u r e s of an impeded e s t r o g e n , and i t 
a l s o i n h i b i t e d t h e express ion of s imu l t aneous ly a d m i n i s t e r e d 
f r ank e s t r o g e n s . I t s SD-,00 i s 50 [ ig/kg/day. N e v e r t h e l e s s , 
t h e compound's apparen t a n t i e s t r o g e n i c i t y was no t t h e b a s i s 
f o r i t s a n t i f e r t i l i t y a c t i v i t y , s i n c e c o n t r a c e p t i v e doses 
of t h i s compound were a s s o c i a t e d w i t h i n t r i n s i c u t e r o t r o p h i c 
a c t i v i t y . And, t h e r e f o r e , even w i th t h i s compound a n t i -
f e r t i l i t y and e s t r o g e n i c i t y were a p p a r e n t l y i n s e p a r a b l e * 
0CH2CH2N 
58 R = Ph, R± = CH2CH2Ph, R2 = H 
52 R = 0CH2CH2N J t &i - CH2CH2Ph, R2 = H 
60 R = H, Rx = CH2CH(CH3)Ph 
R2 = p_-(0CH2CH2N j )06H4 
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CHAPTER 2 
3,4-DIARYL-CHROMENES AND -CHROMANS 
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2.1 INTRODUCTION AND BASIS OF WORK 
Triarylethylenes (TAEs) constitute an important 
class of non-steroidal estrogens. The hormonal activity 
of these compounds differ markedly from that of the 
'typical' or frank estrogens such as estradiol-17P (Ep) 
and diethylstilbesterol (DJUS) . For example, some of 
these compounds increase uterine weight without causing 
vaginal cornification and exhibit both an estrogenic and 
antiestrogenic activity. On account of this mixed profile 
of action on estrogen target organs, these compounds could 
be termed as 'atypical' estrogens. TAEs thus offer the 
possibility of interfering with normal hormonal balance 
wherever estrogens are involved and may thus possibly find 
use in clinical situations where estrogens are the causative 
factor. 
It is well recognized that the events from the time 
of ovulation to implantation of the blastocyst are engineer-
ed by a critical interplay of estrogen and progesterone on 
the genital tract. The mutually synergistic and anta-
gonistic actions of these hormones are responsible for 
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normal passage of ovum through the fallopian tubes, its 
fertilization and eventual implantation in the uterus'". 
Administration of TAEs during the preimplantation phase of 
pregnancy could interfere with these physiological manifes-
tations by sex hormones and prevent implantation. TAEs, 
thus, offer the possibility of being used as post-coital 
contraceptive agents . 
The development of post-coital contraceptive 
agents from among TAEs has been a subject of considerable 
interest. The main objective in these studies has been 
to discover compounds which can prevent implantation 
without causing adverse reactions commonly associated with 
the inherent estrogenic character of an 'atypical' estrogen. 
The main endeavour has, therefore, been the dissociation of 
post-coital contraceptive activity from 'frank' estrogenic 
activity. 
Based on this rationale, in earlier work done in 
3 4 
this laboratory and elsewhere ' , carbocyclic and hetero-
cyclic compounds incorporating a triarylethylene structural 
unit were designed and some of them were found to exhibit 
marked antiimplantation activity. This continued quest 
has led to the discovery of a number of promising post-
coital contraceptive agents. Among these, 'centchroman', 
314-trans-2,2-dimethyl-3-phenyl-4-[p_-(p-pyrrolidinoethoxy) j 
phenyl-7-methoxychroman (1) has shown a good therapeutic 
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acceptor sites. According to the current consensus, the 
cellular response to estrogens results from regulation of 
7 
gene transcription "by estrogen-receptor complexes » 
With the recognition that estrogen receptor has 
an obligatory involvement in estrogen action, attention 
has been focussed on receptor interaction of non-steroidal 
estrogens in the efforts to understand the possible 
Q 
reasons for their atypical estrogenic activity . It 
appears reasonable to presume that centchroman exercises 
its post-coital contraceptive effect by its interaction 
with the estrogen receptor, Centchroman has weak receptor 
affinity in vitro but causes nuclear translocation of the 
cytosol receptors and their prolonged retention at the 
nuclear sites, which is presumably responsible for its 
g 
uterotrophic and antiestrogenic activities , 
Receptor binding of structurally multifunctional 
ligands such as centchroman may be visualized on the basis 
of interaction of various discrete substructures in this 
molecule with the complementary subsites on the receptor. 
Modification of one substructure at a time in centchroman 
and the effect of such a modification on its receptor 
affinity and biological activity can be a fruitful method 
for analysis of topography of binding site and SAR at 
molecular level. The OMe and t-aminoalkoxy side chain are 
apparently critical for the biological activity of TAEs.. 
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In order to study the role of these substituents in the 
receptor binding and biological activity, centchroman 
analogs in which these residues are modified or transposed 
to other positions in the molecule were synthesised and 
their receptor interaction and biological activities were 
studied. The results of this study form the subject matter 




2.2 STRUCTURAL CORRELATES OF 
THE BIOLOGICAL ACTIVITY 
OF CENTCHROMM 
Centohroman (1) has two asymmetric centres; while 
having 5»4-trans geometry it exhibits antiimplantation 
activity at 250 \xg/kg in rats when administered from day 
1-5 of pregnancy, the corresponding 5»4-cis diastereomer 
did not show antiimplantation activity upto 50 mg/kg in 
this test. 
Centohroman is a racemic mixture. In accordance 
with the well known stereospecificity of estrogen receptor , 
it is possible that one of the centohroman isomers would 
be biologically active and would have high receptor affinity. 
In order to establish the validity of this presumption, 
resolution of centohroman was undertaken and absolute confi-
guration of the optical antipodes was determined with the 
help of CD spectroscopy, and their receptor affinities and 
biological activity studied. 
From SAR studies, it has been shown that presence 
of a free phenolic group corresponding to C,-0H of E~ is 
essential for high receptor affinity and biological activity 
o in 
of estrogens ' . The relatively poor receptor affinity of 
centohroman may, therefore, be due to the presence of OMe 
group in this molecule. It, therefore, appeared of interest 
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to synthesise 7-hydroxy analog of centchroman, a possible 
metabolite responsible for biological activity, and deter-
mine its receptor binding affinity and biological activity. 
Presence of a t-aminoalkoxy side chain at a 
suitable position in the TAEs is apparently important for 
their characteristic suboptimal estrogenic activity and 
11 
antiestrogenic activity . In order to ascertain the role 
of this side chain in centchroman for its receptor inter-
action and biological activity certain homologs of the t_-
aminoalkoxy side chain residue and with the chain at 
different positions in the molecule have been synthesised 
and evaluated for their receptor binding affinity and 
biological activity. 
Metabolism can play an important role in modulat-
ing the hormonal activity of triarylethylenes. Metabolic 
hydroxylation of aromatic ring at C~ in centchroman could 
in particular have profound influence on its biological 
activity. Since such a metabolite -would simulate the 
structure of meso-hexestrol rather closely, this might 
lead to potentiation of the estrogenic activity of 
centchroman. In order to test this possibility and 
analyse its influence on the biological activity of cent-
chroman, analogs carrying OH or an alkoxy residue at p_ 
position in the C^-phenyl residue have also been synthesised 
and their receptor affinity and biological activity studied. 
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The different aspects of the study enumerated 
above are discussed in deta i l in the following sub-
sections. 
2.2.1 stereochemistry and biological ac t iv i ty of 
centchroman: Resolution of dl-5»4-trans-2»2-
dirnethyl-3-phenyl-4-[E.-(p-pyrrolidinoethoxy) ] 
phenyl-7~methoxychroman (dl-Gentchroman) 
Studies of the biological ac t iv i t i e s of optical 
isomers have provided useful information about s tereo-
specific nature of drug action. The basis for stereo-
specif ici ty i s now recognised to reside in the ligand 
discriminant capacity of the receptor system. In fact 
one of the important cr i ter ion for the definition of a 
receptor system i s i t s ligand binding s tereospecif ici ty . 
With the avai labi l i ty of techniques to study receptor 
12 interact ion in vi tro , i t i s possible to determine stereo-
specif ici ty of the receptor-ligand in teract ion. These 
studies give useful information about the topography (or 
three dimensional structure) of the receptor binding s i t e . 
I t i s well known that more often only one of the 
optical isomer of a drug molecule or a hormone i s biologi-
cally act ive, and the other isomer may ei ther be inactive 
or weakly act ive. In some cases i f the less active isomer 
has high receptor aff ini ty i t may even act as an antagonist 
to the action of the more potent isomer. In some cases the 
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optical antipodes may even have different "biological 
13 
activities. In the case of tetramisole J for example, 
levamisole the (-) isomer, has anthelmintic and immuno-
stimulant activity while the corresponding (+) isomer has 
mainly antidepressant activity. It is, therefore, always 
of importance to study the biological activities of the 
optical antipodes of biologically active compounds possess-
ing molecular dissymmetry. 
Estrogen receptors are known to possess stereo-
specificity in ligand binding, d.- and 1-Isomers of 
estradiol have considerable difference in their receptor 
affinities as well as estrogenic potency; 1-estradiol, the 
inactive isomer, has nearly 20 fold lower receptor affinity 
than the d-isomer . It would, therefore, not be unexpect-
ed that centchroman would also display stereospecificity 
in receptor binding and biological activity. In order 
to assess the validity of this assumption optical resolu-
tion of centchroman was undertaken. 
The optical activity in centchroman arises from 
the presence of two asymmetric centres at C, and C. in 
the chroman moiety. Since the aryl substituents at these 
positions have a trans geometry, the CU and C . can have SS 
or RR absolute configuration. These isomers are mirror 
images and are thus antipodal forms of the racemic pair, 
dl-cent chroman. 
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Resolution of dl-cent chroman to d.-cent chroman 
was achieved by preparat ion of i t s d ias tereoisomeric s a l t 
with di~p_-toluoyl-d- tar tar ic aoid (Scheme 1 ) . After 
s e l ec t ive and repeated c r y s t a l l i z a t i o n s pure d-centchroman-
di-p,~toluoyl-d-t a r t r a t e (2.) was obtained. Aqueous a lka l ine 
hydrolysis yielded pure d-centchroman (2.) • 
Similarly 1-centchroman (£) was obtained using 
d i -p_ - to luoy l - l - t a r t a r i c acid monohydrate as op t i c a l l y 
ac t ive acid. Circular dichroism spectra of d- and 1-
centchroman were mirror images (Pig. 1 ) , an ind ica t ion of 
the op t i ca l pur i ty of the respect ive isomers and hence 
ef fec t ive r e so lu t ion . 
Determination, .of absolute configuration us ing 
c i r c u l a r dichroism 
1-0entchroman: [a]p°-192.9° (CHClJj (CD, 0 .42) ; ( 9 ) 2 q 0 °» 
( 0 ) 2 8 5 + 14 x 105j (Q) 2 ? 7 0j (Q) 2 ? 2 
, 5 5 - 2 x l O 3 ; ( 6 ) 2 3 6 - 10 x 10 5 ; ( ^ ) 2 5 5  2  10 5 (d). 
- 72 x 10 3 . 
d-Centchroman: [ a ] | ° + 1 9 2 . 5 ° (CHC1»); (CD, 0 .405) : ( e ) 2 9 0 
0; ( 0 ) 2 8 5 - 12 x 103 j ( 8 ) 2 ? 7 0; ( 0 ) 2 ? o 
+ 9.5 x 10 3 ; ( 0 ) 2 5 3 + 2 x 10?; (&)23s 
+ 62 x 10 3 . 
1-0entchroman: The rotational strength RK of various 
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A. K = Gaussian band wid th 
s M d 
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5 
s = sensitivity = ::2 x 10 
M = molecular wt. = 493.5 
d = deviation in mm in the GD spectrum 
from zero line 
c = cone* in gm/ltr = 0.42 g/ltr 
1 = path length in cm = 0.1 cm 
A K - wavelength of particular transition 
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* K - 0.598h where h is the hand width at half height 
of the band. 
Prom above calculations it is evident that this 
molecule has a high negative rotatory power at lower wave-
length. 
1-Centchroman exhibits two absorption bands 
centred around 238 and 280 nm in the UV absorption 
spectrum. The CD couplet (of low rotatory power) at 
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longer wavelength is attributed to the isotropic absorption 
band around 280 nm. The strongst CD band centred at 236 nn 
(Fig. 1) is attributed to the, it—> it* transition. 
One of the centchroman isomers, with 3-phenyl 
residue below the plane, or a, and the 4-phenyl (3, can be 
15 projected in the aromatic quandrants and viewed through 
the asymmetric carbon at 0., G, and C7 as shown in Fig, 2. 
The chroman moiety lies almost in one plane i.e. pldne A 











With this projection, the 3-phenyl residue resides 
in the lower left quadrant while the 4-aryl residue 
occupies the upper right quadrant (Pig. 3), each of these 
residues thus contributing to the negative rotatory power 
in this particular isomer with 3R» 4R absolute configura-
tion. An identical situation is found if the projection 
shown in Pig. 2 is rotated by 180°. Thus the overall 
contribution to the allowed it —> n* transition at 236 nm 
is negative in the case of 3R> 4R isomer of centchroman. 
Therefore, 1-centchroman isomer should have 3R> 4R 
absolute configuration. 
A similar analysis of 3S, 4S centchroman isomer 
indicates that the two aryl residues in this isomer 
contribute to the positive rotatory power. On this 
reasoning the centchroman isomer with (+) sign of rotation 
was assigned the 3S, 4S absolute configuration. 
Biological Activity 
Evaluation of the biological activities of the 
antipodes showed that the binding affinity, uterotrophic 
potency and antiimplantation activity was associated with 
1-centchroman (_£) and the corresponding d-isomer Q ) was 
only marginally active in these tests. 
The parent dl-centchroman (l) had a binding 






was 0.25 mg/kg/day. A two fold increase in the binding 
affinity was observed in the case of 1-isomer (£) while 
its antipode Q ) had only marginal binding affinity. An 
identical enhancement in the antiimplantation potency of 
the 1-isomer was observed, thus £ prevented pregnancy at 
a dose of 0.125 mg/kg/day, while 2 w a s completely inactive 
at 0.5 mg/kg/day as an antiimplantation agent. The utero-
trophic activity was also found to be associated largely 
with the more active 1-isomer (£). 
Conclusion 
Results obtained for d- and 1- isomers of 
centchroman clearly demonstrate the stereospecific nature 
of estrogen receptor. In principle one would expect the 
less active isomer to have relatively poor binding 
affinity. It may be pointed out that 1-E?> n a s nearly 20 
fold lower receptor affinity than the naturally occurring 
d-isomer. In comparison to this, the less active d-isomer 
of centchroman has marginal binding affinity compared to 
the 1-isomer. Smaller magnitude of separation in the 
binding affinities of the optical antipodes of centchroman 
may be related to the presence of only two asymmetric 
centres in the molecule. The marginal binding affinity 
associated with d.-centchroman may arise from interaction 
of the essentially unchanged chromah moiety in this isomer 
with the receptor. 
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The study also substantiate the presumption that 
the biological activity of centchroman is mediated through 
estrogen receptor, since the uterotrophic potency as well 
as antiimplantation activity were associated "with the 
isomer which had high binding affinity. On the basis of 
this study it can also be concluded that antifertility 
activity of centchroman is due to its estrogenic activity 
since centchroman isomer which showed no uterotrophic 
activity was also inactive as antiimplantation agent. 
2.2.2 Role of 7-methoxy group: Synthesis of 3<4-trans-
2,2-dimethyl~3-phenyl-4-[p_-(p-pyrrolidinoethoxy)] 
phenyl-7-hydroxychroman (6) 
In some cases it has been shown that the free 
phenolic compounds bind much more strongly to the receptor 
than the corresponding methoxy analogs ' ' . This 
binding subsite on the receptor apparently has a hydrogen 
bond accepting role. Methyl ether of estradiol and of 
other potent estrogens like DES usually have poor receptor 
affinities in vitro, but are often as active as their 
I p TO 
parent phenols in vivo ' . This anamoly is explained 
by the fact that ether derivatives usually act as pro-
hormonal agents and are slowly dealkylated in vjvo to the 
19 parent phenol, which is the true estrogenic species . 
Based on these facts a suggestion has been made recently 
in work published from this laboratory that the estrogen 
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receptor has amongst i t s subs t i e s , a subs i t e , i n which the 
phenolic group i s involved as a hydrogen bond donor . I t 
thus appeared most l i k e l y tha t the methoxybenzene r ing of 
centchroman simulates the aromatic residue of Ep, and binds 
a t a common subs i te on the estrogen receptor , and i n 
analogy with e s t r a d i o l , the demethylated centchroman i s 
the r ea l ac t ive spec ies . 
In order to e s t ab l i sh the v a l i d i t y of t h i s presump-
t i o n , 7-hydroxy analog of centchroman was synthesised in 
order to study i t s in v i t r o and in vivo receptor i n t e r -
act ion and b io log ica l a c t i v i t y . 
Synthesis of 3»4-trans~2,2-dimethyl-5-phenyl-4-
[p_-((3-pyrrolidinoethoxy)]phenyl-7-hydroxychroman could be 
achieved by two a l t e r n a t i v e methods v i z . a de_ novo 
synthes is from appropr ia te ly subs t i tu ted s t a r t i n g ma te r i a l s , 
involving a mul t i s tep synthes is , or by s e l e c t i v e dealkyla-
t i o n of centchroman. The l a t t e r route appeared more 
convenient, though considerable d i f f i c u l t i e s were envisaged 
owing to the presence of three 0-a lkyl res idues in the 
molecule v i z . 7-OMe, pyran r i ng and O-t-aminoalkyl side 
chain. Ether cleavage can be affected by both a l k a l i s and 
a c i d s . As ac id ic conditions are more l i k e l y to form side 
products , and l e s s l i k e l y to be affected by s t e r i c 
cons t ra in t s around the ether l inkage , i t appeared more 
appropriate to t r y a lka l ine conditions for demethylation 
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which may not touch the chroman ether l inkage . 
Dealkylation of centchroman (1) in d ie thy lene-
glycol and potassium hydroxide in the presence of c a t a l y t i c 
amount of hydrazine hydrate a t 250° for 30 minutes furn ish-
ed besides the desired 3,4~trans-2,2-dimethyl-3-phenyl-4-
[p_-(p-pyrrolidinoethoxy) ]phenyl-7-hydroxychroman (6.), 
3»4-trans_-2,2-dimethyl-3-phenyl-4-(p_-hydroxy)phenyl-7-
methoxychroman (2) and 3»4-trans-2,2-dimethyl-3-Phenyl-4-
(p_-hydroxy)phenyl-7-hydroxychroman (8) along with about 30$ 
of the unreacted s t a r t i n g m a t e r i a l . Separation of the 
products was affected through column chromatography over 
bas ic alumina and e lu t ing with increas ing amounts of 
methanol in chloroform. An increase in r eac t ion time only 
f a c i l i t a t e d the formation of undesired products 2 a^d §_• 
6 R = H, R± = CH2CH2N 
7 R = Me, R± = H 
8 R = R1 = H 
Reagent ; 
KOH, d i e t h y l e n e g l y c o l , NH2NH2sH20 
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The receptor affinity, nuclear retention, profile 
in the immature rat uterus and antiimplantation activity 
of 7-hydroxy analog of centchroman were studied. 
Biological Activity 
Evaluation of the receptor affinity and biological 
activities showed that 6 was markedly potent in receptor 
binding and uterotrophic assays as compared to the parent 
centchroman. 
Thus 6 has a binding affinity of 112# (20 fold 
higher than that of 1) and has a 16 fold increased utero-
trophic potency than centchroman. There was, however, no 
change in the antiimplantation activity and 6_ was still 
active at 0.25 mg/kg/day, although at 0.20 mg/kg/day 
reduced number of implants were observed. 
In vivo receptor interaction studies with 6_ showed 
that it is very efficient in translocating cytosol receptor 
(Re) into the uterine nuclei, maintaining high.nuclear 
receptor (Rn) levels for prolonged periods as compared to 
Conclusion 
An important prerequisite proposed for high receptor 
affinity of estrogens is the presence of a free phenolic 
group corresponding to C,-0H of E?. Centchroman, possessing 
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an OMe group in the chroman residue, has poor receptor 
affinity as compared to Ep. The increased binding affinity 
of the 7-hydroxy analog (6.) and a 16 fold increase in its 
uterotrophic potency substantiate this presumption. These 
observations also indicate that the chroman nucleus in 
centchroman and rings A and B of Ep might be involved in 
binding with a common region of the Ep receptor. 
2.2.3 Role of pyrrolidinoethoxy side chains Synthesis of 
3«4-trans-2t2-dimethyl-3-phenyl-4~[p-(t~amino-
alkoxy)]phenyl-7-methoxychromans 
The estrogenic activity in alkoxy (hydroxy) 
20 
substituted TAEs was discovered quite early . A variety 
of triarylethylene analogs were synthesised and their 
endocrine properties studied. Most of these compounds 
21 
were orally active and also long acting . Incorporation 
of hydroxy groups in phenyl residues usually led to decrease 
in their duration of activity. The profile of activities 
of these parent TAEs, however, was more or less the same 
as that of other classical estrogens of the steroidal, 
stilbene and doisynolic acid types. They resembled the 
latter compound in shape of dose-response curves, and 
acted as synergist to the activity of Ep. 
22 Lerner et_ al demonstrated that incorporation of a 
t_-aminoalkoxy residue in one of the phenyl rings in TAEs 
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markedly modulated the activity of the parent molecules-. 
It was thus shown that incorporation of this chain at 
suitable position in many TAEs led to suboptimal estrogenic 
activity and some of these molecules even acted as 
21 
estrogen antagonists; MER-25 was found to be a potent 
antiestrogen, with very weak estrogenicity. The activity 
was, however, found to be dependent upon the geometry of 
the molecules as well as the animal species employed. 
23 24 Some of the important antiestrogens like clomiphene ^' , 
per p f. p7 
nafoxidine , and tamoxifen ' were thus discovered. 
It is, however, not known' whether modulation in 
the biological activity results from the altered pharma-
kokinetics of the parent TAE, or that the side chain has 
a direct role in binding to the receptor, leading to 
altered biological activity. In order to study the 
receptor binding contribution of the basic side chain 
residue in TAEs and to establish a correlation between 
its propensity to bind with the receptor and biological 
activity, some side chain homologs of centchroman were 
synthesised. 
Some work has been carried out on the effect of 
the basic ether side chain on the biological activity of 
1 -I pp 
compounds structurally related to nafoxidine * . There 
have, however, been no reports, todate, about the contri-
bution of the side chain in receptor binding. It, therefore, 
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appeared of i n t e r e s t to study the ro le of the s ide chain 
on the receptor binding and b io log ica l a c t i v i t y of 
centchroman. The synthesis of centchroman analogs with 
varying length of the side chain and the subs t i t uen t s a t 
n i t rogen atom was undertaken. Thus compounds 12,, 1^ and 
15 were synthesised, and t h e i r receptor a f f i n i t y and 
b io log ica l a c t i v i t y s tudied. 
3 ,4- trans-2,2-Dimethyl-3-phenyl-4- (p_-hydroxy)phenyl-
7-methoxychroman would be the most appropriate s t a r t i n g 
mate r ia l for the synthesis of(12), (1^ and(l!??, which in turn 
could be prepared by isomerizat ion of corresponding 3>4-
ci.s-2 t2-dimethyl-5-phenyl-4-(p-hydroxy) phenyl -7 -methoxy-
chroman by a base catalysed r eac t i on . Under the bas ic 
condi t ions , however, the phenolic group present i n the 
molecule might i n t e r f e r e with the isomerizat ion process 
and, the re fore , i t had to be protected by prepar ing i t s 
benzyl e ther de r iva t i ve . 
Thus 3,4-cis~2,2~dimethyl~3-phenyl-4~(p~hydroxy) 
phenyl-7-methoxychroman (£) was converted to the cor res -
ponding 3,4-cis-2,2-dimethyl-3-phenyl-4-(p_-benzyloxy )phenyl-
7-methoxychroman (10.) by ref luxing in acetone in the 
presence of benzylchloride and anhyd. potassium carbonate 
(Scheme 2 ) . Base catalysed isomerizat ion of 10 with n -
butyl l i th ium gave 3«4-trans~2,2-dimethyl-3-phenyl--4- (p-
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by hydrogenation with Raney-Ni to furnish 3»4-transj-2,2 
dimethyl-3-phenyl-4-(p_-hydroxy)phenyl-7-methoxychroman (12) . 
Alkylation of 12 with N,N'-diethylaminoethyl chlor ide 
hydrochloride, N,H"'-dimethylaminoethyl chloride hydrochlo-
r ide and NjN'-diethylaminopropyl chloride hydrochloride 
gave the required alkylated compounds r3_, 14. and 1J> 
r e spec t ive ly . 
Biological Act iv i ty 
"Variation in the length of the bas ic e ther s ide 
chain and nature of subs t i t u t i on a t ni t rogen atom markedly 
af fect the binding a f f i n i t y and b io log ica l a c t i v i t y of 
centchroman. Thus, centchroman analog with N ,N ' -d ie thy l -
aminopropoxy side chain as in 1,5 having a binding a f f i n i t y 
of A»5%, very close to tha t of 1 also had ant i implanta t ion 
a c t i v i t y close to tha t of centchroman (MED 0.3 mg/kg/day). 
The nature of subs t i t u t ion a t ni t rogen atom of 
the basic ether s ide chain also g rea t ly af fec ts the b io lo -
g i c a l potency of centchroman. Thus receptor a f f i n i t y fo r 
N,N'-diethylaminoethoxy compound (1J5) descended to a value 
of 3.22$. The ant i implanta t ion potency was, however, not 
s i gn i f i can t ly affected and 1/3 prevented pregnancy at a 
dose of 0.3 mg/kg/day. A fur ther decrease in binding 
a f f i n i t y was observed for NjN'-dimethylaminoethoxy compound 
(1.4.) which had a binding a f f i n i t y of 1.89$ and was ac t ive 
a t 2.0 mg/kg/day as an ant i implanta t ion agent . 
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Gonclusion 
The foresaid results clearly demonstrate the bind-
ing specificity of pyrrolidinoethoxy side chain in 
centchroman. Although the 2 carbon or 3 carbon chain 
length does not have much influence on binding affinity 
and antiimplantation activity, the nature of substitution 
at nitrogen plays an important role in these potencies. 
The alkyl group on the t.-amino residue particularly a 
pyrrolidino residue seems to impart the critical hydro-
phobicity to the molecule for an optimum receptor inter-
action. 
2.2.4 Effect of the position of the basic ether side 
chain 
A study of the more active triaryl-ethylenes, 
-ethanes and related compounds would reveal that a t-
aminoalkoxy side chain, which is to a considerable extent 
responsible for their 'atypical' estrogenic behaviour, is 
present at p_ position of C,-phenyl residue in these 
molecules. It has, however, been observed that the pro-
file of endocrine activities of these TAB compounds 
critically depends upon the geometrical relationship 
between this aryl group (which carries the basic side 
chain) and the vicinal phenyl residue. Thus in the open 
chain TAE analogs, which can exist as ci.s and trans 
isomers, the geometry of the molecule has a marked effect 
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on the receptor affinity and hormonal profile of activity 
27 29 
of the respective isomers ' . Centchroman, which incor-
porates a 1,1,2-triarylethane system in a rigid framework, 
carries the t-aminoalkoxy side chain at p_ position of the 
C.-phenyl residue which corresponds to 0-,-phenyl residue of 
TAE's and has a 'cisoid' relationship with the phenyl 
residue at C,. 3 
It was of interest to establish a correlation 
between the position of this side chain and its affect on 
receptor binding and biological activity of triarylethylene/ 
ethane estrogens, particularly that of centchroman. For 
this purpose the synthesis of some position isomers of 
centchroman, in which the side chain is transposed to o_ and 
m positions of G.-phenyl residue and p_ position of CU-phenyl 
residue has been carried out and their receptor binding and 
biological activity studied. 
Synthesis of 3,4-trans_-2,2-dimethyl--3-phenyl-4-[m~(p-
pyrrolidinoethoxy) Jphenyl-7*-methoxychroman (22) 
Friedle-Crafts reaction of m-hydroxybenzoic acid 
with m-methoxyphenol in the presence of stannic chloride 
gave 2,3'-dihydroxy-4-methoxybenzophenone (16) (Scheme 3)-
Condensation of 16, with phenylacetic acid in triethylamine 
and acetic anhydride mixture gave 3-phenyl-4-(m-acetoxy) 






i m(0H)C6H4C02H, SnCl4 
ii PhCH2C02H, Et,N, AG 20 
iii MeMgl, THF, Et~0 (dry) 
iv G10H2CH2N 
anhyd. KpCO^, 
ace tone (dry) 
v H2 , 10# Pd-C, MeOH 
v i n - B u t y l - l i ^ h i u m , DMSO 
subjected to Grignard react ion with excess of MeMgl to 
afford 2,2-dimethyl-3-phenyl-4-(m~hydroxy)phenyl-7-me thoxy-
chromene (18) . Alkylation of 18 with |3-pyrrol idineethyl 
chloride hydrochloride led to 2,2~dimethyl~3-phenyl-4~ 
[m-(p-pyrrolidinoethoxy)]phenyl-7~methoxychromene ( l £ ) . 
C a t a l y t i c hydrogenation of 18 with 10$P&-C gave 5«4-c i s -
2,2-dimethyl-3-phenyl-4-(m-hydroxy)phenyl-7-methos:ychroinan 
(20^). cijs-Geometry was confirmed from the coupling constant 
value (7 Hz) of C~ and C. proton s igna l s in the PMR 
spectrum of 20_. Alkylation of cis-hydroxychroman (20) 
with p-pyrro l id inoethyl chloride hydrochloride furnished 
21 , which was isomerized with n -bu ty l - l i th ium in dimethyl 
sulphoxide, to the thermodynamically more s tab le 3«4- t rans-
2,2-dimethyl-3-phenyl-4-[m-(p-pyrrol idinoethoxy)]phenyl-7-
methoxychroman (2_2). A 13 Hz coupling constant value for 
C* and 0 . proton s igna ls in the PMR spectrum of 22_ confirm-
ed the 314-trans geometry. 
Synthesis of 3»4-tran^-2,2-dimethyl-3-phenyl-4-[p_-(p-
pyrrolidinoethoxy)Jphenyl-7-methoxychroman (41) 
Reaction of s a l i c y l i c aoid with m-methoxyphenol 
in the presence of s tannic chloride or super phosphoric 
acid gave 2,2'-dihydroxy-4-methoxybenzophenone (2_3_) 
(Scheme 4) in none too sa t i s f ac to ry y i e l d . In order to 
avoid the formation of isomeric mixture of coumarins a t 
the next s t ep , at tempts were made to prepare the c o r r e s -
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MeO 
24 R = H 
25. R = COCH3 
26 R = £-N0 2 -C 6H 4G0 
MeO' 
M e ( r ^ > ^ T ) R 
21 R = H 
^28 R = COCH, 
2_9 R = £-N0o-CVH.C0 2{ o 4 
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r ^ V ^ 








21 R = COCH, 
14 R = CH5 
^ R = CH2GH2N 
Reagents; 
i PhGH2C00H, Bt-N, Ac20 
ii MeMgl, THE, Et20 (dry) 
iii EtOHsHCl 
iv ACpO, Pyridine (dry) 
RX, anhyd. K2C0,, Acetone (dry) 
Scheme 4 
ponding substituted benzophenone with 2'-hydroxy group 
protected. With this objective condensation of p_-benzyl-
oxybenzoic acid with m-methoxyphenol in the presence of 
P0Cl~-ZnCl2 as well as BF,-Et20 was carried out. However, 
under these conditions only the debenzylated product was 
obtained. Moreover selective alkylation of 2'-hydroxy in 
2J5 could not be achieved. Therefore, an alternative 
synthetic strategy for the title compound starting from 
the benzophenone 2^ was followed. 
Condensation of 2J5 with phenylacetic acid in 
triethylamine and acetic anhydride afforded a mixture of 
3-phenyl-4-(o._acetoxy)phenyl-7-methoxycoumarin (2£) and 
3-phenyl-4-(2-acetoxy-4-methoxy)phenylcoumarin (.28) in 
1:1 ratio. 'The isomeric mixture was monitored by HPLO 
and PMii spectrum in which two signals were obtained for 
OCEL groups. 
The isomeric coumarin mixture 2£ and 28 could not 
be separated by TLC using a variety of adsorbents and 
solvent systems. Attempted purification of the free 
phenols 2J. and 27, obtained by alkaline hydrolysis of the 
acetoxycoumarins, also proved infructuous. Attempted 
purification of 2J5 and 28 via their corresponding p_-nitro-
benzoylesters (26. and 2_9) also did not succeed. 
In view of the difficulty experienced in separat-
ing 23. z^d- 28 it was decided to proceed further with the 
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mixture and attempt separat ion of the reac t ion products 
a t the next s t age . The mixture was thus subjected to 
G-rignard reac t ion with MeMgl; usual work up of the reac t ion 
product yielded c i s - and trans_-2-methyl~3-phenyl-4-(o-
hydroxy)phenyl-4-(2-hydroxy-4-methoxy)phenyl~but-3> 4-ene-
2-o l s (.20. and 2i) • Attempted separat ion of the products 
30 and 2ik on TLC p l a t e f a i l e d . I n t e r e s t i n g l y enough, acid 
catalysed cyc l iza t ion of the isomeric butenols 20. and 2 i 
yielded the required 2,2~dimethyl-3-phenyl-4-(o_-hydroxy) 
phenyl-7-methoxychromene (22.) as the sole reac t ion product . 
The pu r i ty of 22. was confirmed by HPIC and PMR spec t ra 
which showed only one peak for O0H~ group. 
Exclusive formation of the chromene 22. from the 
mixture of the isomeric butenols 20. aii-^ 2k c a n 1°e r a t i o n a -
l i z e d on the basis t ha t so lvolys is of t-hydroxy groups in 
a c i d i c conditions,employed for the cyc l iza t ion reac t ion , 
would give r i s e to a ib-carbonium ion (Scheme 5) • D e r e a l i -
za t ion of the carbonium ion with 3>4-double bond would 
permit free ro t a t ion around the 3,4-bond. Cyclizat ion of 
the intermediate in a thermodynamically control led process 
involving favourable s t e r i c approach between the t.-carbonium 
• 
ion and phenolic group could lead exclusively to the 
chromene 22* 
The homogenity of chromene 22. was established by 
HPIC and PMR. Chromene 22. was acylated with acetic 
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Reagent : EtOH:HCl 
Scheme 5 
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anhydride and pyridine to afford the corresponding acetyl 
derivative 22> it was alkylated with methyl iodide and 
(3-pyrrolidinoethyl chloride hydrochloride to yield the 
alkylated compounds 24 a n d 2£ respectively; 22> 24 ^nd 32 
were found to be homogenous by HPLC. 
The acid catalysed cyclization could proceed in 
two different ways involving one of the two phenolic groups 
of the carbinol. It remained to be decided whether 
chromene32 is the one which corresponds to the coumarin 2Ji, 
in which OMe and OAc groups are in two different aromatic 
rings or the one which corresponds to coumarin 2B in which 
OMe and OAc are in the same aromatic part of the molecule. 
In order to clarify this point a similar sequence of . 
reactions was followed starting from 2-hydroxy-2', 4-
dimethoxybenzophenone (2j5). Thus Friedel-Grafts reaction 
of o_-anisic acid with m-methoxyphenol in stannic chloride 
(Scheme 6) gave ;56_, which was condensed with phenylacetic 
acid in triethylamine and acetic anhydride to give 3-phenyl-
4-(o_-methoxy)phenyl-7-methoxycoumarin (2Z). Grignard 
reaction of 2Z with MeMgl gave ci_s- and trans-2-methyl-3-
phenyl-4-(p_-methoxy)phenyl-4-(2-hydroxy-4-methoxy)phenyl-
but-3,4-ene-2-ols (18 and 25 respectively). The 3,4-double 
bond might be involved in the Grignard reaction, which 
would explain the formation of isomeric butenols. The 
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and t h e i r geometry was infer red on the bas i s of t h e i r mass 
fragmentation p a t t e r n . Both butenols gave molecular ion 
peak a t m/e 390, however, in the case of one of the 
isomers the base peak appeared at m/e 372, corresponding 
to loss of a molecule of water . This can happen in the case 
of the cis- isomer (,3,8) where there would be more f a c i l e 
formation of the chromene by lo s s of water. While on the 
o ther hand the mass spectrum of the second isomer showed 
only a very weak peak at m/e 372 but had a very strong base 
peak a t m/e 344. The acid catalysed cyc l i za t ion of 3_8 was 
very f ac i l e as compared to 3_9 which also supported c is 
geometry for t h i s isomer. The mixture of 2s. and 3_9 also 
on acid catalysed cyc l iza t ion afforded exclusively 2 ,2 -
dimethyl~3-phenyl-4-(2~methoxy)phenyl-7-methoxychromene (40.). 
The reason for the exclusive formation of 4.0 from ^8 and 39 
appears to be the same as described for 32. The chromenes 
2.4_ and 40 were i d e n t i c a l as evidenced by superimposible 
IR spectrum, m.p. and mixed m.p. , thus confirming the 
i d e n t i t y of the hydroxy chromene j$2_ as 2,2-dimethyl-3-phenyl-
4-(p.-hydroxy)phenyl-7-methoxy chromene. 
Chromene 2^_ was hydrogenated over 10$ Pd-C to 
y ie ld 3,4-cis-2,2-dimethyl-3-phenyl~4-(p_-hydroxy)phenyl-7-
methoxychroman (^1) (Scheme 7 ) . The 3«4-cis geometry was 
supported by a 6.0 Hz coupling constant value for C~ and 0, 
proton s ignal in the PMR spectrum of 4JL. Alkylation of &L 







Reagen ts ; 
i H 2 , 10$ Pd-C, MeOH 
i i C1GH2GH2N j , anhyd. E^CO,, Acetone (dry) 
i i i n - B u t y l - l i t h i u m , DMSO ( d r y ) . 
Scheme 7 
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with p-pyrrolidinoethyl chloride hydrochloride afforded 42 
•which upon base catalysed isomerization with n-butyl-
lithium gave the desired thermodynamically more stable 
i somer, 3, 4*-trans-2,2-dimethyl-3-phenyl~4- [ o- (P -pyrroli-
dine ethoxy)]phenyl-7-methoxychroman (4^). A change in 
coupling constant value from 6.0 Hz in £1 to 12.5 Hz in 43 
supported the 3»4-trans geometry. 
Synthesis of 3 > 4-trans-2»2-dimethyl-3-fP-(g-pyrrolidino-
ethoxy)]phenyl-4-phenyl-7-methoxychroman (50) 
Benzoylation of m-methoxyphenol followed by Pries 
rearrangement of m-benzoyloxyanisol gave 2-hydroxy-4~ 
methoxybenzophenone^ (4_4_). Condensation of 4ji. x^ ith p_-
hydroxyphenylacetic acid in triethylamine and Ac„0 
(Scheme 8} gave the acetoxycoumarin 4J> which was converted 
to 2,2-dimethyl-3-(p.-hydroxy)phenyl-4-phenyl-7-methoxychro-
mene (4_6) by reaction with excess of MeMgl. Alkylation of 
4_5_ with p-pyrrolidinoethyl chloride hydrochloride gave the 
alkylated chromene 4_2_. Catalytic hydrogenation of 4_6 with 
10$ P.d-C gave 3,4-cis_-2,2-dimethyl-3-(p_-hydroxy)phenyl-4-
phenyl-7-methoxychroman (4J3). Alkylation of 4.8 with p-
pyrrolidinoethyl chloride followed by isomerization with 
n-butyl-lithium gave the desired 3,4-trans.-2,2-dimethy 1-3-
[p_-(P-pyrrolidinoe thoxy) ]phenyl-4-phenyl*-7-met hoxy chroman 
(50). The 3»4-trans geometry of ^0, was established as 
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Transposition of the basic ether side chain to 
other positions in the molecule as discussed above greatly 
affects the binding affinity and biological potency of 
centchroman. Thus trans.-chroman analogs of centchroman 
incorporating basic ether side chain at g or o positions 
of G .-phenyl residue and p_ position of C,-phenyl residue 
(22., 42 and ^0. respectively) displayed only marginal bind-
ing affinity and antiimplantation activity as compared to 
the parent centchroman. In fact when the basic ether side 
chain was present at o. position of 0,-phenyl residue as in 
42., the compound had no binding affinity at all. The 
reduced binding affinity associated with these compounds 
is reflected on their antiimplantation activity, while the 
cis-chromans 21., 42. and 42. were completely inactive at 
2.0 mg/kg/day, in the trans series 2_2 and £0 were found 
to be active at this dose level and 42 x-ath side chain at 
p_ position of C .-phenyl was inactive perhaps owing to its 
lack of binding affinity. 
In the corresponding chromene analogs, however, 
interestingly lj9, incorporating basic side chain at m 
position of C.-phenyl residue, was found to possess anti-
implantation activity at 1.0 mg/kg/day. The other two 
positional analogs 22 a n d 41 were, however, inactive at 
73 
2.0 mg/kg/day. 
The trans-chroman analog ^0., incorporating the 
basic ether side chain at p_ position of C,-phenyl residue, 
although having relatively poor receptor affinity (0.14$ ) 
was found to be four times more estrogenic than centchroman. 
Conclusion 
Studies with the side chain positional isomers of 
centchroman indicate that the position of the side chain 
is highly specific for receptor binding and biological 
activity of centchroman. Transposition of this side chain 
to other parts of the molecule as described above resulted 
in compounds with subdued binding affinities and anti-
implantation activity as compared to centchroman. However, 
when the basic ether side chain was transposed to the p_ 
position of C,-phenyl ring, the compound exhibited a marked 
uterotrophic potency than the parent 1. This increased 
estrogenicity of j?0 may be due to certain metabolic changes 
which would result in a oompound incorporating a potential 
frank estrogenic prototype. This assumption is supported 
by the studies described in the following section. 
On the basis of these studies it can be concluded 
that the optimum position for basic ether side chain which 
results in highest receptor affinity is the p_ position of 
G.-phenyl ring, and that when present at this position, the 
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side chain in a specific alignment binds with the receptor 
in an optimum manner. Moreover, incorporation of this side 
chain at the p_ position of C,-phenyl residue results in 
increased estrogenicity which indicate the presence of a 
binding subsite in this region of the receptor, 
2,2.5 3-(p_-Hydroxy)phenyl-4-aryl-7-methoxy-chromenes 
and -chromans 
The triaryl-ethylene and -ethane molecules incor-
porate a DBS or hexesterol core. This has been suggested 
to be the reason for their interaction with the estradiol 
31 
receptor site and, therefore, of biological activity , 
However, it has been established unequivocally that inter-
action of DES and hexesterol with the estradiol sites 
depends critically upon the presence of two phenolic groups 
which simulate 3- and 17-hydroxy groups of E?, which can 
form hydrogen bonds at the binding sites . Most of the 
active TAEs, including centchroman, do not have free OH 
groups at the corresponding position in the 3-phenyl 
residue. However, the possibility cannot be ruled out 
that this phenyl residue may undergo hydroxylation in vivo 
to generate a hexesterol type species which is responsible 
for the biological activity. It was, therefore, considered 
of interest to synthesise analogs of centchroman incorpora-
ting p_-hydroxy and -alkoxy functions in the 3-phenyl residue 
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and study t h e i r receptor a f f i n i t y and hormonal a c t i v i t y . 
Synthesis of 3,4-trans_~2,2-dimethyl-3-(p_-hydroxy)phenyl-4-
[p_-(p-pyrrolidinoethoxy)]phenyl-7~methoxy chroman (59) 
The synthet ic s t ra tegy for the t i t l e compound was 
s imi la r to the one followed e a r l i e r (Scheme 9 ) . Conden-
sa t ion of 2,4'-dihydroxy-4-methoxybenzophenone (£1) with 
p_-benzyloxyphenylacetic acid in t r ie thylamine and a c e t i c 
anhydride gave the corresponding 3-(p_-benzyloxy)phenyl-4-
(p_-acetoxy)phenyl-7-methoxycoumarin (£2.). Reaction of %2 
with excess of MeMgl gave 2,2-dimethyl-3-(p_-benzyloxy) 
phenyl-4-(p_-hydroxy)phenyl-7-methoxychromene (££) . The 
chromene ^_ had a remarkable capacity to form c la the ra te 
compound with organic solvent such as acetone, which was 
used for c r y s t a l l i z a t i o n . The IR and PMR spec t ra of the 
c la the ra te exhibited acetoxy peaks for carbonyl and methyl 
group r e spec t ive ly . Similar inc lus ion of organic solvents 
by s t r u c t u r a l l y re la ted compounds has been repor ted 
-, • 34 ea r l i e r^ . 
Alkylat ion of £5. with (3-pyrrolidinoethyl chloride 
gave 2,2-dimethyl-3~(p_-benzyloxy)phenyl-4~[p_-((3-pyrrolidi-
noethoxy)]phenyl-7-methoxychromene (£6) . Ca t a ly t i c hydro-
genation of £6 with 10$ Pd-C at atmospheric pressure and 
temperature afforded 2,2-dimethyl-3-(p_-hydroxy)phenyl-4-
Cp_-(p-pyrrolidinoethoxy) ]phenyl-7-methoxychromene (52), 
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phenyl-7-methoxychroman (£8), and at 800 ps i pressure and 
at 60° exclusively £8 was obtained. The 3,4-cis . s t e r e o -
chemistry was assigned on the bas is of PMR. Isomerization 
of 58_ with n-buty l - l i th ium in dry DMSO yielded the desired 
3 7 4 - t rans-2 ,2-d imethyl -3- (p_-hydroxy) phenyl-4-Cp_- (P-
pyrrolidinoethoxy)]phenyl-7-methoxychroman (£2) . The 3 ,4-
t r a n s geometry of ££ was es tabl i shed as usual on the basis 
of higher coupling constant value (5 Hz to 12 Hz) of CU and 
C. proton s igna l s in the PMR spectrum. 
Synthesis of 3 > 4-trans_-3~C2.-( p-pyrrolidinoethoxy) ]phenyl-4-
phenyl-7-methoxychroman (67) 
Reduction of 4J5 with Ni-Al a l loy in IN NaOH at 
80-85° for hal f an hour or in 5N NaOH at 95-100° for 5 h r 5 5 
gave exclusively one isomer of 2-(p_-hydroxy)phenyl-3-phenyl-
3-(2-hydroxy-4-methoxy)phenyl-propionic acid (62.). Theore-
t i c a l l y reduct ion can form two dias tereoisomeric acids with 
RR and RS configuration of the two asymmetric carbon atoms* 
The stereochemical assignments for 62, were made on the basis 
of ea r l i e r work on re la ted s e r i e s of compounds from t h i s 
33 
labora tory . 
On the basis of ' r e luc tance towards cyc l i za t ion ' 
i n benzene-PTSA, 62. was assigned 2S, 3R configurat ion 
(erythro) • An examina^g]»Dipfg^erythro isomer rotamers 
GOOH 
MeO MeO' 
MeO' N ^ ^ o H GOOH 
I I I 
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ph X " ^ 0 R 
MeO 
Ph /^Sv-OH 
45, R = Ac 
60 R = H 
61 R = Bz 
MeO 




i IN NaOH, 80-85°, M e c T ^ ^ O 
30 min. 67 
5N NaOH, 95-100", 5 hr. 
ii Ac?0, Benzene (dry) 
iii LAH, THE, EtgO (dry) 
iv £-(OH,)C6H4S02Cl, pyridine 
v EtOHsNaOH 
vi CICHgCHgN J, anhyd. KgCO-, Acetone (dry) 
Scheme 10 
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reveals that the conformation I, has the least Gauche 
interactions and would thus be the most preferred confor-
mation. In this rotamer the Op and G~ protons are trans 
to each other, which can be monitored by PMR spectrum. 
PMR of 62, showed doublets for H& and H, as expected with 
a J value of the order of 13 Hz. According to the Karplus 
equation this high J value would indicate that the two 
protons in 62. are in a trans,-diaxial arrangement with a 
dihedral angle of about 180°. In a population of rotamers, 
the J value is a weighted mean of the contribution of 
different rotamers. Prom this high J value it would 
appear that the conformation I is the only contributor to 
the rotameric population. 
The erythro assignment to the propionic acid 62_ 
is only tentative and needs further support which is being 
collected. When the acid 6£ wasrefluxed in benzene and 
acetic anhydride, it gave a mixture of cis and trans-3-
(p_-acetoxy)phenyl-4-phenyl-dihydrocoumarin (6^ .)-(Scheme 10), 
Lithium aluminium hydride reduction of the acid 
6_2 in THP - ether gave the corresponding erythro-2-(p-
hydroxy)phenyl-3-phenyl-3-(2-hydroxy-4-methoxy)phenyl-
propanol (64_)-(J, H2, H, = 12 Hz). The propanol 6± was 
then reacted with excess of p_-toluenesulphonyl chloride in 
pyridine. Instead of the formation of the corresponding 
tritosylate, erythro-2-(p-tosyloxv)phenyl-3-r>henvl-3-(2-
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tosyloxy-4-methoxy)phenyl-propyl chloride (6Jj_) was i so l a t ed 
as the sole reac t ion product . S t ruc tura l assignment was 
made on the basis of i t s s p e c t r a l data . The PMR spectrum 
showed two s i n g l e t s for two methyl groups which in tegra ted 
for 3 protons each. Further t he re was no change in the 
chemical sh i f t value of CH2 group. Had there been a t o sy l 
group at tached to t h i s methylene, i t would have suffered an 
appreciable deshi.elding. Ins tead t h i s methylene appeared 
a t 3.7 6, a pos i t ion normally assigned to -CHpCl r a the r 
than -CELOTS. Moreover, mass fragmentation pa t t e rn of the 
molecule was in agreement with t h i s assignment. 
Cycl izat ion of 6J5 with e thanol ic a l k a l i gave 3>4-
trans-3~(p-hydroxy)phenyl-4-phenyl-7-methoxychroman (66) , 
which was pur i f ied by column chromatography on s i l i c a ge l . 
The t r ans geometry was es tabl i shed on the bas i s of 9 Hz 
coupling constant value for C~ and C, protons in the PMR 
spectrum of 66.. Alkylation of £6 with p-pyr ro l id inoe thy l 
chlor ide gave the desired 3»4~trans-3-fp- (3-pyrro l id ino-
ethoxy)]phenyl-4-phenyl-7-methoxychroman (67) . 
Synthesis of 3 > 4-trans-2,2-dimethyl-3-(p-hydroxy)phenyl--4-
phenyl-7-methoxychroman (71) 
36 
2,4-Dihydroxybenzophenone (.68) , prepared from 
reso rc ino l through i t s dibenzoyl e s t e r followed by Fr ies 
rearrangement, was condensed with p_-hydroxyphenylacetic 
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acid in t r ie thylamine and ace t i c anhydride (Scheme 11) to 
afford the corresponding 3-(p_-acetoxy)phenyl-#4-phenyl-7-
acetoxycoumarin (.69). Reaction of ,69. with excess of MeMgl 
gave 2,2-dimethyl-3-(p_-hydroxy)phenyl-4~phenyl-7-hydroxychro-
mene (70.). This was also prepared by demethylation of 4_6 
with HBr-HOAc, but the product was not clean and had to be 
chromatographed over s i l i c a ge l . To get the t i t l e compound, 
however, 4J3 was isomerized with n -bu ty l - l i th ium in DMSO. 
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Incorporation of a hydroxy group in the p_ position 
of 0,-phenyl residue results in increased uterotrophic 
potency than the parent centchroman. Thus 71, was found 
to he roughly four times more estrogenic than centchroman. 
The evaluation of binding affinities and biological 
activity of rest of the compounds described above is in 
progress* 
Con elusion. 
Although detailed results of the biological 
screening are not available as yet, on the basis of present 
knowledge and studies included in this chapter, it can be 
expected that compounds incorporating a hydroxy function 
in the p_ position of C^-phenyl residue will have relatively 
high binding affinities and uterotrophic potencies than 
the prototype centchroman. However, no comment can be made 
on the antiimplantation activity of these compounds. 
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2.3 BIOLOGICAL ACTIVITY 
The relative binding affinity, uterotrophic 
activity in mice and rats and antiimplantation activity 
of compounds listed in Table 1
 weT.e evaluated in the 
Endocrinology Division of this Institute, Methods for 
determining these potencies are described below. 
Relative binding affinity (RBA) 
The relative binding affinities of the compounds 
listed in Table 1 for estrogen receptor were determined 
by competition assay, employing radiolabelled estradiol 
([ H]-Ep), as the reference compound. The test ligands 
and [JEJ-E- w e r e incubated (4°) with cytosol estrogen 
receptors obtained from immature rat uteri. At the end of 
the incubation (20-24 hr) 'under suitable experimental 
conditions (0-4°), dextran coated charcoal (DCC) suspension 
was employed for removal of the unbound radiolabelled 
[^H]-Ep. The competition curves, obtained for varying 
concentrations of test compound at constant concentration 
of pHj-Ep, had a sigmoidal shape for protein binding. 
Affinity of the test compound was computed from a graph 
plotted between per cent bound radioactivity versus log 
concentration of the test substances. At 50$ inhibition, 
the log concentration of the test compound relative to 
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that of Ep, gives the affinity of the test compound relati-
ve to Ep. This when multiplied with 100 gives the value in 
percentage, designated as RBA. 
log concentration of reference compound 
RBA = < • — x 100 
log concentration of t e s t compound 
The procedure i s "briefly as follows: 
200 |il of cytosol + 30 |il of t e s t compound + 
15000-18000 cpm of 5H-E2 ( in 30 \il of assay buffer) 
V 
Incubated at 0-4° for 20-24 hr 
V 
After the end of incubation 2.5% of DGC suspension 
in 0.1 ml of incubation buffer was added 
V 
Incubated for a further period of 10 min (0-4°) 
I 
Oentrifuged at 800 g for 10 min at 0-4° 
V 
* 
Radioactivity in the supernatant was counted in 
10 ml of aqueous scintillation fluid. 
37 Uterotrophic activity in mice 
Female mice (20 days old) were used to determine 
the uterotrophic activity of the test compounds. Animals 
were administered various doses of the test compounds 
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subcutaneously (s.c.) in 0.2 ml of propylene glycol:saline 
(1:1 v/v) on three consequitive days. Autopsy was perform-
ed 24 hr after the last administration and the uteri were 
weighed after pressing the tissue "between the folds of a 
filter paper, to remove the intra-luminal fluid. 
Semilograthim plots were then constructed and the 
doses which producedfour fold increase in the uteri weight 
were computed from the graph. Relative uterotrophic 
activity was then computed as the per cent of reference 
compound (in the present case, estradiol-17p). 
"37 Uterotrophic activity in rats 
The procedure for the determination of uterotrophic 
activity was essentially the same as adopted for mice. In 
short, the animals in groups of six each were injected the 
test compounds subcutaneously in 0.5 ml of propylene glycol: 
saline (1:1 v/v) for three consequitive days. Autopsy was 
performed 24 hr after the last administration and uteri, 
blotted on filter paper, were weighed. Control animals 
received the vehicle only. 
The dose-response curves were constructed and 
doses which doubled the uterine weight were taken for the 
determination of the relative uterotrophic activity and 
expressed as percentage of estradiol-17(3. 
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Anti-implantation activity 
The compounds were tested for their antiimplantat-
ion activity in sperm positive female albino rats of proven 
fertility. The compounds were administered orally as 
suspension in gum acacia and fed from day 1 to 7 of preg-
nancy using five animals in each group. The animals were 
examined by leprotomy on.day 10 of pregnancy for the number 
of implants; control animals had an average of seven implants 
implants. The test also included antizygotic and early 
abortifacient activities. Results of the testing are given 
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2.4 C O N C L U S I O N 
It is a well accepted notion that the hormonal 
activity of estrogens and manifestations of the estrogen 
antagonists are mediated through the estrogen receptor. 
It is also well established that molecules which interact 
with the estrogen receptor have considerable diversity in 
21 their chemical structures . In view of this, it appears 
unlikely that compounds having grossly different molecular 
structures such as steroidal and stilbene estrogens on one 
hand and triarylethylene and related estrogens/antiestrogens 
on the other, could be accommodated on the estradiol site 
in an identical manner. It appears more likely that only 
some substructures common to these molecules, interact with 
a common region, with other features unique to a particular 
type of compound interacting with different regions of the 
receptor binding site. These differences in receptor bind-
ing may perhaps be causally related to the differences in 
the hormonal activity of various estrogenic prototypes. 
Since Ep and centchroman compete for binding with 
the estrogen receptor, a critical comparison of the receptor 
binding components of these molecules can reveal useful 
information about topography of the estrogen binding site 
and may also reveal the possible differences in their 
91 
receptor interaction. 
From the SAR studies carried out with Ep analogs 
and other estrogenic prototypes, such as stilbenes, doisy-
nolic acid, and related compounds, four distinct binding 
subsites on the estrogen receptor can be identified (Fig#4). 
These subsites may be arbitrarily designated as A, B, C_ and 
I), according to their proximity to various rings of estra-
diol. 
The ring A of Ep and the corresponding phenolic 
residue of DES and doisynolic acids having comparable bind-
12 31 32 38 39 ing specificity " ' ^  ' ^  ,v may be presumed to interact 
with the 'common subsite A. Since these residues are 
presumably involved in hydrogen bonding with the receptor 
site and are thus essential for high receptor affinity of 
estrogen. Molecules in which this phenolic group is 
protected or replaced by H have comparatively poor binding 
17 
affinities 
A hydrophobic subsite B may be implicated for the 
binding of ring B and portions around C, of E?. High 
receptor affinity of 7a-methyl E„ substantiates the presence 
39 
of such a subsite on the receptor^ . One of the ethyl 
groups of DES may be involved in binding to this subsite. 
The lower receptor affinity of DMS would appear to high-




A subsite 0, implicated in the binding of elements 
corresponding to C-,-,, 0-,2 and Glg of Ep, also appears to be 
essentially hydrophobic in nature. E? analog with methyl 
39 
group at C1? has high receptor affinity . The relevance 
of this subsite is further revealed by the importance of 
a,a'-dimethyl residue for the activity of allenoic acid 
and related compounds, which are totally lacking in the 
elements corresponding to ring C of estradiol. 
The subsite D involved in the binding of 17p-0H of 
Ep and the corresponding phenolic residues in stilbene 
estrogens and the C00H group of doisynolic acid analogs, 
also appears to be primarily a hydrogen bonding region 
like subsite A. Bp analogs with 17-0H group protected or 
replaced by H have poor receptor affinities ' . 
It may be concluded that due to the similarity 
in their chemical structure, typical estrogens such as E„, 
DES, hexestrol, phytoestrogens and seco-steroidal carboxy-
lic acids such as doisynolic acids can interact with a 
common binding site. Due to the importance of polar 
residues for their receptor binding and biological activity, 
and an essentially linear relationship between these 
residues, these molecules may be designated as 'linear 
bifunctional prototypes' (LBPs). This definition clearly 
distinguishes these compounds from those incorporating a 
triaryl-ethylene and -ethane or a gem,-diarylethylene moiety. 
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TAEs in general and centchroman in particular do not 
incorporate the essential characteristics of LBPs and yet 
some of these molecules, such as 7-hydroxy analog of 
centchroman, have comparatively high receptor affinities. 
This suggests that TAEs can differ from LBPs in receptor 
binding in some important respects. 
Most of the TAEs possess a well defined stilbene or 
dihydrostilbene core. This has often been argued to be 
31 
responsible for their binding with the estradiol site . 
However, as already pointed out most of the TAEs do not 
possess an appropriate polar group which could interact 
with the subsite D as in case of LBPs. The present study 
is an extension of the previous efforts in this Institute 
to study the receptor interaction of TAEs in comparison to 
the LBPs , which may form a basis for explanation of the 
difference in hormonal behaviour of compounds belonging to 
these diverse chemical categories. 
Studies with 7-hydroxy analog of centchroman substan-
tiate the presumption that the free phenolic group corres-
ponding to C--0H of Ep is essential for high receptor 
affinity of a molecule. The marked increase in binding 
affinity and uterotrophic potency of 7-hydroxy analog 6. as 
compared to centchroman and a similar observation with Ep 
and Ep-3-methyl ether would indicate that ring A of cent-
chroman (the methoxy benzene ring) might be involved in 
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binding with the subsite A. 
This observation along with the knowledge that C2~ 
methyl groups help in the binding affinity of centchroman 
and a similar effect observed with the methyl group in 
39 
7a-MeEp strongly suggests that rings A and B of cent-
chroman.i.e. the chroman nucleus and A, B rings of E„ bind 
with the receptor in an identical manner implicating the 
subsites A and B. 
The comparable binding affinity of 7-hydroxy analog 
of • centchroman and E?, in the absence of a polar group in 6, 
which could simulate 17-OH of Ep and interact with the sub-
site D, is thus noteworthy. The high binding affinity of 6 
is rationalized on the basis of its additional receptor 
interaction via p__-pyrrolidinoethoxyphenyl residue with an 
auxiliary binding subsite (Pig. 5) which is not involved 
in the binding of LBPs. This additional binding subsite 
is arbitrarily designated as E and its nature and importance 
in the biological activity of TAEs is discussed in the 
following pages. 
If it is presumed that the chroman nucleus in 
centchroman simulates the rings A, B of Ep on the receptor 
site, the C--phenyl residue in this molecule would be 
oriented towards subsite D, while the CL-aryl residue would 
be projected outside the general area of the Ep binding site, 
Moreover if centchroman and Ep are binding in an identical 
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ft - 0CH2CH2lQ 
FIG. 5 
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maimer, the absolute configuration of the more active anti-
pode of centchroman should he identical with the configu-
ration at Co and CQ in d-Ep. 
On the basis of GD studies it has been found that . 
the 1-isomer of centchroman has 3R> 4R absolute configura-
tion. If this isomer of centchroman is viewed along the 
projection in which its chroman nucleus is superimposed 
over A, B rings of E?, the C~ and C. protons in this isomer 
are {3 and a respectively. The identical configuration of 
d-estradiol at Cg and GQ is, therefore, noteworthy. This 
stereochemical identity appears to be an additional argument 
in favour of the hypothesis that the chroman nucleus in this 
molecule binds with the receptor in a manner identical with 
the rings A and B of estradiol-17(3, implicating the sub-
sites A and B. 
The pyrrolidinoethoxy residue is an important 
feature which contributes to the binding affinity of 
centchroman. Earlier studies from this laboratory have 
shown that removal of this side chain results in decreased 
receptor affinity as well as antiimplantation activity of 
centchroman . The present studies have now shown that the 
role of this chain in receptor affinity of centchroman is 
highly specific. Any alteration in its length or the 
substituents on nitrogen atom results in diminished activity 
of centchroman. Transposition of this side chain to other 
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positions has more pronounced influence on the activity of 
centchroman., Since its presence at p_ position of C.-phenyl, 
as in centchroman, is most important for high receptor 
affinity, the position of subsite E and its binding speci-
ficity appears to be defined. 
The fact that the incorporation of basic ether side 
chain or hydroxy group in the p_ position of C^-phenyl 
residue results in the increased estrogenicity of cent-' 
chroman, is noteworthy. This suggests that incorporation 
of a polar residue in centchroman, which simulates 17-OH 
in Ep can lead to potentiation of estrogenic activity of 
TAEs.. On this basis it may be pointed out that the estro-
genic activity associated with centchroman may be due to 
in vivo hydroxylation of G^-phenyl residue. This observa-
tion also indicates the role of appropriate subst'ituent 
binding to subsite E or D in the biological activity of the 
estrogenic prototypes. 
Thus on the basis of these arguments it may be 
postulated that centchroman and estradiol-17p interact 
with a common binding site on the receptor, albeit with 
subtle difference in their binding orientation. These 
differences may be responsible for the expression of the 
biological activities characteristic to the respective 
molecules. Perhaps, the 'atypical' activity of centchroman 
resides in its inability to simulate 17-OH of Ep and in:its 
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additional receptor interaction through the p_-pyrrolidino-
ethoxyphenyl residue with a region not implicated in bind-
ing of E». 
Thus 'typical' estrogens exemplified by Ep, DES 
and seco-steroid carboxylic acicfeon the basis of their 
linear relationship between two polar groups interacting 
with the subsites A and D are termed as LBPs, in the same 
way, 'atypical' estrogens, exemplified by TAEs and cent-
chroman on the basis of angular relationship between the 
two anchoring groups interacting with subsites A and E may 
be designated as 'angular bifunctional prototypes' (ABPs). 
This classification may have merit because it takes its 
basis in the important differences in the receptor inter-
action of respective molecular types, which may have a 
causal relationship with the hormonal properties unique to 
these molecules. 
Correlation between receptor interaction and 
biological activities 
SAR of estrogens may be rationalized on the premise 
that interaction with the receptor is an obligatory require-
ment for the expression of their estrogenic activities.. In 
principle, it should be possible to carry out this exercise 
' 'for the antiimplantation activity of estrogens as well. 
Paucity of the data do not permit such a rationalization 
at the present moment. A better appreciation of SAR. of 
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estrogens should, however, help in the identification of 
molecular prototypes which would be best suited as anti-
implantation agents, owing to their diminished hormonal as 
well as antihormonal activities. 
Interaction with the receptor is an essential but 
not the sufficient condition for the expression of optimal 
estrogenic activity. A good parallelism is observed between 
RBA and estrogenic potencies of LBPs, provided an allowance 
is made for the influence of pharmakokinetics on the acti-
12 
vity of some of these molecules . This is apparently not 
the case with ABPs. While some of these molecules are 
potent estrogens, there are some which are either sub-
optimal estrogens or have estrogenic potencies which are 
disproportionately poor as compared to their receptor 
affinities ' ' . 7-Hydroxy analog of centchroman (<5) is 
apparently one such notable example. The weak uterotrophic 
potency of this molecule could, in principle, result from 
its poor bioavailability at the target site. This is 
apparently not the case. In vivo receptor interaction 
Q 
studies in this laboratory have shown that 6, is very 
efficient in translocating cytosol receptor (Re) into the 
uterine nuclei and maintenance of high nuclear receptor (Rn) 
levels for prolonged periods. In this respect the 7-hydroxy 
analog 6_ is superior to centchroman as well as E~ in promot-
ing Rn binding. These findings may, therefore, be taken as 
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an argument that 6. has comparatively poor intrinsic activity 
than Bp. 
The correspondence between RBA and relative utero-
trophic potencies of centchroman and its 7-hydroxy analog 
(5 may lead to the deceptive conclusion that both these 
molecules are active per se. If centchroman is presumed 
to be a prohormonal form of its 7-hydroxy analog 6, one 
would expect these molecules to have nearly comparable 
estrogenic potencies. This discrepancy may be explained 
on the reasoning that presumably 6_ is the active estrogenic 
species in vivo, and is generated by demethylation of 
centchroman. However, administration of centchroman leads 
to poor bioavailability of 7-hydroxy analog 6_, because 1 
is only partly metabolised to 6, while rest of it is 
inactivated or cleared from circulation. This understand-
ing is based on the in vivo studies following administration 
of comparable doses of centchroman and its 7-hydroxy analog 
9 6. In these experiments centchroman produces comparatively 
delayed onset of nuclear receptor translocation which is an 
indication of rate limiting nature of the presumed demethy-
lating step,; resulting in its in vivo conversion to j6. 
Almost comparable RBA of Ep and 7-hydroxy analog of 
centchroman and the difference in their intrinsic activity 
is an indication that some property of a ligand other than 
its receptor affinity is important for estrogenic activity. 
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' Consideration of the receptor binding specificity of LBPs 
and ABPs may reveal the molecular basis for intrinsic 
activity of estrogens. 
A close correlation between interaction with the 
subsites A, B, C and D and high activity of LBPs would 
suggest a causal relationship between these two properties. 
Weaker intrinsic activity of ABPs may, therefore, be 
related with the inability of these molecules to engage 
receptor subsites A and D in simultaneous interaction, 
while their high affinity results from an additional inter-
action with the subsite E. This reasoning appears to be 
further justified by the observation with centchroman 
isomer in which the pyrrolidinoethoxy residue is trans-
posed to the p_ position of the phenyl residue at C~ as in 
50. This transposition resulted in potentiation of utero-
tropic activity of centchroman. Comparatively high estro-
genic activity of £0 despite its poorer receptor affinity 
than centchroman is, therefore, noteworthy. Increased 
estrogenicity associated with £0 may be due to the fact 
that in vivo deblocking of the side chain would result in 
the hydroxy compound which can interact with the subsite D 
and hence simulate the IBP pattern of receptor binding. 
This assumption appears to be supported by the fact that 
71, which is devoid of the side chain and possess a free 
OH instead, is equipotent to £0 in the uterotrophic assay. 
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On the basis of this important observation it may be 
surmised that metabolic intervention can have a profound 
influence on the estrogenic activity of ABPs. 
Metabolic deletion of the characteristic side 
chain from TAEs, which is known to be the case with 
tamoxifen, can compromise the ability of TAEs to interact 
with the subsite E. It is well known that deletion of this 
side chain changes the activity of TAEs from suboptimal 
uterotrophic activity to optimal uterotrophic activity 
Possible hydroxylation of the phenyl residue at Cp of the 
TAE can have particularly profound influence on their 
estrogenic activity by virtue of interaction of such 
metabolites with the subsite D. The intriguing obser-
vation that the hormonal activity of some of the TAEs such 
as clomiphene and tamoxifen isomers, are species 
specific ~ , may, therefore, be explainable on the 
grounds of differences in their metabolic disposition in 
different animal species. 
Although no in depth studies have been carried out 
on the SAR of antiestrogenic activity, it may be mentioned 
that centchroman is considerably less potent as an anti-
estrogen than nafoxidine. Although this difference in 
their activities could be modulated by metabolism, it is 
tempting to suggest that this property may also have a 
-causal relationship with the orientation of a molecule at 
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the receptor site. Potent antiuterotrophic activity of 
TAEs is apparently related to their interaction with the 
sutasite E. Centchroman and nafoxidine have comparable 
receptor affinities and yet they have important difference 
in the relative distribution of binding interaction with 
the different subsites. Compared to nafoxidine, centchro-
man has relatively weaker interaction with subsite E, 
apparently due to the difference in their geometries. On 
the other hand centchroman has comparatively more potent 
interaction with the subsite B through methyl residues 
at its Cp . It remains to be seen whether the difference 
in the activities of centchroman and nafoxidine is modula-
ted by this difference in their receptor binding. 
Finally, from the preceding discussion on SAB. 
it may be surmised that perhaps due to its characteristic 
binding specificity, centchroman is a weak estrogen, which 
does not display even potent antiestrogenic activity. This 
may be an important reason why centchroman is more suited 
as an antiimplantation agent than either potent estrogens 
like Ep or antiestrogens like nafoxidine. 
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2.5 E X P E R I M E N T A L 
The melt ing points were determined in an e l e c t r i c a l 
heated block (Townson and Mercer Ltd. Groyden, England) or 
i n sulphuric acid bath and are uncorrected. All the 
compounds were checked rou t ine ly for t h e i r s t r uc tu r e by IR 
on Perkin-Elmer 137, 157 or 177 model and are expressed in 
cm"" . The PMR spectra were recorded on Varian A-60D and 
R~32 spectrophotometers using TMS as i n t e r n a l s tandard. 
The chemical s h i f t values are expressed in 6 and J values 
i n Hz. Mass spect ra were recorded on Hitachi RMU-6E f i t t e d 
with a d i rec t i n l e t system and JMS-Jeol D300 ins t ruments . 
The CD spectrum was recorded on Dichrograph I I I - Jobin 
Yuon. The pu r i ty of compounds was rout ine ly checked by 
s i l i c a gel G- or bas i c /neu t r a l alumina TLC p l a t e s . 
d-3,4-trans-2,2-Dimethyl~3-phenyl-4-[p-(P~pyrrolidinoethoxy) 
phenyl-7-methoxychroman-di-p_-toluoyl-d-tartrate (2) 
dl-3,4~trans~2,2-Dimethyl~3-phenyl-4-[p~ ( p - p y r r o l i -
dinoethoxy)]phenyl-7-methoxychroman ( 1 , 457 mg, 1.0 mmol), 
di~p_~toluoyl~d-tartaric acid (193 mg, 0.5 mmol) and methanol 
(absolute) 30 ml were s t i r r e d for 2 hr a t room temperature. 
Methanol was evaporated off, the residue was s e l e c t i v e l y 
and repeatedly c rys t a l l i s ed to afford d-3.4~trans~2.2~ 
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dimethyl-3-phenyl-4-[n-(p-pyrrolidinoethoxy)]phenyl--7-
methoxychroman-di-p_-toluoyl-d-tartrate (2.) as white 
c r y s t a l l i n e so l id , y ie ld 150 mg (46$), m.p. 138 ; [ a ] D 
+117.2° (c , 1.0 in CHC1,). 
d-3,4-trans_-2,2-Dimethyl-3-phenyl-4-[p_""( P-pyr ro l id ino-
ethoxy)]phenyl-7-methoxychroman Q ) 
The d - sa l t (2_) was hydrolysed by taking i t i n 
chloroform and t r e a t i n g with d i l u t e aqueous a l k a l i . The 
organic l aye r was washed with water to n e u t r a l , dried over 
anhyd. sodium sulphate and concentrated to y i e l d d.~3»4-
;trans-2,2-dimethyl-3~phenyl-4-[p_-( p-pyrrolidinoethoxy) ] 
phenyl-7-methoxychroman (;5), m.p, (as hydrochloride s a l t ) 
197°; [a]^° +192.9° (c, 1.0 in OHCl^. 
l~3,4-trans-2,2-Dimethyl-3-phenyl-4-[p_-(P-pyrrolidinoethoxy) ] 
phenyl-7-methoxychroman-di-p_-toluoyl-l-t art rate monohydrate 
_ - . . _ . _ 
dl-3,4-trans-2,2-Dimethyl-3-phenyl-4-[p_-( p -
pyrrolidinoethoxy)]phenyl-7-methoxychroman ( 1 , 457 mg, 
1.0 mmol) and d i -p_- to luoy l - l - t a r t a r i c acid monohydrate 
(202 mg, 0.05 mmol) were taken i n methanol (absolute) 30 ml 
and s t i r r e d for 2 h r . Methanol was then evaporated off and 
the spongy res idue was s e l ec t i ve ly and repeatedly c rys t a -
l l i s e d to give l -3 .4 - t r ans -2 .2 -d ime thy l -3 -pheny l -4 - rp - (3 -
pyrrolidinoethoxy)]phenyl-7-methoxychroman-di-p_ i-toluoyl-l-
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t a r t r a t e monohydrate, y i e l d 135 mg (40%), m.p . 120 ; [ a ] D 
-117.-2° (o , 1.0 i n CHCl^). 
A n a l y s i s : Found: C, 7 0 . 0 9 ; H, 6.16 
G 5 0H 5 5N0 1 2 R e q u i r e s : C, 69 .68 ; E, 6,52$. 
1 - 3 » 4 - t r a n s - 2 , 2 - D i m e t h y l - 3 ~ P h e n y l - 4 ~ [ p - ( g - p y r r o l i d i n o e t h o x y ) ] 
phenyl-7-rnethoxychroman (£,) 
1 - 3 , 4 - t r a n s - 2 , 2 - D i m e t h y l - 3 - p h e n y l - 4 - [ R - ( P - p y r r o l i -
d ine ethoxy) ]phenyl -7-methoxychroman-d i -p_- to luoyl - l - t a r t r a t e 
monohydrate (4) was hydro lysed as desc r ibed f o r 2_ t o a f fo rd 
1 . - 3 . 4 - t r a n s - 2 , 2 - d i m e t h y l - 3 - p h e n y l - 4 - r p ~ ( 0 - p y r r o l i d i n o e t h o x y ) ] 
phenyl-7-methoxychroman (5.), m.p. ( a s h y d r o c h l o r i d e s a l t ) 
1 9 7 ° ; [a]^°- - 192 .9° ( c , 1.0 i n CHC1 ) . 
3 , 4 - t r ans -2 ,2-Dime thy l -3 -pheny l -4 - [p_ - ( p - p y r r o l i d i n o e t h o x y ) ] 
phenyl-7-hydroxychroman (6) 
3 ,4 - t r ans -2 ,2 -Dime thy l -3 -pheny l -4 - [p_ - ( p - p y r r o l i d i n o -
ethoxy)]phenyl-7-methoxychroman ( 1 , 4.57 g, 0 . 0 1 mol) and 
f i n e l y powdered potass ium hydroxide (12.8 g, 0 .22 mol) were 
t a k e n i n d i e t h y l e n e g l y c o l (120 m l ) , hydraz ine h y d r a t e (1 .0 
ml) was added t o i t and t h e r e a c t i o n mix tu re was hea t ed a t 
240 f o r 30 min. under dry n i t r o g e n a tmosphere , cooled and 
poured over sodium d i t h i o n a t e s o l u t i o n ( 1 . 4 g i n 1600 ml 
HpO), a c i d i f i e d with minimum amount of cone. HC1. So l id 
t h u s s e p a r a t e d out was c o l l e c t e d th rough f i l t r a t i o n , d r i e d 
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and purified by column chromatography (basic alumina; 1% 
MeOH-CHCl,), yield 1.1 g (25$), m.p. 296°; M+ m/e 443. 
IR (KBr)j 3300, 2900 and 1600. 
PMR (DMSO-dg): 1.12 (s, 3H, CHj, 1.25 (s, 3H, CH-), 1.65 
(m, 4H, 20H2) , 2 .5 (m, 4H, 2NCH2), 2 .71 ( t , 
2H, KCH2, J = 6 ) , 3.26 (d, 1H, PhCH, J = 1 3 ) , 
3 .94 ( t , 2H, 00H2 , J = 6 ) , 4 .45 (d , 1H, 
PhCHPh, J = 13) and around 6 .3 - 7 .3 (m, 
12H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: C, 7 8 . 5 5 ; H, 7 .50 ; N, 3.17 
C ^ H ^ N O - R e q u i r e s : C, 7 8 . 7 7 ; H, 7 . 6 5 ; N, 3 .06$ . 
3 , 4 - t r a n s - 2 , 2 - D i m e t h y l - 3 - p h e n y l - 4 - (p_-hydroxy ) p h e n y l - 7 -
methoxychroman (2) 
j • 4 — t r a n s - 2 ,2~Dimethyl -3-phenyl -4- (p-hydroxy)phenyl~ 
7-methoxychroman (7.) was ob ta ined from the r e a c t i o n mixture 
of 6_, y i e l d 25$, m.p . 264° . 
IR (EBr): 3300, 2900 and 1610. 
PMR (DMSO-dg): 1.19 ( s , 3H, CH-J, 1.29 ( s , 3H, CH-), 
3.22 (d, 1H, PhCH, J = 1 2 . 5 ) , 3 .67 ( s , 3H, 
0CH-), 4.37 (d , 1H, PhCHPh, J = 12 .5 ) and 
around 6.2 - 7.20 (m, 12H, a romat ic p r o t o n s ) . 
3 .4 - t r ans -2 ,2 -Dime th .v l -3 -phen ,v l -4 - (p -hydroxy)pheny l -7 -
hydroxychroman (8) 
The t i t l e compound was i s o l a t e d from the mix tu re of 
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products obtained in the above experiment and has been 
characterized on the basis of PMR spectrum, yield 10$, 
m.p. 282°. 
IR (EBr): 3350, 2850 and 1600. 
PMR (0D013 + DMSO-dg): 1.1 (s, 3H, CEL), 1.23 (s, 3H, GHj), 
3.85 (d, 1H, PhCH, J = 12) , 4 .1 (d, 1H, 
PhCph, J = 12) and around 6.1 - 7.2 (m, 
12HS aromatic p ro tons ) . 
3 ,4-cis-2,2-Dimethyl-3-phenyl-4- (p_-benzyloxy )phenyl-7-
raethoxychroman (10) 
3,4-cis-2,2-Dimethyl-3-phenyl-4~(p_-hydroxy)phenyl-
7-methoxychroman (9, 21.6 g, 0.06 mol), benzyl chloride 
(7.59 g, 0.06 mol) and potassium carbonate (anhyd.) 50 g 
were taken in dry acetone (300 ml) . The reac t ion mixture 
was refluxed for 35 hr , cooled and f i l t e r e d . Acetone was 
d i s t i l l e d off and the res idua l o i l was taken in ethyl 
ace t a t e (200 ml) and washed with water to n e u t r a l . The 
organic layer was dried over anhyd. sodium sulphate and 
concentrated. 3,4~cis-2,2-Dimethyl-3-pkenyl-4-(p_-benzyloxy) 
phenyl-7-methoxychroman (lp_) thus obtained was c rys t a l l i zed 
with benzene-hexane, y ie ld 20.5 g (80$), m.p. 114°. 
IR (KBr): 2950 and 1610. 
PMR (CC14): 1.1 ( s , 3H, CH-), 1.49 ( s , 3H, CH^), 2.72 
(d, IB, PhCH, J = 6) , 3.63 ( s , 3H, OCHj, 
4.42 (d, 1H, PhCHPh, J = 6) , 4.76 ( s , 2H, 
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0CH2Ph) and around 6.1 - 7.1 (m, 17H, 
aromatic protons). 
Analysis Pound: 0, 82.65; H, 7.06 




7-methoxychroman (10_, 15 g) was dissolved in dry DM SO (200 
ml). The whole assembly was evacuated by using suction pump 
and dry nitrogen was flushed in. n-Butyl-lithium (50 ml, 
20$ solution in hexane) was gradually added, the reaction 
mixture turned pink. It was then left at room temperature 
for 16 hr, decomposed with water, solid thus separated out 
was collected through filtration and crystallized with 
benzene-hexane, yield 14 g (95$), m.p. 149°. 
IR (KBr): 2900 and 1610. 
PMR (CC14): 1.13 (s, 3H, C H j , 1.29 (s, 3H, CH^), 3.02 
(d, 1H, PhCH, J = 12), 3.6 (s, 3H, OCH,), 
4.16 (d, 1H, PhCHPh, J = 12), 4.7 (s, 2H, 
OCHpPh) and 6.1 - 7.1 (m, 17H, aromatic 
protons). 
Analysis Found: C, 82.35; H, 6.92 
^31^30^3 Requires: G, 82.66; H, 6. 
I'll 
3 , 4 - t r a n s - 2 , 2 - D i m e t h y l - 3 - p h e n y l - 4 - (pj-hydroxy) phenyl - 7 -
methoxychroman (12) 
3 > 4- t rans-2 ,2-Dimethyl-3-*phenyl-4-(E. -benzyloxy) 
phenyl-7-methoxychroman ( 1 1 , 4 g) was debenzyla ted by 
hydrogena t ion over Raney-Ni (2 g) a t 60 p s i hydrogen 
p r e s s u r e i n methanol (100 ml) f o r 8 h r . C a t a l y s t was 
removed by f i l t e r i n g the c o n t e n t s th rough hy f lo s u p e r c e l , 
concen t r a t ed and c r y s t a l l i z e d wi th THF-benzene, y i e l d 3 g 
( 9 3 # ) , m.p.- 264° . 
IR (EBr) : 3300, 2900 and 1610. 
PMR (DMS0-d6): 1.19 ( s , 3H, CH J , 1.29 ( s , 3H, CP^), 3.22 
(d , 1H, PhCH, J = 1 2 . 5 ) , 3.67 ( s , 3H, 0CH-), 
4 .37 (d , 1H, PhCKPh, J = 12 .5 ) and around 
6.2 - 7.2 (m, 12H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: G, 8 0 . 1 0 ; H, 6.64 
C24H24°3 R e q u i r e s : G, 8 0 . 0 0 ; H, 6 .66$ . 
314- t rans-*2,2-Dimethyl-3-phenyl-4-[p_-(p-die thylaminoethoxy.) j 
phenyl-7-methoxychroman h y d r o c h l o r i d e (13) 
A mix tu re of 3 » 4 - t r a n s - 2 , 2 - d i m e t h y l - 3 - p h e n y l ~ 4 - ( p -
hydroxy)phenyl-7-methoxychroman (12, 900 mg, 2.5 mmol), 
N , N ' - d i e t h y l a m i n o e t h y l c h l o r i d e h y d r o c h l o r i d e (427 .5 mg, 
2 .5 mmol), anhyd. potass ium ca rbona te (8 g) and dry acetone 
(60 ml) were r e f l u x e d f o r 14 h r , cooled and f i l t e r e d . 
Acetone was t h e n d i s t i l l e d off and the r e s i d u a l o i l was 
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t a k e n i n e t h y l a c e t a t e , washed wi th wa te r , d r i ed over 
anhyd. sodium s u l p h a t e and c o n c e n t r a t e d . The o i l y r e s i d u e 
was p u r i f i e d by f i l t r a t i o n th rough b a s i c a lumina (benzene) 
t o give 3 , 4 ~ t r a n B ~ 2 , 2 - d i m e t h y l - 3 - p h e n y l - 4 - [ £ - ( p - d i e t h y l -
aminoethoxy)]phenyl-7-methoxychroman (800 mg). I t was 
conver ted to i t s cor responding h y d r o c h l o r i d e s a l t , m.p. 163 . 
IR (KBr): 3300, 2950 and 1610. 
1.06 ( t , 6H, 2CH,, J = 7 . 8 ) , 1.16 ( s , 3H, 
0H 5 ) , 1.3 ( s , 3H, CH5h 2.72 (bh, 6H, 3NCH2), 
3.06 (d , 1H, PhCH, J = 1 2 ) , 3 .63 ( s , 3H, 
0CH-), 3.95 (bh, 2H, 0CH2), 4 .21 (d , 1H,< 
PhCHPh, J = 12) and 6.15 - 7.0 (m, 12H, 
a romat ic p r o t o n s ) . 
Pound: C, 72 .90 ; H, 7 . 9 3 ; N, 2 .78 
Requ i r e s : C, 7 2 . 6 5 ; H, 7 . 66 ; N, 2 .82^ . 
PMR (0D01-): 
Ana lys i s 
30 3o 3 
3 ? 4 - t r ans -2 ,2 -Dime thy l -3 -pheny l~4 - rp - (3 -d ime thy laminoe thoxy) J 
phenyl-7-methoxychroman h y d r o c h l o r i d e (14) 
3 $ 4 - t r an s -2 ,2 -D ime thy l -3 -pheny l -4 - [p . - ( P -d ime thy l -
aminoethoxy)]phenyl-7-methoxychroman was p r e p a r e d as d e s c r i -
bed f o r 12 u s i n g p-d imethylaminoethyl c h l o r i d e h y d r o c h l o r i d e . 
I t was conver ted t o i t s cor responding h y d r o c h l o r i d e s a l t , 
m.p . 218° . 
IR (KBr): 3350, 2900 and 1610. 
PMR (CDC1-): 1.15 ( s , 3H, CH^), 1.29 ( s , 3H, C g 5 ) , 2.28 
( s , 6H, 2NCH-), 2 .67 ( t , 2H, NCH2, J = 4 ) , 
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3.06 (d, 1H, PhCH, J = 12), 3.62 (s, 3H, 
0CH-), 3.88 (t, 2H, 0CH2, J = 4), 4.19 
(d, IE, PhCHPh, J = 12) and 6.15 - 7.10 
(m, 12H, aromatic protons). 
Pound: G, 71.55; H, 7.12; N, 2.89 
Requires: C, 71.27; H, 7.27; Nf 2.99$. 
3 ,4 - t r ans~2 ,2 -Dime thy l -3~pheny l -4 - [p_ - (P -d ie thy lamino-
Analys i s 
C28H34N05C1 
propoxy)]phenyl-7-methoxychroman hyd roch lo r ide (15) 
3 > 4- t rans- -2 > 2-Dimethyl - -3-phenyl~4- [p- - (P-d ie thy l -
aninopropoxy)jphenyl-7-methoxychroman was p repa red as 
d e s c r i b e d f o r 12. u s i n g N ,N ' -d i e thy l aminop ropy l c h l o r i d e 
h y d r o c h l o r i d e . Converted t o t h e cor responding hyd roch lo r ide 
s a l t , m.p. 215° . 
IE (KBr): 3350, 2950 and 1610. 
1.05 (m, 8H, 2CH, and CH2), 1.18 ( s , 3H, 
CH^), 1.30 ( s , 3H, OH,), 2.70 (bh, 6H, 
3NGH2), 3.07 (d , 1H, PhCH, J = 1 2 ) , 3 .68 
( s , 3H, OCH^), 3.92 (bh, 2H, 0CH_2), 4.23 
(d , 1H, PhCHPh, J = 12) and 6.19 - 7.02 
(m, 12H, a romat ic p r o t o n s ) . 
Found: C, 73.20-; H, 7 . 6 2 ; N, 2 .84 
R e q u i r e s : C, 7 3 . 0 1 ; H, 7 . 8 5 ; N, 2 . 7 4 $ . fj 
PMR (CDG1-): 
Ana lys i s 
31\^41 3 - /*/) 
2J3 ' -Dihydroxy-4-iaethoxybenzophenone (16) 
A mix tu re of m-methoxyphenol (12 .4 g, 0 . 1 mo l ) , 
m-hydroxybenzoic ac id (13 .8 g, 0 . 1 mol) and s t a n n i c oh lo r id t 
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(100 ml) was refluxed for 8 hr, cooled and poured over 
crushed ice (500 g) , extracted with ethyl acetate. The 
organic layer was washed x^ ith sodium bicarbonate solution 
and then with water to neutral. Dried over anhyd. sodium 
sulphate and concentrated. Purified by column chromato-





Ana lys i s 
C14H12°4 
3400, 1620 and 1580. 
3.75 ( s , -3H, OCHj and 6.2 - 7 .4 (m, 7H, 
a r o m a t i c ) . 
Pound: 0, 69 .10 ; H, 5.06 
Requ i r e s : C, 6 8 . 8 5 ; H, 4 .91# . 
3~Phenyl-4-(m-acetoxyphenyl)-7-methoxycoumarin (17) 
A s o l u t i o n of 2,3 ,*-dihydroxy-4-methoxybenzophenone 
(16_, 10 .7 g, 0 .043 mol) and p h e n y l a c e t i c a c i d ( 5 . 8 4 g, 
0 .043 mol) i n a c e t i c anhydr ide (20 ml) and t r i e t h y l a m i n e 
(9 ml) was r e f luxed under anhydrous c o n d i t i o n s f o r 10 h r . 
The r e a c t i o n mix ture was d i l u t e d wi th e t h a n o l and s o l i d t h u s 
s e p a r a t e d was c o l l e c t e d th rough f i l t r a t i o n , washed thorough-
l y w i t h e t h a n o l and c r y s t a l l i z e d from benzene-hexane , y i e l d 
13 .5 g (81jg), m.p . 149° . 
IR (KBr): 1770, 1710 and 1600. 
2 .16 ( s , 3H, OCOCHj, 3.76 ( s , 3H, 0CH-) 
and 6.5 - 7 .2 (m, 12H, a roma t i c p r o t o n s ) . 
Pound: G, 74 .50 ; H, 4 .84 
Requ i r e s : C, 7 4 . 6 1 ; H, 4 . 6 6 $ . 
PMR (CDClJ 





To a s t i r r e d s o l u t i o n of methyl magnesium i o d i d e , 
p repa red from 27.97 g of methyl i o d i d e (0 .197 mol) and 
4 .74 g of magnesium (0.197 g atom) i n dry e t h e r (200 m l ) , 
was added dropwise a s o l u t i o n of 3~phenyl-4-(ni-acetoxy) 
phenyl-7-methoxycoumarin (17_, 13 g, 0 .033 mol) i n dry THP 
(250 m l ) . The r e a c t i o n mix tu re was r e f l u x e d f o r 4 h r , 
cooled and decomposed wi th minimum amount of cone . HC1. 
THF was d i s t i l l e d off and t h e r e s i d u a l o i l was t aken i n 
e t h y l a c e t a t e , washed wi th wa te r to n e u t r a l , d r i e d over 
anhyd. sodium s u l p h a t e and c o n c e n t r a t e d . P u r i f i e d by column 
chromatography ( s i l i c a g e l , 1% EtOAc-benzene), y i e l d 6 g 
( 5 1 # ) , m.p. 1 8 4 ° . 
IE. (KBr): 3350, 2950 and 1605. 
PMH ( C D C l J : 1.38 ( s , 6H, 2CH,), 3 .21 (nh, 1H, OH), 
3 .61 ( s , 3H, OCH,) and 6 .1 - 7 . 1 (m, 12H, 
a romat ic p r o t o n s ) . 
Ana lys i s Found: C, 8 0 . 6 0 ; H, 6.10 
C24H22°3 Requ i r e s : C, 8 0 . 4 4 ; H, 6 .14$ . 
2 , 2 - D i m e t h y l - 3 - p h e n y l - 4 - [ m - ( p - p y r r o l i d i n o e t h o x y ) ] p h e n y l - 7 -
methoxychromene (19) 
The t i t l e compound was p repared by a l k y l a t i o n of 18 
wi th p - p y r r o l i d i n o e t h y l c h l o r i d e hyd roch lo r ide as d e s c r i b e d 
f ° r i 2 . The o i l y product was converted t o the h y d r o c h l o r i d e 
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s a l t which c r y s t a l l i z e d from a b s o l u t e e t h a n o l - d r y e t h e r as 
a c o l o u r l e s s amorphous s o l i d , y i e l d 64 .2$ , m.p . 179 . 
IR (KBr): 3400, 2900 and 1600. 
PMR (CDGl.,)i 1.45 ( s , 6H, 2CH-), 1.8 ( b s , 4H, 2CH2), 
2 .68 ( b s , 4H, 2NCH2), 2 .85 ( t , 2H, NCg2, 
J = 4 . 5 ) , 3.78 ( s , 3H, 0GH5), 3 .99 ( t , 2H, 
00H2 , J = 4 .5) and 6.3 - 7.15 (m, 12H," 
a romat ic p r o t o n s ) . 
Ana lys i s Found-. 0, 7 3 . 3 5 ; H, 7 . 2 1 ; N, 2.62 
C ^ H ^ J K ^ C l Requ i r e s : 0, 73 .24 ; H, 6 . 9 1 ; N, 2^84$. 
3 ,4 -c i s -2 ,2 -Dime thy l -3 -pheny l -4 - (m-hydroxy)pheny l -7 -me thoxy-
chroman (20) 
2,2-Dimethyl~3--phenyl-4-(m-hydroxy)phenyl-7-methoxy-
chromene (18, 100 mg) was hydrogenated over 10$ Pd~C (50 mg) 
in methanol at 60 psi hydrogen pressure for 8 hr. The 
catalyst was removed by filtration through hyflo supercel 
and the filtrate concentrated, solid thus obtained was cry-
stallized from benzene-hexane, yield 90 mg (90$), m.p. 178 •. 
IR (KBr); 3400, 2900 and 1600. 
PMR (CDC1, + DMS0-d6); 1.11 (s, 3H, C H j , 1.52 (s, 3H, CHj, 
2 .9 (d , 1H, PhCH, J = 7 ) , 3 .78 ( s , 3H, O C H j , 
4 .59 (d , 1H, P h C p h , J = 7) and 6.2 - 7.05 
(m, 12H, a roma t i c p r o t o n s ) . 
Ana lys i s Found: G, 8 0 . 0 0 ; H, 6.76 
C24H24°3 R e q u i r e s : C, 8 0 . 0 0 ; H, 6 .66$ . 
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3 , 4 - c i s - 2 , 2 - D i m e t h y l - 3 - p h e n y l - 4 ~ [ m - ( ( 3 - p y r r o l i d i n o e t h o x y ) ] 
phenyl-7-methoxychroman (21) 
A l k y l a t i o n of chroman 20 wi th p - p y r r o l i d i n o e t h y l 
c h l o r i d e h y d r o c h l o r i d e as de sc r ibed f o r 12. gave 3 , 4 - c i s ~ 
2 , 2 - d i m e t h y l - 3 - p h e n y l - 4 - [ m - ( p - p y r r o l i d i n o e t h o x y ) ] p h e n y l - 7 -
methoxychroman (21) i n 74 .3$ y i e l d , conver ted to i t s 
h y d r o c h l o r i d e s a l t which c r y s t a l l i z e d from a b s o l u t e e t h a n o l -
dry e t h e r , m.p. 153° . 
IR (KBr): 3350, 2900 and 1610. 
PMR (CDC15): 1.13 ( s , 3H, CH-), 1.5 ( s , 3H, CH^), 1.70. 
(m, 4H, 2CH2), 2 .46 (in, 4H, 2NCH2), 2 .62 ( t , 
2H, N0H2, J = 6 . 5 ) , 2 .81 (d , 1H, PhCH, J = 
7 ) , 3.55 ( t , 2H, 0CH2, J = 6 . 5 ) , 3 .7 ( s , 3H, 
0GH3), 4.52 ( d , 1H, PhOph , J - 7) and 6.2 -
7.0 (m, 12H, a roma t i c p r o t o n s ) . 
Ana lys i s Pound: C, 72.55? H, 7 . 6 3 ; - N, 2 .62 
05OH5fiNO5Cl Requ i r e s : C, 72.90* H, 7 . 2 9 ; N, 2 . 8 3 $ . 
3 »4- t r a r i s_ -2 ,2 -Dimethy l -3 -pheny l -4 - [m-(p -pyr ro l id inoe thoxy) j 
phenyl-7-methoxychroman (,22,) 
ci_s-Ghroman (21) was i somer ized to t h e cor responding 
t r a n s - i s o m e r as desc r ibed f o r 1 1 . Thus 3 » 4 - t r a n s - 2 , 2 ~ 
dimethyl-3-phenyl~4-[m~( {3-pyrrol id inoethoxy) ]pheny l~7-
m.ethoxychroman (22) was ob ta ined a s o i l which was conver ted 
t o i t s h y d r o c h l o r i d e s a l t , c r y s t a l l i z e d from a b s o l u t e 
e t h a n o l - d r y e t h e r , y i e l d 80$, m.p . 181° . 
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Analysis 
30 36 3 
IR (KBr): 3250, 2900 and 1600. 
PMR (CDClJ: 1.11 (s, 3H, CH3), 1.25 (s, 3H, CH,), 1.65 
(m, 4H, 20H 2 ) , 2 .42 (m, 4H, 2NCH2), 2 .63 
( t , 2H, NCH2, J = 6 ) , 3.07 (d, 1H, PhCH, 
, J = 1 2 ) , 3 .6 ( s , 3H, 0CH-), 3 .78 ( t , 2H, 
- 0CH2, J = 6 ) , 4 .19 (d, 1H, PhCKPh, J = 12) 
and 6 .1 - 6 .9 (m, 12H, a roma t i c p r o t o n s ) . 
Pound: 0 , 7 2 . 6 2 ; H, 7 . 5 2 ; N, 2.46 
R e q u i r e s : G, 72 .90 ; H, 7 . 2 9 ; Nf. 2 .80$ . 
2 , 2 ' ~Dihydroxy-4-methoxvbenzophenone (23) 
m-Methoxyphenol (12 .4 g, 0 . 1 mol) and s a l i c y l i c 
a c i d (13 .8 g, 0 . 1 mol) were added t o PPA (p repa red from 
24 g H,P0 . and 40 g phosphorous pen ta oxide) and the 
r e a c t i o n mix tu re was hea ted over a wate r ba th (80 ) f o r 
40 rain, decomposed wi th i c e cold wate r and e x t r a c t e d wi th 
e t h y l a c e t a t e . The o rgan ic l a y e r was washed w i t h sodium 
b i c a r b o n a t e s o l u t i o n and t hen wi th wate r to n e u t r a l , d r i ed 
over anhyd. sodium s u l p h a t e and c o n c e n t r a t e d , chromatogra-
phed over s i l i c a ge l (25$ hexane-benzene) , y i e l d 4 .7 g (20$),-
m.p. 71°. 
IR (KBr): 3000, 1620 and 1590. 
3 .7 ( s , 3H-, OCH*) and 6.15 (m, 7H, a romat ic 
p r o t o n s ) . 
Pound: C, 69 .10 ; H, 5 . 2 1 . 
R e q u i r e s : C, 6 8 . 8 5 ; H, 4 .91$ . 
PMR (CDClJ 3 
Ana lys i s 
G14H12°4 
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3-Phenyi-4-(p_-acetoxy)phenyl-7-methoxycoumarin (2J>) and 
3-Phenyl -4- (2-ace toxy-4-methoxy)phenylcoumar in (28) 
Condensat ion of benzophenone 2^. wi th p h e n y l a c e t i c 
a c i d i n a c e t i c anhydride and t r i e t h y l a m i n e as d e s c r i b e d fo r 
17 gave t h e i s o m e r i c mix ture of 3-phenyl-4-(p . -"acetoxy)phenyl-
7-methoxycoumarin (2£) and 3 -pheny l -4 - (2 -ace toxy-4-methoxy) 
phenylcoumarin (.28) i n 81$ y i e l d , m.p. 218° . 
IR (KBr): 1760, 1700, 1610 and 1590. 
PMR (CDC1-): 1.88 and 1.91 " ( s , 3H, 0C0CH-), 3 .7 and 3.8 
( s , 3H, 0CH-)- and 6.6 - 7 .4 (in, 12H, aroma-
t i c p r o t o n s ) • 
Ana lys i s Found: C, 74.65J H, 5.04 
G24H18°5 Requ i r e s : C, 7 4 . 6 1 ; H, A,66%. 
3-Phenyl-4-(p_-hydroxy)phenyl-7-methoxycoumarin {2±) and 
3-phenyl -4- (2-hydroxy-4-methoxy)phenylcoumar in (27j 
The i s o m e r i c mix ture of acetoxycoumarins (2£ and 
28 , 0.386 g, 1.0 mmol), sodium hydroxide ( 0 . 4 g, 10 mmol) 
and e thano l (30 ml) were r e f l u x e d fo r 1 h r , e t h a n o l was 
t h e n evapora ted off and t h e r e s i d u e was d i l u t e d wi th wa t e r , 
a c i d i f i e d wi th cone. HC1. So l id t h u s s e p a r a t e d was c o l l e c t e d 
th rough f i l t r a t i o n and d r i e d . C r y s t a l l i z e d w i t h benzene-
e t h y l a c e t a t e , y i e l d 0.282 g (81$ ) , m.p. 2 0 7 ° . 
IR (KBr):.-' 3290, 1690, 1680 and 1600. 
PMR (DMS0-d6): 3 .63 ( s , 3H, 0CH-), 3.80 ( s , 3H, OC&J and 
6 .18-7 .45 (m, 12H, a roma t i c p r o t o n s ) . 
Analysis Found; G-, 76.53; H, 4.76 
G22H16°4 Requires: C, 76.74? H, 4.65#. 
3-*Phenyl-4-[ o-( 4-nitrobenzoyl) oxy]phenyl-7-methoxycoumarin 
(26) and 3-Phenyl-4-[2-(p_-nitrobenzoyl)oxy-4-methoxy] 
phenylcoumarin (29) 
A mixture of hydroxycoumarins 2,4 and ZJ_ (0.172 g, 
0.05 mmol), p_-nitro benzoyl chloride (0.185 mg, 1.0 mmol) 
and dry pyridine (5 ml) were heated on a'water bath (80 ) 
for 2 hr. Pyridine was evaporated off and residue was 
diluted with water, extracted with ethyl acetate. The 
organic layer was washed with dilute acetic acid and then 
with water to neutral, dried over anhyd. sodium sulphate 
and concentrated. Crystallized with benzene-hexane, nup. 
184°. 
IR (KBr): 3400, 1730, 1705 and 1600, 
PMR (CC14 + DMS0-d6): 3.76 (s, 3H, 0GH-), 3.80 (s, 3H, 
0CH3), 6.82-7.35 (m, 12H, aromatic protons) 
and 7.83-8.28 (m, 4H, aromatic protons). 
Analysis Pound: C, 70.72; H, 4.04; N, 2.56 
G29H19N07 Requires: C, 70.58; H, 3.85; N, 2.85$. 
cis.- and trans-2-Methyl-3-phenyl-4-(o-h.vdroxy)phenyl-4-
(2-hydroxy-4-methoxy)phenyl-but-3,4-ene-2-ols (20. and 21) 
The isomeric mixture of acetoxycoumarins 2£ and 28 
was reacted with Grignard reagent (MeMgl) as described for 
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1 8 . The u s u a l work up af forded c i s - and t r ans -2 - -me thy l -
3 -pheny l -4 - (£ -hydroxy)pheny l -4 - (2 -hydroxy-4~methoxy)pheny l -
b u t - 3 » 4 - e n e - 2 - o l s (2Q. and 21) which could n o t be p u r i f i e d , 
y i e l d 59%, m.p . 97° . 
IR (KBr): 3400, 2950 and 1600, 
PMR (CDC15 + DMSO-dg): 1.2 ( s , 6H, 2CH3), 3.60 ( s , 3H, 
O C H j , 4.65 (bh, 2H, 2 OH) and 6 . 2 5 - 7 . 2 1 
(m, 12H, a roma t i c p r o t o n s ) . 
.Analysis Found: 0 , 7 6 . 3 6 ; H, 6.62 
G24H24°4 Requ i r e s : C, 76 .59 ; H, 6 .35# . 
2 ,2 -Dime thy l -3 -pheny l -4 - (o -hydroxy)pheny l -7 -me thoxy-
chromene (32) 
c i s - and t r ans -2 -Methy l -3 -pheny l~4- (o -hydroxy) 
pheny l -4 - (2 -hyd roxy -4 -me thoxy )pheny l -bu t -3 , 4 - e n e - 2 - o l s 
(20 and 21) ( 1 . 2 g) was taken i n e t h a n o l i c HC1 (30 m l ) . 
The mix tu re was r e f luxed f o r 30 min. E thanol was then 
evapora ted off and r e s i d u e was p u r i f i e d by column chromato-
graphy ( s i l i c a g e l , benzene) , y i e l d 1.0 g ( 8 7 $ ) , m.p . 196° . 
IR (KBr): 3450, 2950 and 1600. 
PMR (CDC13): 1.41 ( s , 3H, C H j , 1.49 ( s , 3H, C H j , 3 .6 
( s , 3H, 0CH-) and 6 . 1 - 6 . 9 (m, 12H, a romat ic 
p r o t o n s ) . 
Ana lys i s Found: C, 8 0 . 6 0 ; H, 6,10 




A mixture of chromene (22., 100 mg), acetic anhydride 
(2.5 ml) and dry pyridine (1.0 ml) was heated over water 
bath (80°) for 30 min. Pyridine was evaporated off in 
vacuum and residue was decomposed with water, extracted 
with ethyl acetate. The organic layer was washed with 
sodium bicarbonate solution and then with water to neutral, 
dried over anhyd. sodium sulphate and concentrated. 
Crystallized from ethanol, yield 90 mg (81$), m.p. 106°. 
IR (KBr): 2900, 1750 and 1610. 
PMR (0D015): 1.405 (s, 6H, 2CH-), 1.92 (s, 3H, OCOGH^), 
3.68 ( s , 3H, OCHj and 6 .15 -6 .95 (m, 12H, 
a romat ic p r o t o n s ) . 
2 ,2-Dimethyl -3-phenyl -4- (2-methoxy)p 'henyl -7-methoxy-
chromene (21) -
2,2-Dimethyl-3-phenyl-4-(o_-hydroxy)phenyl-7-methoxy-
chromene (22.) was a l k y l a t e d a s de sc r ibed f o r 12 u s i n g methyl 
i o d i d e t o g ive 2 , 2 - d i m e t h y l - 3 - p h e n y l - 4 - ( o - m e t h o x y ) p h e n y l - 7 -
methoxychromene (21)» y i e l d 85$ , m.p . 141° . 
IR (KBr): 2850, 1610 and 1590 . 
PMR (CDC13): 1.42 ( s , 6H, 2 C H J , 3 .51 ( s , 3H, 0CH3), 
3.67 ( s , 3H, 0CH ) and 6 . 1 - 6 . 9 2 (m, 12H, 
a romat ic p r o t o n s ) . 
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Analys i s Pound: G, 7 6 . 1 5 ; H, 6.45 
C25H24°3 Requ i r e s : C, 7 6 . 5 3 ; H, 6 .12$ . 
2 , 2 - D i m e t h y l - 3 - p h e n y l ~ 4 - [ 2 - ( P ~ P y r r o l i d i n o e " f c i l o x y ) j p h e n y l -
7-methoxychromene (35) 
A l k y l a t i o n of 2 , 2 -d ime thy l -3 -pheny l -4 - (o -hyd roxy ) 
phenyl-7-methoxychromene (22) w i th p - p y r r o l i d i n e e t h y l 
c h l o r i d e h y d r o c h l o r i d e as de sc r ibed f o r 12. gave 2 ,2-dimethyl* 
3 - p h e n y l - 4 - [ o - ( j3-pyrrol id inoethoxy)]phenyl-7-methoxychromene 
(25.) t converted to i t s h y d r o c h l o r i d e s a l t which c r y s t a l l i z e d 
from a b s o l u t e e t h a n o l - d r y e t h e r , m.p . 218 . 
IR (KBr)t 3430, 2960 and 1605. 
PMR (0DC13): 1.19 ( s , 3H, CH-), 1.39 ( s , 3H, CH-), 1.62 
( b s , 4H, 2GH2), 2.62 ( b s , 4H, 2NCH2), 2 .81 
( t , 2H, NCH2, J = 6 . 4 ) , 3 .54 ( s , 3H, 0 C H j ? 
4.05 ( t , 2H, 0GH2, J = 6.4) and 6 .0 -6 .82 
(m, 12H, a roma t i c p r o t o n s ) . 
Ana lys i s Pound: C, 7 2 . 8 9 ; H, 6 .99 ; N, 2.78 
G^QH^.NO^GI Requ i r e s : C, 7 3 . 2 4 ; H, 6 . 9 1 ; N, 2 .84$ . 
2-Hydroxy-2 ' ,4-dimethoxybenzophenone (36) 
P r i e d i e - G r a f t e r e a c t i o n of o - a n i s i c a c i d w i th 
m-methoxyphenol i n s t a n n i c c h l o r i d e as desc r ibed f o r 16 
gave 2-hydroxy-2 ' ,4-dimethoxybenzophenone ( 2 6 ) , m.p . 91° . 
IR (KBr): J 0 g £ 1620 and 1600. ~ 3 ^ ^ 
PMR (C01 4 ) : 3 .61 ( s , 3H, OCH^), 3.70 ( s , 3H, OCH^), 
6 .0 -6 .35 (m, 2H, a romat ic p r o t o n s ) , 6 . 7 0 -
7.30 (m, 5H, a romat ic p r o t o n s ) and 12 .41 
( s , 1H, OH, exchangeab le ) . 
Ana lys i s Pound: C, 7 0 . 0 3 ; H, 5.74 
G15H14°4 R e q u i r e s : 0, 69 .76 ; H, 5 .42$ . 
3-Phenyl-4-(2-methoxy)phenyl-7-methoxycoumarin (3J7) 
2-Hydroxy-2 ' ,4-dimethoxybenzophenone (3J>) was 
condensed w i t h p h e n y l a c e t i c ac id i n t r i e t h y l a m i n e and 
a c e t i c anhydride as desc r ibed f o r 17 t o a f fo rd 3 - p n e n y l - 4 -
(o_-methoxy)phenyl-7-methoxycoumarin ( IX) , m.p . 169 . 
IR (KBr): 1760, 1600 and 1570. 
PMR (GD01-): 3 .41 ( s , 3H, 0CH,) , 3.66 ( s , 3H, 0CH-), 
and 6 .45 -6 .9 (m, 12H, a roma t i c p r o t o n s ) . 
Ana lys i s Pound: C, 76 .72 ; H, 5 .43 
C23H18°4 R e q u i r e s : C, 77 .09 ; H, 5 . 02$ . 
c i s - and t rans-2-Methyl-3--phenyl-4~(o-methoxy)phenyl~4"-
(2 -hydroxy-4 -me thoxy)pheny l -bu t -3 ,4 -ene~2-o l s (28 and 22) 
Reac t ion of 3-phenyl-4-(o_-methoxy)phenyl-7-methoxy-
coumarin (22.) wi th excess of G-rignard r e a g e n t (MeMgl) 
y i e l d e d c i s - and t rans_-2-methyl-3-phenyl-4-(o,-methoxy) 
p h e n y l - 4 - ( 2 ~ h y d r o x y - 4 - m e t h o x y ) p h e n y l - b u t - 3 , 4 - e n e - 2 - o l s . 
P u r i f i c a t i o n was made by column chromatography. 
c i s_ -2-Methy l -3 -pheny l -4 - (o -methoxy)phenyl -4 - (2 -hydroxy-4-
m e t h o x y ) p h e n y l - b u t - 3 , 4 - e n e - 2 - o l ( 2 8 ) , m.p. 150° , M+ m/e 
390, 372 (base p e a k ) . 
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IR (KBr): 3300, 1620 and 1580. 
PMR (CD013): 1.31 (s, 3H, 0H,)f 1.34 (s, 3H, GH^), 2.1 
( b s , 1H, OH), 3 .59 ( s , 3H, OCH^), 3.64 
( s , 3H, OCH-) and 6 . 3 - 7 . 1 (m, 12H, aromatic^ 
p r o t o n s ) . 
t r ans i -2~Methy l -3 -pheny l -4 - (o-methoxy) p h e n y l - 4 - (2-hy droxy-
4 - m e t h o x y ) p h e n y l - b u t - 3 , 4 - e n e - 2 - o l (^1)
 t m.p, 152° , M+ m/e 
390 , 344 (base p e a k ) . 
IR (KBr): 3200, 2950, 1610 and 1580. 
PMR (CDC13): 1.2 ( s , 3H, CH^), 1.3 ( s , 3H, CH^), 3.44 
( s , 3H, 0CH-), 3.62 ( s , 3H, OCE,) and 6 . 0 -
7 . 1 (m, 12H, a romat i c p r o t o n s ) . 
2 ,2-Dimeth.yl-3-phenyl-4-(p_-methoxy)phenyl-7-methoxy-
chromene (4Q) 
cis- and trans-2~Methyl-3-phenyl~4-(o-methoxy) 
phenyl-4-(2-hydroxy-4-methoxy)phenyl-but-3,4-ene-2-ol (28 
and 22) collectively as well as independently were cyclized 
with BtOH-HGl as described earlier for 12 to give 2,2-
dimethyl-3-phenyl-4-(o.-methoxy)phenyl-7-methoxychromene (40), 
yield 80$, m.p. 141°. 





chromene (%2) was hydrogenated over 10.# Pd-C in methanol at 
60 psi hydrogen pressure for 8 hr, worked up as described 
for 20_. Crystallized from benzene-ethyl acetate, yield 90$, 
m.p. 199°. 
IB. (KBr): 3390, 2950, 1610 and 1580. 
PMR (CDC13 + MSO-dg) : 1.11 ( s , 3H, GE^), 1 .51 ( s , 3H, CH^), 
3 .16 (d, 1H, PhCH, J = 7 ) , 3 .7 ( s , 3H, 0CH3), 
5.17 (d , 1H, PhCKPh, J = 7) and 6 .15-6 .82 
(m, 12H, a roma t i c p r o t o n s ) . 
Ana lys i s Found; C, 79 .80 ; H, 6.67 
G24H24°3 Requ i r e s : C, 8 0 . 0 0 ; H, 6 .66$ . 
3 . 4 - c i s - 2 . 2 - D i m e t h y l - 3 - p h e n y l - 4 - f o - ( f t - p y r r o l i d i n o ethoxy)1 
phenyl-7-methoxychroman (42) 
A l k y l a t i o n of 3 » 4 - c i s - 2 . 2 - d i m e t h y l - 3 - p h e n y l - 4 -
(o.-hydroxy)phenyl-7~methoxychroman (4.1) w i th p - p y r r o l i d i n o -
e t h y l c h l o r i d e hyd roch lo r ide as desc r ibed f o r l^, gave 3>4-
c a s - 2 , 2 - d i m e t h y l - 3 - p h e n y l - 4 - [ p_-( p - p y r r o l i d i n o e thoxy) ] p h e n y l -
7-methoxychroman (.42) which was conver ted t o h y d r o c h l o r i d e 
s a l t , c r y s t a l l i z e d from a b s o l u t e e t h a n o l - d r y e t h e r , m.p .241° . 
IR (KBr): 3300, 2950, 1620 and 1580. 
PMR (CDC13): 1.08 ( s , 3H, CH^), 1.48 ( s , 3H, OH^), 1.68 
(m, 4H, 2CH2), 2.52 (m, 4H, 2NCH2), 2 .87 
( t , 2H, NCH2, J = 6 ) , 3 .08 (d , 1H, PhCH, 
J = 6 ) , 3 .64 ( s , 3H, 0CH3), 4 .05 ( t , 2H, 
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OCH2, J = 6 ) , 5.13 (d, 1H, PhCHPh, J = 6) 
and 6 .14-6 .79 (m, 12H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: C, 72 .62 ; H, 7 . 6 2 ; N, 2 .43 
0-0H3 6N03Cl R e q u i r e s : C, 72 .94 ; H, 7 . 2 9 ; N, 2 .83$ . 
3 , 4 - t r a n s - 2 , 2 - D i m e t h y l - 3 - p h e n y l - 4 - [ o - ( p " - p y r r o l i d i n o e t h o x y ) ] 
phenyl-7-methoxychroman (43) 
314-cis_-2,2-Dime t h y l - 3 - p h e n y l - 4 ~ [ £ - ($ -py r r o l i d i n o -
ethoxy)]phenyl-7-methoxychroman (4_2) was i somer ized wi th 
n - b u t y l - l i t h i u m i n dry DMSO as desc r ibed f o r 11 t o g ive 
3 ,4 - t r ans -2 ,2-d ime th .y l -3 -phen .y l -4 - [ o - ( 3 - p y r r o l i d i n o e t h o x y ) ] 
phenyl-7-methoxychroman (4J5), which was conver ted to i t s 
h y d r o c h l o r i d e s a l t i n 83% y i e l d . C r y s t a l l i z e d from e t h a n o l -
e t h e r , m.p. 170 -71° . 
IR (KBr): 3400, 2950, 2600, 1620 and 1580. 
PMR (CDC15): 1.18 ( s , 3H, CH-), 1.3 ( s , 3H, CH,) , 1.7 
( b s , 4H, 2CH2), 2.52 ( b s , 4H, 2UCH2), 2.83 
( t , 2H, NCH2, J = 6 ) , 3 .2 (d , 1H, PhCH, J = 
1 2 ) , 3 .61 ( s , 3H, 0CH3), 3 .98 ( t , 2H, 0CH2, 
J = 6 ) , 5.07 (d , 1H, PhCHPh, J = 12) and 
6 .1 -7 .2 (m, 12H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: C, 72 .64 ; H, 7 . 6 1 ; N, 2.70 
C^H^NO^Cl R e q u i r e s : C, 7 2 . 9 4 ; H, 7 . 2 9 ; N, 2 .83$ . 
2-Hydroxy-4-methoxybenzophenone (44) 
m-Methoxyphenol was benzoy la ted wi th benzoyl 
c h l o r i d e i n aqueous a l k a l i t o m-benzoyloxy a n i s o l e , P r i e s 
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rear rangement of m-benzoyloxyphenol i n aluminium c h l o r i d e 
gave 2-hydroxy-4-methoxybenzophenone ( 4 4 ) , m.p. 64 ( l i t . 
m.p . 6 4 - 6 5 ° ) . 
IR (KBr): 3400 and 1615. 
3-(p_-Acetoxy)phenyl-4-phenyl-7-methoxycoumarin (45) 
2-Hydroxy-4-inethoxybenzophenone (4_4j was condensed 
wi th p_-hydroxyphenylacetic ac id i n t r i e t h y l a m i n e and a c e t i c 
anhydr ide as desc r ibed f o r 12 t o g ive 3-(p_-acetoxy)phenyl-
4-phenyl-7-methoxycoumarin (4^.), y i e l d 11%, m.p . 198 . 
IR (KBr): 1770, 1710 and 1600. 
PMR (CDC1 ) : 2 .18 ( s , 3H, 0C0CHJ, 3-82 ( s , 3H, 0CEL), 
and 6 . 7 - 7 . 4 (m, 12H, a romat i c p r o t o n s ) . 
Ana lys i s Pound: C, 7 5 . 0 0 ; H, 4 .98 
G24H18°5 R e q u i r e s : C, 7 4 . 6 1 ; H, 4 . 6 6 ^ . 
2 ,2-Dimethyl -3- (p_-hydroxy)phenyl -4-phenyl -7-methoxy-
chromene '(4.6) 
3-(p_-Acetoxy)phenyl-4-phenyl-7-methoxycoumarin (45.) 
was r e a c t e d wi th excess of MeMgl as desc r ibed f o r 18 t o 
g ive 2 , 2 - d i m e t h y l - 3 - (p_-hydroxy)phenyl-4-phenyl-7-methoxy-
chromene (4J5.) , y i e l d 69$, m.p . 1 5 3 ° . 
IR (KBr): 3390, 2980 and 1600. 
PMR (CDC1-): 1.50 ( s , 6H, 2 C H J , 3 .81 ( s , JH, 0CH-), 
5.15 ( b s , 1H, OH), 6 . 3 - 7 . 3 (m, 12H, 
a romat ic p r o t o n s ) . 
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Analys i s Pound: C, 8 0 . 0 6 ; H, 6.34 
C24H22°3 Requ i r e s : C, 80 .44 ; H, 6 .14$ . 
2 , 2 - D i m e t h y l - 3 - [ 2 . - ( p - p y r r o l i d i n o e t h o x y ) ] p h e n y l - 4 - p h e n y l ~ 
7-methoxychroiaene (47) 
A l k y l a t i o n of 2 ,2 -d ime thy l -3 - (p . -hydroxy)pheny l -4 -
phenyl-7-met.hoxychromene (46J wi th p - p y r r o l i d i n o e t h y l 
c h l o r i d e h y d r o c h l o r i d e as d e s c r i b e d f o r 13_ a f forded 47, i n 
8 8 $ y i e l d . Converted to i t s h y d r o c h l o r i d e s a l t , m.p . 203° . 
IR (KBr): 2900, 2500 and 1600. 
PMR (CDC15): 1.45 ( s , 6H, 2CH '), 2.09 ( b s , 4H, 2CH2), 
3 .31 ( b s , 4H, 2NGH2), 3.39 ( t , 2PI, NCHg, 
J = 5 ) , 3.80 ( s , 3H, OCH^), 4 .38 ( t , 2H, 
00H2 , J = 5) and 6 . 3 - 7 . 2 (m, 12H, a romat i c 
p r o t o n s ) . 
Ana lys i s Pound: C, 7 3 . 2 5 ; H, 6 . 8 8 ; N, 2 .53 
C-gELJJO-Cl R e q u i r e s : C, 73 .24 ; H, 6 . 9 1 ; N, 2 .84$ . 
3 ,4 -c i s p -2 ,2 -Dimethy l -3 - (p . -hydroxy)pheny l -4~pheny l -7 -
methoxychroman (4,8) 
Hydrogenation of 2 ,2-dimethyl-3-(p_-hydroxy)phenyl--
4-phenyl-7-methoxychromene (£6) over 10$ Pd-C a t 60 p s i as 
d e s c r i b e d f o r 20_ afforded 3 , 4 - c i s - 2 , 2 - d i m e t h y l - 3 - ( p ' - h y d r o x y ) 
phenyl-4~phenyl-7-methoxychroman (_4_8), m.p . 196 . 
IR (KBr): 3310, 2900 and 1600* 
PMR (0DC13 + DMS0-d6): 1.13 ( s , 3H, CIj^), 1.55 ( s , 3H, 
0H,3), 2.88 (d, 1H, PhCH, J = 7 ) , 3.80 ( s , 
3H, OCH-), 4 .65 (d , 1H, P h C p h , J = 7) and 
6 . 4 - 7 . 2 (m, 12H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: C, 80.10,° H, 6.40 
C24H24°3 R e q u i r e s : 0 , 8 0 . 0 0 ; H, 6 .66$ . 
3 ,4 -c i s -2 ,2 -Dimethy l -3 - [p_- ( p - p y r r o l i d i n o e t h o x y ) ] p h e n y l - 4 -
phenyl-7-methoxychroman (4Ji) 
A l k y l a t i o n of 4jB wi th p - p y r r o l i d i n e e t h y l c h l o r i d e 
h y d r o c h l o r i d e as desc r ibed fo r 1^, gave 3* 4 - c i s - 2 , 2 - d i m e t h y l -
3-[p_-( P - p y r r o l i d i n o e t h o x y ) ]phenyl-4-phenyl-7-methoxychroman 
( 4 9 ) , conver ted t o i t s h y d r o c h l o r i d e s a l t which c r y s t a l l i -
zed from e t h a n o l - e t h e r , m.p . 148° . 
IE. (KBr): 3350, 2900, 2550 and 1570. 
PMR (CDCl^ + DMS0-d6): 1.18 ( s , 3H, C R J , 1.60 ( s , 3H, 
C H j , 2 .09 (m, 4H, 2CH2), 2 .94 (d , 1H, 
PhCH, J = 7 ) , 3-39 (m, 4H, 2NCH2), 3.47 
( t , 2H, NCH2, J = 5), 3 .33 ( s , 3H, 0CH~), 
4.35 ( t , 2H, 0CH2, J = 5 ) , 4 .71 (d , 1H, 
PhCHPh, J = 7) and 6 . 4 - 7 . 2 (m, 12H, a romat ic 
p r o t o n s ) . 
A n a l y s i s Pound: G, 7 2 . 6 5 ; H, 7 . 5 3 ; N, 2 .53 
C^jH-gNO-Cl Requ i r e s : G, 72 .94 ; H, 7 . 2 9 ; N, 2 .83$ . 
i 
3 , 4 - t r a n s . - 2 , 2 - D i m e t h y l - 3 - [ p , - ( p - p y r r o l i d i n o e t h o x y ) ] p h e n y l - 4 -
phenyl-7-methoxychroman (^0.) 
I s o m e r i z a t i o n of 3 » 4 - c i s - 2 , 2 - d i m e t h y l - 3 ~ [ p - ( g -
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pyr ro l id ine )e thoxy) ]phenyl-4-phenyl-7--methoxychroman (4J3) 
i 
with n - b u t y l - l i t h i u m i n dry DMSO as d e s c r i b e d f o r 11 gave 
3 • 4 - t rans-2 .2-d imethyl - -3- l "p- ( B-py r ro l id inoe thoxy) ] p h e n y l -
4-phenyl-7~methoxychroman ( £ 0 ) , m.p. 135° . 
IR (KBr): 3300, 2950 and 1600. 
PMR (ODCl^): 1.18 ( s , 3H, CH^), 1.30 ( s , 3H, OH^), 1.79 
(bs, 4H, 20H2), 2.69 (bs, 4H, 2NCH2), 2.88 
(t, 2H, NGH2, J = 5.8), 3.07 (d, 1H, PhCH, 
J = 12), 3.67 (s, 3H, OCH^), 4.0 (t, 2H, 
0CH2, J = 5.8), 4.21 (d, IK, PhCHPh, J = 
12) and 6.15-7.0 (m, 12H, aromatic protons). 
Analysis Found: 0, 78.59; H, 7.92; N, 2.96 
C^H^NO- Requires: C, 78.87; H, 7.65; N, 3.06$. 
50 was conver ted to i t s hyd roch lo r ide s a l t which 
c r y s t a l l i z e d from m e t h a n o l - e t h e r , m.p . 204° . 
Ana lys i s Found: 0 , 7 2 . 6 5 ; H, 7 . 16 ; N, 2.67 
S o H 3 6 N 0 3 G 1 R e q u i r e s : 0 , 72 .94 ; H, 7 . 2 9 ; N, 2 .83$ . 
3~(p_-Benzyloxy)phenyl-4-(p_-acetoxy)phenyl-7-methoxy-
coumarin (£2j. 
2,4 '-Dihydroxy-4-iflethoxybenzophenone^^ was condensed 
wi th p_-benzyloxyphenylacet ic ac id i n t r i e t h y l a m i n e and 
a c e t i c anhydr ide as desc r ibed f o r 17 t o give 3-(]>-benzyloxy) 
phenyl-4-(p_-acetoxy)phenyl~7-methoxycoumarin (£2.), y i e l d 
73%, m.p. 196° . 
IR (KBr): 1760, 1700 and 1600. 
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PMR (CD015): 2 .19 ( s , 3H, OCOCH,), 3.74 ( s , 3H, OCH^), 
4 .85 ( s , 2H, OCH2Ph) and 6 . 5 - 7 . 2 (m, 16H, 
a romat ic p r o t o n s ) . 
Ana lys i s Found: C, 7 5 . 7 8 ; H, 5 . 0 2 . 
°31H24°6 R e q u i r e s : C, 75 .60 j H, 4 . 8 5 $ . 
3-( p_-Benzylo xy) p h e n y l - 4 - (p_-hy droxy) phenyl -7-methoxy-
ooumarin (fjj3) 
3~(p_-Benzyloxy)phenyl-4~(p_--acetoxy) phenyl -7 -methoxy-
coumarin (£2) was hydrolysed by e t h a n o l i c a l k a l i as d e s c r i -
bed f o r 24. t o y i e l d 3-(p_-benzyloxy)phenyl-4-(p_-hydroxy) 
phenyl-7-niethoxycoumarin (£2.), y i e l d 68$, m.p. 235 • 
IR (KBr): 3350, 1700 and 1610. 
PMR (CDCl^ +-DMS0-d6): 3.72 ( s , 3H, OCH,), 4 .84 ( s , 2H, 
0CH2Ph) and 6 . 5 - 7 . 3 (m, 16H, a r o m a t i c 
p r o t o n s ) . 
Ana lys i s Pound: C, 7 7 . 6 2 ; H, 5.14 
C29H22°5 Requ i r e s : C, 77 -33 ; H, 4 . 8 8 $ . 
3 - (p_-Benzyloxy)phenyl -4- [p . - (p-pyr ro l id inoe thoxy) Jpheny l -
7-methoxycoumarin (54) 
A l k y l a t i o n of £2. wi th B - p y r r o l i d i n o e t h y l c h l o r i d e 
h y d r o c h l o r i d e as desc r ibed f o r 12. afforded 3-(l>-benzyloxy) 
p h e n y l - 4 - [ P . - (B-pyr ro l id inoe thoxy) ]phenyl-7-methoxycoumarin 
(54)» y i e l d 80$ , m.p . 179° . 
IR (KBr): 3300, 2950, 1700 and 1610. 
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PMR ( C D C l J : 1.7 (m, 4H, 2CH2), 2.55 (m, 4H, 2NCg2), 
2 .8 ( t , 2H, NCH2, J = 6 ) , 5.75 ( s , 3H, 
OCH-), 3.99 ( t , 2H, OCH2, J r= 6 ) , 4.87 ( s , 
2H, 00H2Ph) and 6 .5 -7 .25 ( i , 16H, a romat ic 
p r o t o n s ) . 
A n a l y s i s Pound: C, 76 .50 ; H, 6 . 2 3 ; N, 2,32 
C-5H-J!T05 R e q u i r e s : C, 7 6 . 7 8 ; H, 6 . 0 3 ; N, 2 .55$ . 
2 , 2 - D i m e t h y l - 3 - ( £ - b e n z y l o x y ) p h e n y l - 4 - ( £ - h y d r o x y ) p h e n y l -
7-methoxychromene (5j?) 
G-rignard r e a c t i o n of 3-(]2.-benzyloxy)phenyl-4-(p_-
acetoxy)phenyl-7-methoxycoumarin (52) wi th excess of 
MeMgl as desc r ibed f o r 18 gave 2,2-dimethyl-3-(E.- 'benzyloxy) 
phenyl-4-(p_-hydroxy)phenyl-7-niethoxychroiiiene (££.), y i e l d 
58$, m.p. 141° . 
IR (KBr): 3390, 2950, 1600 and 1560. 
PMR (CD013): 1.47 ( s , 6H, 2GH,), 3.78 ( s , 3H, OCH,), 
4.95 ( s , 2H, 0GH2Ph), 5 .4 ( s , 1H, OH) and 
6 . 2 5 - 7 . 3 (m» 16H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: G, 7 9 . 9 8 ; H, 6.03 
G31H28°4 R e q u i r e s : 0, 8 0 . 1 7 ; H, 6 .22# . 
2 ,2-Dimethyl-3-(p . -benzyloxy )phenyl-4~[p_-( f 3 -py r ro l i d ino -
ethoxy)]phenyl-7-methoxychromene (£6) 
A l k y l a t i o n of 2 ,2 -d imethy l -3- (p_-benzyloxy)phenyl -
4-(p.-hydroxy)phenyl-7-methoxychromene {££) wi th f3 -pyr ro l i -
d i n o e t h y l c h l o r i d e hydroch lo r ide as descr ibed f o r 2J5. 
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yielded ^6 in 76% yield, m.p. 119°. 
IR (KBr): 
PME (CDC1,) 
3400, 2900, 1605 and 1500. 
1.44 (s, 6H, 2CH-), 1.78 (ID, 4H, 20H2), 
2.62 (m, 4H, 2N0H2), 2.86 (t, 2H, NCH2, 
J = 6), 3.79 (s, 3H, 00g3), 4.04 (t, 2H, 
0CH2, J = 6), 4.98 (s, 2H, OCHgPh) and 
6.4-7.4 (m, 16H, aromatic protons). 
Pound: C, 79.06; H, 7.18; N, 2.28 
Requires: C,, 79.14; H, 6.95; N, 2.49$. 




Chromene £6. was debenzyla ted by hydrogena t ion over 
10# Pd-C a t room tempera ture and p r e s s u r e f o r 2 h r . Usual 
work up gave 2 ,2 -d imethy l -3- (p_-hydroxy)phenyl -4- [p . - (p -
pyr ro l id inoe thoxy) ]phenyl -7-methoxychromene ( 5 2 ) , y i e l d 
80$ , m.p . 275° . 
IR (KBr): 3300, 2900, 2800 and 1600. 
PMR (EMSO-dg): 1.34 ( s , 6H, 2CH,), 1.83 (m, 4H, 2GH2), 
3.05 (m, 4H, 2NCH2), -3.23 ( t , 2H, N0H2, 
J = 5 ) , 3 .71 ( s , 3H, O0H3), 4 . 2 1 ( t , 2H, 
0CH2, <J = 5) and 6 . 4 - 6 . 9 (m, 11H, a romat ic 
p ro tons ) • 
Ana lys i s Found: 0, 7 6 . 7 0 ; H, 7 . 2 3 ; N, 2 .68 
C5 0H5 5N04 R e q u i r e s : C, 7 6 . 4 3 ; H, 7 .60 ; N, 2 .97# . 
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3,4--cis-2,2-Dimethyl~3-(pj-hydroxy)phenyl-4--[p_--( p - p y r r o l i -
d ine ethoxy ) ]phenyl~7-methoxychroman (£8) 
Hydrogenat ion of £6, a t 800 p s i and 60° over 10$ 
Pd--C fo r 10 h r a f forded 3 , 4 - c i s - 2 , 2 ~ d i m e t h y l - 3 - ( p - h y d r o x y ) 
phenyl-4-[p_-( p - p y r r o l i d i n o e t h o x y ) ]phenyl-7-methoxychroman 
(£8) as v i s c o u s o i l , y i e l d 73^ -
PMR ( C D C l J : 1.12 ( s , 3H, CH_), 1.48 ( s , 3H, C H j , 1,70 
(m, 4-H, 2CH2), 2 .51 (m, 4H, 2NCH2), 2 .71 (d, 
1H, PhCH, J = 5 ) , 2.74 ( t , 2H, NCH2, J = 6 ) , 
3.70 ( s , 3H, O C H j , 3.89 ( t , 2H, 0CH2, J = 
6 ) , 4.45 (d , 1H, PhCKPh, J = 5) and 6 . 2 5 -
6.70 (m, 11H, a romat i c p r o t o n s ) . 
Converted to i t s hyd roch lo r ide s a l t which c r y s t a l l i z e d from 
e t h a n o l - e t h e r , m.p. 153° . 
IR (KBr): 3300, 2900, 2750 and 1610. 
Ana lys i s Pound: G, 70.49? H, 7 . 2 4 ; N, 2 .51 
C^H^HO HC1 R e q u i r e s : C, 70.65? H, 7.06? N, 2 .76$ . 
3 t4 - t r ans -2 ,2 -Dimethy l -3 - - (p -hydroxy)T)heny l -4 - - rp - (B-Pvr ro l i -
dinoethoxy)]phenyl-7~methoxychroman (59) 
I s o m e r i z a t i o n of %8 w i th n - b u t y l - l i t h i u m i n dry 
DMSO as desc r ibed f o r 11 gave 3 , 4 - t r a n s - 2 . 2 - d i m e t h y l - 3 -
(p . -hydroxy)phenyl -4- [p_-(p-pyrro l id inoethoxy) ] p h e n y l - 7 -
methoxychroman ( £ 9 ) , c r y s t a l l i z e d from THP-benzene, 
y i e l d 83#, m.p . 211° . 
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IB. (KBr): 3350, 2950, 2800 and 1600. 
PMR (CDC1- + DMS0-d6): 1.18 (s, 3H, CH ), 1.28 (s, 3H, 
CH-), 1.70 (m, 4H, 2CH2), 2.52 (m, 4H, 
2N0H2), 2.77 (t, 2H, NCH2, J * 6), 3.06 
(d, IB, PhCH, J = 12), 3.70 (s, 3H, OCH^), 
3.97 (t, 2H, 00H2, J = 6), 4.24 (d, 1H, 
PhCHPh, J = 12) and 6.2-7.4 (m, 11H, 
aromatic protons). 
Analysis Found: C, 76.32; H, 7.50j N, 2.81 
0-0H35N04 Requires: 0, 76.10; H, 7.39; N, 2.95$. 
3~(pj-Benzyloxy)phenyl-4-phenyl~7-methoxycoumarin (60) 
Condensation of 2-hydroxy-4~methoxybenzophenone (44J 
with p_-benzyloxyphenylacetic aoid in triethylamine and 
acetic anhydride as described for 12 gave 3-(p_-benzyloxy) 
phenyl-4-phenyl-7~methoxycoumarin (60.), yield 79#> m.p. 165 < 
IE (KBr): 1700, 1610 and 1595. 
PMR (CDC1,): 3.78 (s, 3H, OCEL), 4.87 (s, 2H, 0CH2Ph) 
and around 6.52-7.24 (m, 17H, aromatic 
protons)• 
Analysis Pound: C, 80.02; H, 5.24 
°29H220^ Requires: C, 80.18; H, 5.06$. 
3-(p_-Hydroxy)phenyl-4-phenyl-7-methoxycoumarin (61) 
Alkaline hydrolysis of 3-(p_-acetoxy)phenyl-4-
phenyl-7-methoxycoumarin (4j?) as described for 24. afforded 
3-(p_-hydroxy)phenyl-4-phenyl-7-methoxycoumarin ( 6 1 ) , 
y i e l d 73#, m.p. 244° . 
IR (KBr): 3300, 1680, 1610 and 1590. 
PMR (CDC1, + DMS0-d6): 3.78 ( s , 3H, OGH )^ and 6 . 4 - 7 . 2 6 
(m, 12H, aromatic protons). 
Analysis Pound: C, 76.55; H, 4.82 
C22H16°4 Requires: C, 76.74; H, 4.65$. 
Erythro-2-(p~hydroxy)phenyl-3-phenyl-3-(2-hydroxy-4-
— — — -... , ,—... ;>—-—J 
methoxypropionic acid (62) 
? 
(a) A mixture of 3-(p_-acetoxy)phenyl~4-phenyl~7-
methoxycoumarin (4_5_, 3.5 g> 0.009 mol), methanol (50 ml) 
and IB NaOH (100 ml) was heated till clear solution. 
Methanol was removed by distillation. To the aqueous 
solution, Raney-M alloy (7 g) was added during 30 min, 
under mechanical stirring at 80-85° (internal temperature). 
After the addition had completed, the reaction mixture was 
stirred for another 15 min, cooled and filtered through 
hyflo supereel. The filtrate was acidified strongly with 
cone. HG1, solid thus separated was collected through 
filtration, washed with water, dried and crystallized from 
ethyl acetate-benzene, yield 0.8 g (43$)» m.p. 256°. 
(b) A mixture of the acetoxycoumarin (.4J5., 2 g, 0.0052 
mol), methanol (20 ml) and 5N NaOH (60 ml) was heated till 
a clear solution was obtained. Methanol was then distilled 
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of f . The a l k a l i n e s o l u t i o n was h e a t e d t o 95-100° ( i n t e r n a l 
t empera tu re ) and Raney-Ni a l l o y (7 g) was added t o i t 
d u r i n g 1 h r under s t i r r i n g , and s t i r r i n g cont inued a t t h i s 
t e m p e r a t u r e f o r f u r t h e r 4 h r . The r e a c t i o n mix tu re was 
worked up as above and the p r o p i o n i c a c i d 62, o b t a i n e d 
was c r y s t a l l i z e d from e t h y l a c e t a t e - b e n z e n e , y i e l d 1,8 g, 
( 5 4 . 6 3 ) , m . p . 256° . 
IR (KBr): 3350, 1700, 1610 and 1590 
PMR (DMS0-d6): 3*45 ( s , 3H, 0CH,) , 4 .43 (d , 1H, P h C p h , 
J = 1 3 ) , 5.02 (d , 1H, ArCHCO, J = 13) and 
6 . 0 - 7 . 4 (m, 12H, a romat ic p r o t o n s ) . 
A n a l y s i s Pound; C, 7 2 . 3 5 ; H, 5.72 
G22H20°5 Requ i r e s : 0, 7 2 . 5 2 ; H, 5 .49# . 
p i s - and t rans -3- (p -Ace toxy)phenyl -4 -phenyl -7 - -methoxy-
dihydrocoumarin (6J5.) 
A mix tu re of ery t h r o - p r o p i o n i c ac id (6_2, 0 . 1 g ) , 
a c e t i c anhydride (0 .3 ml) and dry benzene (20 ml) was 
r e f l u x e d fo r 7 h r . The r e a c t i o n mix tu re was t h e n concen-
t r a t e d and d i l u t e d wi th wa t e r . So l id t h u s s e p a r a t e d out 
was taken i n e t h y l a c e t a t e and washed wi th sodium b i c a r b o -
n a t e and w a t e r , d r i e d over anhyd. sodium s u l p h a t e and 
c o n c e n t r a t e d , p i s - and t rans-3- - (p~Acetoxy)phenyl -4~Phenyl -
7-methoxydihydrocoumarin (6£) t h u s ob ta ined was c r y s t a l l i -
zed from benzene-hexane, y i e l d 800 mg (75^)» m.p. 172 . 
IR (KBr): 1780, 1750, 1620, 1605 and 1590. 
139 
PMR (CDC1J: 2 .15 and 2 .19 ( s , 3H, OCOCHj, 3 .7 and 3.72 
( s , 3H, OCH-), 4 . 1 (m, 1H, ArCH), 4 .3 (m, 
1H, PhCHPh) and 6 . 5 - 7 . 2 (m, 12H, a romat ic 
p r o t o n s ) . 
Ana lys i s Found: C, 74 .20 ; H, 5.35 
°24H20°5 R e q u i r e s : C, 7 4 . 2 2 ; H, 5 .15# . 
S r y t h r o - 2 ~ ( p - h y d r o x y ) p h e n y l - 3 - p h e n y l - 3 - ( 2 - h y d r o x y - 4 -
methoxy)phenylpropanol (6_4_) 
A s o l u t i o n of p r o p i o n i c ac id (62_, 0 .7 g, 0.002 mol) 
i n dry THF (70 ml) was g r a d u a l l y added t o a suspens ion of 
l i t h i u m aluminium hydr ide (0 .5 g) i n dry e t h e r (150 ml) 
under s t i r r i n g . The r e a c t i o n mix tu re was r e f l u x e d f o r 
5 h r , cooled and c a r e f u l l y decomposed wi th w a t e r , a c i d i f i e d 
and e x t r a c t e d wi th e t h y l a c e t a t e . The o r g a n i c l a y e r was 
washed w i th sodium b i c a r b o n a t e and then w i th water t o 
n e u t r a l , d r ied over anhyd. sodium su lpha t e and concen t ra t ed 
t o y i e l d e r y t h r p - 2 - ( p - h y d r o x y ) p h e n y l - 3 - P h e n y l - 3 - ( 2 - h y d r o x y -
4-methoxy)phenylpropanol (64J which c r y s t a l l i z e d from 
e t h y l a c e t a t e - b e n z e n e , y i e l d 0 .55 g (82$) , m.p . 149° . 
IR (KBr): 3400, 2605 and 2595. 
PMR (DMS0-d6): 3 .3 ( b s , 2H, 0CH2) , 3.35 (d , 1H, ArGH, 
J = 1 2 ) , 3.45 ( s , 3H, 0CH3), 4 .53 (d, 1H, 
PhCHPh, J = 12) and 6 . 4 - 7 . 3 (m, 12H, 
a romat ic p r o t o n s ) . 
Ana lys i s Found: G, 7 5 . 2 9 ; H, 6.40 
G22H22°4 Requ i r e s : C, 75 .42 ; H, 6.; 
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Erythro-2- (p~tosy loxy)phenyl -3-phenyl -3- - (2- - tosy loxy- -4-
methoxy)phenylpropyl . c h l o r i d e (6jj.) 
A mix tu re of t h e propanol (6_4_, 350 mg, 1.0 mmol), 
p_-toluenesulphonyl c h l o r i d e (1 .90 g, 10 mmol) i n dry 
p y r i d i n e (5 ml) was hea ted on t h e steam ba th f o r 3 h r 
and poured on to crushed i c e . The o i l y product was taken 
i n e t h y l a c e t a t e , washed with d i l u t e HC1 and then wi th 
wa te r to n e u t r a l , dr ied over anhyd. sodium s u l p h a t e and 
concen t r a t ed to y i e l d e ry thro-2- (p_- tosy loxy)phenyl~3-phenyl -
3 - (2 - tosy loxy-4 -me thoxy)pheny lp ropy l c h l o r i d e ( 6 5 ) , 
c r y s t a l l i z e d from methanol , y i e l d 400 mg ( 5 9 $ ) , m.p.' 163 > 
M+ m/e 640 (M-HC1). 
IR (KBr): 3450, 3050, 2950, 1615 and 1600. 
2.35 ( s , 3H, CH3), 2 .38 ( s , 3H, CH3), 
3.45 (b s , 2H, CH2C1), 3.45 (w, 1H, ArCH), 
3 .49 ( s , 3H, 0CH-), 4 .6 (d, 1H, PhGKPh, 
J = 11) and 6 . 3 - 7 . 7 (m, 20 H, a roma t i c 
p r o t o n s ) . 
Found: C, 63 .59 ; H, 5.03 
R e q u i r e s : C, 63 .85 ; H, 4 .87$ . 
PMR (0DC1 ) : 
Ana lys i s 
314-tr.ans.--3- (p_~Hydroxy )phenyl-4-phenyl~7-methoxy chroman 
(66) 
The e r y ; t h r p - d i t o s y l a t e (6J5, 676.5 mg, 1.0 mmol) 
was taken i n e t h a n o l i c NaOH (200 mg i n 50 ml EtOH) and 
r e f l u x e d f o r 3 h r . The so lven t was removed under vacuum, 
t h e r e s i d u e a c i d i f i e d and e x t r a c t e d wi th e t h y l a c e t a t e . 
The o rgan i c l a y e r was washed w i t h water t o n e u t r a l , d r i e d 
over anhyd. sodium s u l p h a t e and c o n c e n t r a t e d . 3 * 4 - t r a n s -
3-(p_-Hydroxy)phenyl-4-phenyl--7-methoxychroman (6§) t hus 
ob ta ined was p u r i f i e d by column chromatography ( s i l i c a g e l , 
CH2C12), y i e l d 250 mg (51$) , m.p. 199-200° , M+ m/e 332. 
IR (KBr): 3390, 1605, 1580 and 1495. 
PMR (0DC1- + DMS0-d6): 3 .1 (m, 1H, ArCH), 3 .79 ( s , 3H, 
O C H j , 4.24 ( b s , 2H, OCH2), 4.35 (d , 1H, 
PhCHPh, J = 9 ) , 6 . 3 - 7 . 2 (m, 12H, a romat ic 
p r o t o n s ) and 8.53 (bh, 1H, OH). 
Ana lys i s Pound; 0, 7 9 . 4 8 ; H, 6 . 3 1 . 
C22H20°3 Requ i r e s : G, 7 9 . 5 2 ; H, 6 .00^ . 
3 ,4 - t r ans i -3 - [p . - (p -Py r ro l i d inoe t l i oxy ) ]pheny l -4~pheny l -7 -
methoxychroman (6_7) 
A l k y l a t i o n of 3 » 4 - t r a n s - 3 - ( p - h y d r o x y ) p h e n y l - 4 -
phenyl-7-methoxychroman (66>) w i th p - p y r r o l i d i n o e t h y l 
c h l o r i d e h y d r o c h l o r i d e as desc r ibed f o r 13_ gave 3 . 4 - t r a n s -
3~[p . - (p -pyr ro l id inoe thoxy) jphenyl-4-phenyl-7-methoxychroman 
( 6 2 ) , y i e l d 73$, m.p. 151° . 
IR (KBr): 3450, 2920, 2800, 1605 and 1580. 
PMR (CDCi3): 1.82 (m, 4H, 2CH_2), 2 .69 (m, 4H, 2NCH2), 
2 . 91 ( t , 2H, NCH2, J = 5 . 5 ) , 3 .38 (m, 1H, 
ArH), 3.72 ( s , 3H, OCHj , 4 .06 ( t , 2H, 
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0CH2, J = 5 . 5 ) , 4.20 (d , 2H, 0CH2, J = 4 ) , 
4 .31 (d , 1H, PhCHPh, J = 10) and 6 .25-7 .10 
(m, 12H, a romat ic p r o t o n s ) . 
Ana lys i s Found: G, 78 .10 ; H, 7 . 4 3 ; N, 3.08 
°28H31N 03 R e q u i r e s : 0, 7 8 . 3 2 ; H, 7 .22 ; N, 3 . 2 6 1 
3-(p_-Acetoxy)phenyl-4-phenyl-7-acetoxycoumarin (6g) 
36 2 ' ,4-Dihydroxybenzophenone^ (68) was condensed 
wi th p_-hydroxyphenylacetic ac id i n the p resence of t r i e thy l -
amine and a c e t i c anhydride as desc r ibed f o r 17 t o a f fo rd 
3- (p_-ace toxy)phenyl -4-phenyl -7-ace toxycoumar in (j5£), y i e l d 
19%, m.p . 216° . Z> 
IR (KBr): 1760, 1720, 1710^ and 1600. 
PME (CDC15): 2.11 (s, 3H, 0C0CH,), 2.21 (s, 3H, 0C0CH-) 
and 6.7-7.23 (m, 12H, aromatic protons). 
Analysis Found: C, 72.28; H, 4.56 




was sub j ec t ed to excess of MeMgl as desc r ibed f o r 18 t o 
g ive 2 ,2 -d imethy l -3- (p_-hydroxy)phenyl -4-phenyl -7-hydroxy-
chromene ( 7 0 ) , y i e l d 67$, m.p . 183° , M+ m/e 344. 
IR (KBr): 3300, 3000 and 1600. 
PMR (CDC13 + DMSO-dg): 1.31 ( s , 6H, 2CH-) and 6 . 0 - 6 . 9 5 
(m, 12H, a romat i c p r o t o n s ) . 
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Analys i s Found: G, 8 0 . 3 6 ; H, 6*04 




I s o m e r i z a t i o n of 3 ,4-c i i s- -2 ,2-dimethyl-3-(p . -hydroxy) 
phenyl-4-phenyl-7-methoxychroman (4J3) wi th n - b u t y l - l i t h i u m 
i n dry DMSO as de sc r ibed f o r 11 gave 3 . 4 ~ t r a n s - 2 , 2 -
dimethyl-3-(p.-hydroxy)phenyl-4-pl ienyl~7-niethoxychroman 
(21) > y i e l d 84^ , m.p. 213° . 
IR (KBr): 3500, 2950, 1605 and 1580. 
PMR (DMS0-d6): 1.13 ( s , 3H, GEL), 1.22 ( s , 3H, C H j , 
3.17 (d , 1H, ArCH, J = 1 2 ) , 3.70 ( s , 3H, 
O C H j , 4.45 (d , 1H, PhCHPh, J = 12) and 
6 .3 -7 .15 (m, 12H, a romat ic p r o t o n s ) . 
Ana lys i s Pound: 0, 8 0 . 2 3 ; H, 6.82 
C24H24°3 R e q u i r e s : 0S 8 0 . 0 0 ; E, 6.i 
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CHAPTER 3 
PG- METABOLIC INHIBITORS AS POSSIBLE 
ANTIIMPLANTATION AGENTS 
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3.1 ROLE OF PROSTAGLANDINS IN 
FERTILITY CONTROL; AN OVERVIEW 
Introduction 
The increasing incidence of side effects observed 
with the steroidal contraceptive 'Pill' has sharply 
focussed attention on the need for alternative methods 
for fertility oontrol. The demonstration of the powerful 
uterine contracting activity in different phases of 
pregnancy of prostaglandins (PGs) and their ability to 
cause luteolysis in experimental animals in early 1970s, 
opening the possibility of having self-medicated non-
surgical abortion, offers a most attractive new approach 
to fertility control. This field, therefore, has attra-
cted world wide interest. Prostaglandin research is 
passing through the same phase as perhaps sulfonamides 
and steroid research in 1940s. 
Prostaglandins are a family of naturally occurring 
C^Q-cyclopentane carboxylic acids which have been isolated 
from tissues of various species including mammals, 
amphibia and even corals e.g. Plexaura Homomalla . 
Recently workers at Texas State University claim to have 
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isolated a substance from the fatty acid extract of yellow 
2 
onion, that in all probability is PGA~ . This can be 
regarded as the first report of the presence of prosta-
glandins in the plant kingdom. 
The six parent natural compounds (Fig, 1) which 
possess high biological activity belong to two main series, 
PGE and PGF, differing only in the presence of a keto or 
hydroxy functionality at Cg-position, with differing 
degrees of unsaturation, as indicated by a subscript, 
PGE,, PGE~ or PGE-. In the presence of a weak acid or 
alkali PGE readily undergoes dehydration within the ring 
which results in the formation of PGA compounds; in the 
presence of stronger alkali, the CTO-CTI double bond 
rearranges to the 8,12 position, leading to the formation 
of a fourth series 'of compounds designated as PGBs (Fig.l). 
Besides PGG and PGD have also been described. 
Electrical, hormonal or even mechanical stimulation 
of cells and tissues, results in increased biosynthesis of 
prostaglandins. The sequence of events leading to PG 
formation is considered to involve activation of acid 
hydrolases such as phospholipase which releases prosta-
glandin precursor, the Cp0 polyenoic acid from tissue 
phospholipids. These fatty acids are the known 'essential' 
fatty acids and undergo cyclization and incorporation of 
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formation of prostaglandins. The actual site of bio-
synthesis of PG-s is not yet well'established, -but in all 
3 4-probability it is the cell membrane. Bergstrom et al 
have suggested the biosynthetic pathway shown in Pig. 2. 
V - ° 2 H 4 G 0 2 H 
JN. 




Prostaglandins have a very high rate of metabolism 
which is evident from the fact that radioactive PG after 
injection into a subject is metabolised within a minute 
and 40% of the radioactivity is distributed in a number 
5-7 
of m e t a b o l i c p r o d u c t s . Samuelsson e_fc a l ^ have shown 
t h a t metabolism of PG i n v o l v e s o x i d a t i o n of 15-hydroxyl 
group t o a ke tone , r e d u c t i o n of t h e 13 ,14 double bond 
fol lowed by two s t e p s of p - o x i d a t i o n of t h e c a r b o x y l i c 
a c i d c h a i n . In some cases I/O - o x i d a t i o n of t h e a l k y l cha in 
a l s o occurs ( F i g . 3 ) . Of a l l t h e s e e v e n t s , more i s known 
G5H11 
G2H4C02H ^ / C 0 2 H 




about PG-15-hydroxy dehydrogenase than any other enzyme 
involved in the metabolic process. It was isolated by 
Samuelsson from swine lungs and has high specificity for 
PGs and require specifically 15-s-configuration. 
The non-availability of PGs in appreciable 
quantities from natural sources and their demand for 
extensive human pharmacological testing focussed attention 
on their synthesis. Instability of natural PGs in acidic 
or basic media, compounded by the presence of the five 
assymmetric centres, out of which four are in the cyclo-
pentane part of the molecule, posed a great challenge to 
sjm'thetic organic chemists. 
The first synthesis of a biologically active PG 
Q 
was reported by Bagli ejt al-7 in 1966, but total chemical 
synthesis of a natural PG in a stereo-specific manner 
came out from Corey et al in 1969. He has also reported 
the synthesis of a common intermediate which can lead to 
practically all the natural prostaglandins. Since then 
the literature is virtually flooded with the synthesis of 
PGs11"24. 
The therapeutic and pathological significance of 
L O 
PGs lies in their ubiquatus distribution, their ready 
release from tissues with non-specific stimulation and 
their potent pharmacological actions. The specific effects 
observed, depend on the PG administered, for example, PGE 
154 
and PG-F produce quantitatively and in some cases even 
qualitatively, different effects. Physiological effects 
of PGs are, in general, based on some basic factors such 
as the regulation of activity of smooth muscles, of 
secretion including secretion of some endocrine glands, 
or of blood flow. These actions are capable of controll-
ing many aspects of human physiology and have great 
significance in pharmacology* 
It has been observed that in the tissues where 
prostaglandins inhibit hormonal responses, they inhibit 
the accumulation of 3',5'-cyclic-adenosine monophosphate 
(cAMP) induced by the hormone, whereas in most tissues 
where prostaglandins imitate this physiological response 
to the hormone, they like the hormone, increase the 
levels of intracellular cAMP. Thus one of the significant 
features of PG-s lies in the finding that they are ubiqu*-
o 
tus, are readily biosynthesised, on stimulation of cells 
and tissues and potentially may serve as intracellular 
regulators of hormone action by modifying cAMP accumulation. 
The present discussion will be limited to the role 
of prostaglandins in fertility control. The main two 
groups of PG-s responsible for regulation or termination of 
pregnancy are E9 and F~ types. 
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Role of PGs in fertility control 
The discovery that prostaglandins apart from 
other important biological properties can cause luteo-
lysis in very minute quantities created great interest 
in late 1960s and was considered to be the second major 
discovery in the field of antifertility after the steroid 
episode. Premature termination of luteal function by 
PGF2 was initially reported by Gurtknecht eis al ' 
27 
in pseudo-pregnant rats and Blatchley ejt al in hysterec-
tomized guinea pigs. Since then luteolytic effects of 
25 28 29 PGFp have been observed in rabbits. ' , hamsters and 
mice-?0. Criteria used for assessing luteolytic effects 
have ranged from a decrease in the plasma progesterone 
to morphological degeneration of corpora lutea. PGEp and 
E, have found to be luteolytic in hamsters, approximately 
6 and 12 times less potent than PGP- * . Exactly how 
luteolysis is brought about is not clear. Both a local 
32 
effect involving vasoconstriction and a central effect 
involving alterations in the secretion of IE and perhaps 
•33 
other luteotrophic hormones have been implicated. It 
is likely that under experimental conditions involving 
pharmacological doses of PGs a central pathway may 
intervene although this dose does not exclude the existence 
of a local pathway^ -^. j-^
 i s interesting that PGE-,^  
35 
which is a potent vasodilator agent"^  causing increased 
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34 
"blood flow through the ovarian veins in sheep-^ and PG^ct 
35 
which is a vasoconstrictive agent^ are both luteolytic. 
It is not known if a vascular action alone can account for 
the luteolytic effects of these two PGs with contrasting 
properties* 
PGBp and PGFp have a stimulating action on human 
myometrium, an effect of fundamental pharmacological 
importance with regard to the use of these compounds as 
abortifacients. The reactivity and sensitivity of myo-
metrium to PGs ' is a function of the endocrine 
status and varies during different phases of menstural 
cycle and pregnancy, probably due to the influence of 
ovarian hormones. The sensitivity of myometrium is most 
pronounced at ovulation time towards PGE, and decreases 
during secretory phase and pregnancy. In contrast to 
PGE.,, sensitivity of pregnant myometrium to PGF, is 
highly elevated and is responsible for the stimulation 
of the myometrium. 
The synthesis, release and response of PGs on 
myometrium has an important connection with the hormonal 
balance. As a result of several studies in sheep it has 
been suggested that estrogen induces the production of 
PGFp in the myometrium. Progesterone appears to inhibit 
the release of PGF- ^u^ no^ ^ e r e s P o n s e o f myometrium 
towards it. Under experimental conditions estradiol can 
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promote the synthesis of P£F2a a n d i n c r e a s e J3lae sensitivity 
: of myometrium to oxytocin without changing plasma or myo-
metrial progesterone levels. It is not known whether 
PGI' itself has a direct oxytocic effect on sheep myo-
metrium or not. 
The regulation of myometrial activity by PG-s 
possibly involve interaction with an intracellular path-
way involving adenyl cyclase, cAMP and calcium ions. 
PGEp and PG^p have been found to decrease ATP dependent 
calcium binding to isolated muscle cell components 
especially mitochondria, while biologically inactive 
39 PGFpg has no effect^ . Since calcium is required for 
maximal smooth muscle contraction, the regulation of its 
intracellular concentration could be the basis for the 
effects of PG-s on uterine contractility. 
As a result of neuroendocrine changes in the 
foetus, Cortisol and probably estrogens reach the placenta, 
causing a decline in placental progesterone and a dramatic 
rise in maternal estrogen levels. The change in the 
relative proportion of these steroids stimulate the 
irelease of PG-^a f r o m 'ttie maternal placenta and myometrium. 
Increasing myometrial PGs lowers the threshold of the 
uterus so that it responds more readily to oxytocin. Both 
oxytocin and ££F2a» interacting through myometrial adenyl 
cyclase system, cause membrane depolarization resulting in 
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the initiation of la"bor. Although due to various technical 
problems the role of PGs in introduction of labor in human 
is not well understood, there is definite evidence that 
there is a dramatic rise in the levels of PGF2a i n "the 
blood immediately before the uterine contraction during 
41-43 
normal labor40 and that inhibition of PG activity by their 
inhibitors, e.g. indomethacin, delays labor in primates 
These observations indicate that PGs may be useful for 
induction of labor in women at or near term4 . 
Both PGE0 and P0 can initiate labor or abortion 2 2a 
when administered by intravenous, intravaginal, intra-
amniotic, extra-amniotic, oral or extra-vascular routes. 
Extensive reviews on this aspect of PGs and their compari-
son with oxytocin have appeared in the literature * ' 
However, therapeutic effectiveness must be gauged against 
the many other effects seen on prolonged infusion of prosta-
glandins, including nausea, vomiting, diarrhoea, migraine 
and inflammatory reactions. 
Effect of PGs on oviduct motility and egg transport 
One of the primary functions of mammalian oviduct 
is to allow fertilisation to take place and to regulate 
the time at which eggs enter into the uterus. It has been 
suggested that there must be a normal developmental 
synchrony between the embryo and endometrium for the 
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successful continuation of pregnancy. It has been suggest-
ed that an effective contraceptive approach xrould he to 
cause an accelerated egg transport through the oviduct, 
thus disrupting the normal developmental synchrony between 
the embryo and the endometrium. It is generally agreed 
that the isthmus is primarily responsible for preventing 
premature passage of ova through the oviduct. The egg 
transport depends upon many factors including oviductal 
motility, hormonal phase and fluid viscosity. 
The motility of oviducts is to a large extent 
governed by prostaglandins. Recently Aref and Hafez 
have shown that ~P&Fp stimulated oviductal contractility, 
accelerated egg transport and reduced implantation 
significantly while PGE2 inhibited ovuduct contractility 
and did not modify egg transport or interfere with 
implantation. The effectiveness of PG-F? to hasten the 
passage of eggs depend on the time of injection of the 
drug. Efficacy increased when PGEp„ was injected at 36 
hours post-coitum (h.p.c.) compared to when it was 
injected at 12 or 24 h.p.c. In rabbits injection of 
5 mg PGFpa hastened the transport of eggs by approximately 
40 hours. Chang and associates ' reported accelerated 
transport of eggs and disturbed implantation when 5 mg/kg 
PGF2a was injected subcutaneously (s.c,) in rabbits. 
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The observed in vivo oviduot motility in restrained 
rabbits suggested that PG-Eg and PGFp had antagonistic 
effects on the smooth musculature of the oviduct. PGB-
inhibited and ?GP2 stimulated oviduct motility dramati-
cally. Several studies have reported similar effects in 
4-9—51 
women as in rabbits . I n women a stimulatory response 
was observed following the intravenous injection of 100 mg 
PGF oa (i£ vivo)« Injection of 100,mg PGOEL (i.v.), however, 
was followed by inhibition . The intensity of the 
contractile response was related to the dose of prosta-
glandins administered. 
In most mammals, eggs reside in the oviduct for 
52 
about three days . Throughout this interval fertiliza-
tion and concurrent cleavage of eggs takes place. Simul-
taneous with these developmental changes in embryos, the 
\iterus undergoes several changes to facilitate their 
survival and subsequent implantation. Pharmacological 
disruption of this temporal and delicate relationship 
leads to the emergence of effective post-coital contra-
53 
ceptives. Several drugs have been tested in this wayy . 
Large doses of estrogens and estrogen analogues were 
effective as post-coital contraceptives if administered 
p 4.-5 Q 
within 72 hours of unprotected mid cycle intercourse"^" J . 
59 
Blye^ has related the antifertility effects of post-
coital estrogens to acceleration or retention (tube locking) 
161 
58 
of eggs in the oviduct. Morris and Wagenerr have suggest-
ed the name interception for this approach* 
The effectiveness of PGs in modifying the contracti-
lity of the genital organs in vivo ' and in altering 
steroidogenesis, has encouraged the investigators to test 
PGs as adequate substitute for available interceptives. 
Despite the antagonistic effects of PGEp and F2a 
on oviductal motility, the effect of the two PGs on egg 
transport were not antithetical. In PGF , treated rabbits 
stimulated oviductal motility in one oviduct was accom-
panied by accelerated transport of eggs in contralateral 
oviducts. Strong oviductal contractions may overcome 
distal antagonism and expel eggs prematurely to the uterus. 
In PGEp treated rabbits, however, inhibition of oviductal 
motility was not accompanied by delayed transport of eggs. 
The relationship between oviductal contractility and egg 
* transport is probably complex and other factors may be 
involvedj of particular significance is the sphinctor like 
mechanism at ampullary-isthmic and utero-tubal junct-
ions ' . Since physiological levels of estrogen and 
progesterone are prerequisites for timed transport of eggs 
in rabbits ' , prostaglandin induced luteolysis and 
disturbed steroidogenesis may interfere with egg transport 
and implantation ' . Accelerated transport of embryos 




The role of PG-s is not limited to its abortifacient 
activity alone. It has been recently shown that ovulation 
67 
could also be induced in gold fish through prostaglandins 
Their effect on oviductal motility and egg transport which 
has been discussed above have made them important as 
probable antiimplantation agents. PG-s are of no less 
importance than steroids in the regulation of reproductive 
cycle. It may be possible that the effects of gonadotro-
pins and steroids are mediated through prostaglandins. 
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3.2 PG-15-HYDROXY-DEHYDROGENASE 
INHIBITION; BASIS OP THE 
PRESENT WORK 
Owing to the discovery that elevated levels of 
prostaglandins (E~ and P?cc) in amniotic fluid at the time 
of partirution exert frequent and strong contractions on 
the uterus and thus lead to the expulsion of foetus, it 
was a matter of interest to elevate the levels of endo-
genous prostaglandins (E? and P? ) in blood after the 
fertilization of ovum. Prostaglandin levels in the blood 
can be elevated in two ways: by introducing prostaglandins 
from an external source into the body or by giving suitable 
prostaglandin-metabolic inhibitors, which would interfere 
with PG metabolism and thereby raising the levels of 
endogenous prostaglandins. 
Recently Lerner et_ al have reported substituted 
phenyl-triazolo[5,l-a]isoindoles. (1) and isoquinolines (2), 
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as new classes of antifertility compounds which seem to 
act by inhibiting prostaglandin metabolism at the utero 
placental complex. These compounds have no hormonal 
properties. 
Based on the structures 1 and 2. it appeared of 
interest to study compounds of types j5""!2. f° r their post-
coital antifertility activity, mediated through their 
expected PG metabolism inhibition effect. 
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3.3 SYNTHESIS OP POSSIBLE PG-
METABOIIC INHIBITORS 
3*3.1 Syn thes i s of N ~ ( s u b s t i t u t e d b e n z y l i d i n e ) a m i n o -
d i h y d r o i s o i n d o l e s (4) 
For the p r e p a r a t i o n of compounds of t y p e 4 , conden-
s a t i o n of a , a ' - d i b r o m o - o - x y l e n e with hyd raz ine t o make 2T-
amino-d ihydro i so indo le appeared an a t t r a c t i v e approach. 
Condensat ion of hydraz ine h y d r a t e / h y d r a z i n e s u l p h a t e wi th 
69 
a , a ! - d i b r o m o - o - x y l e n e which i n t u r n was p repa red by the 
b romina t ion of p_-xylene, a t d i f f e r e n t t e m p e r a t u r e s always 
r e s u l t e d i n t h e format ion of d i s u b s t i t u t e d h y d r a z i n e s . 
S i m i l a r a t t e m p t s to make mono-addi t ion p roduc t of a r a l d e -
hydes wi th hydraz ine y i e l d e d d i a d d i t i o n compounds as t h e 
major p r o d u c t s , N-Amino d i h y d r o i s o i n d o l e was f i n a l l y made 
by condensing t - b u t y l c a r b a z a t e wi th a , a f ~d ib romo-o-xy lene 
70 
(6) followed by hydrolysis and decarboxylation . Conden-
sation of N-amino-dihydroisoindole (8) with araldehydes by 
refluxing in glacial acetic acid resulted into the format-
ion of the required N-(substituted benzylidine)amino-
dihydroisoindoles of type 4. 
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i NH2NHC02CMe5, Et^N 
i i cone. HC1 
i i i R~C,-H,CHO, AcOH 
3• 3• 2 Syn thes i s of N-( s u b s t i t u t e d benz .y l id ine)amino-
d i h y d r o i s o i n d o l - 1 . 3 - d i o n e s Q ) 
Because of t h e d i f f i c u l t y i n t h e p r e p a r a t i o n of 
d i h y d r o i s o i n d o l e moiety u s i n g h igh ly l a c h r y m a t o r i c a , a ' -
d ib romo-o-xy lene , an a l t e r n a t i v e approach through c o r r e s -
ponding ph tha l imides and t h e i r subsequent convers ion t o 
d i h y d r o i s o i n d o l e was nex t i n v e s t i g a t e d . N-Amino-dihydro-
i s o i n d o l - l , 3 - d i o n e (10) was prepared by r e f l u x i n g a 
s o l u t i o n of ph tha l imide and 9Bf, hydraz ine h y d r a t e i n 
a b s o l u t e e thano l f o r 2 m i n u t e s , fo l lowing t h e method of 
1 
71 Drew and Hatt . On increas ing the ref luxing time or 
hydrazine hydrate the product i s known to rearrange to 
give ph tha laz- l ,4 -d ione (11) . 
N-Amino-dihydroisoindol-l,3-dione as well as 
phthalaz-1,4-dione condense with araldehydes to give the 




i i i ArCHO, AcOH 
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A study of the stereochemistry of Sch i f f ' s bases 
formed by the condensation of araldehydes with N-amino-
dihydroisoindol- l ,3-d ione was undertaken. N-(p_-Methoxy-
benzylidine)aniino-dihydroisoindol- l ,3-dione formed by the 
the condensation of £-anisaldehyde and N-amino-dihydroiso-
indol«-l,3-dione can ex is t in two forms v i z . syn and an t i 
{Pig. 4 ) . 
OMe 
an t i syn 
Fig. 4 
Out of these two structures, theoretically anti 
form should be favoured on steric grounds. PMR study of 
this compound using increasing amounts of the shift 
reagent Eu(fod)^ was carried out (Pig. 5). It was observed 
that H& proton which initially appeared at 550 Hz suffered 
a deshielding of 33 Hz after the addition of 22 mg of the 




for EL protons under the same circumstances and H protons 
shifted through about 20 Hz; the methoxy and the H^ protons, 
however, remained practically unaffected. This would 
suggest a close proximity of H and the carbonyl where the 
complexation would occur and hence the anti-configuration 
shown above. It appears from the PMR shift that the 
Europium complex is taking up a position somewhere between 
EL and EL, and more towards the dihydroisoindol-l,3-dione 
a ct 
nucleus and relatively away from the benzene ring contain-
ing methoxy group. 
In a similar study with N-(3,4,5-trimethoxybenzyli-
dine)amino-dihydroisoindol-l,5-dione (Fig. 7) the effect of 
Bu(fod)~ on the molecule was found to be quite different. 
In this case the addition of 22 mg of the shift reagent 
made the EL proton to shift through 18 Hz downfield from 
its original position of 552 Hz; the H, protons were 
deshielded through 38 Hz and the methoxy signal which 
originally appeared as a singlet at 236 Hz splitted up into 
two singlets at 256 and 298 Hz integrating for 6 and 3 
protons respectively. The multiplet appearing around 470 
Hz due to the four phthalimide protons remained unaffected. 
Since in this case the deshielding effect felt by the Hr. 
protons due to the presence of the complex was twice in 
magnitude to that of H&, it would suggest closeness of H^ 
protons to the dihydroisoindol-l,3~dione carbonyl than H 
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and hence a syn configuration (Fig. 6)* 
MeO OMe 
Hb OMe 








The Pffi result also indicates that the Europium 
complex, in this case, is residing more towards the "benzene 
ring containing the three methoxy ' groups leaving the 
dihydroisoindol-l,3-dione protons unaffected. The formation 
of the exclusively syn form in this case which is apparently 
against the normal expectation, is possibly arising out of 
the electronic and steric influence of the, benzene moiety 
containing three methoxy groups over the stability of the 
intermediate hydroxy compound and the mode of dehydration-. 
Since the N-(3>4>5-trimethoxybenzylidine)amino-
dihydroisoindol-l,3-dione and N-(p_-me thoxybenzyli dine) amino -
dihydroisoindol-l,3-dione behaved in different ways, it 











Due to the insoluble nature of this compound in CDC1~ 
and permitted solvents for such studies, this study could 
not be undertaken. 
For the conversion of N-amino-dihydroisoindol-1,3-
dione Schiff's bases to the corresponding dihydroisoindole 
Schiff's base, lithium aluminium hydride reduction was 
72 
carried out . Treatment of N-(]>-methoxybenzyli dine) amino ~ 
dihydroisoindol-l,3-dione with LAH in THF at room tempera-
ture gave an extremely complex mixture from which the 
required material could be isolated in traces. However, 
when reduction was carried out at 0 , the resulting mixture 
showed the formation of seven compounds on TLC. Separation 
of different constituents could be effected by careful 
column chromatography of the material on silica gel 
starting with increasing amounts of benzene in hexane as 
eluent. Along with the five different constituents which 
have been identified and described below, a tarry material 
obtained in major amounts (85$) could not be characterised. 
The most non-polar compound, m.p. 189-90° obtained in 75$ 
hexane:benzene fractions was found to be identical in all 
respects with the required N-(£-methoxybenzylidine)amino-
dihydroisoindole, prepared from £-anisaldehyde and N-amino-
dihydroisoindole hydrochloride. 
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The second compound obtained from the column in 
75 % hexane:benzene fractions, m.p. 128° gave the following 
analysis: M+ m/e 266, molecular formula GTC HI4 N2°2' I R ^KBr) 
1640 cm*1 (CO); PMR (CDC13) 3-72 (s, ~H, OCH^), 5.3 (s, 2H, 
NCHgPh), 7.5 (m, 8H, aromatic protons) and 8,1 6 (s, 1H, 
PhCHN). On the basis of above spectral data the following 
structure (12) has been assigned to this compound. 
OMe 
12 
Peaks at m/e 132 and 121 in mass fragmentation 
arise out of the units 12.'a1 and 12'b' and are in support 




'Third and f o u r t h p roduc t s ob t a ined i n t r a c e s could 
no t be i s o l a t e d i n pure form. The f i f t h compound from t h e 
column (0 .5 % MeOHsCHCl,) showed two m e l t i n g p o i n t s a t 
128° and then a t 240° . This product gave t h e fo l lowing 
a n a l y s i s : IR (KBr) 3200 (OH), 1670 cm"1 (CO); PMR (CDClJ 
3.7 ( s , 3H, OCHj , 4 . 1 ( s , 2H, P h C i y O , 4 .5 (bh, 2H, NH and 
OH), 5.52 ( s , 1H, CHOH) and around 7.2 6 (m, 8H, a romat ic 
i 
p r o t o n s ) and analysed f o r On £ % g ^ O * . 0 n "t^ie ^ a s i s o f 
above s p e c t r a l da ta t h i s p roduc t was i d e n t i f i e d as N-(p_-
methoxybenzyl )amino~l -hydroxydihydro iso indol -3-one ( ! £ ) . 
" N— NH. 
13 
ff \V_0Me 
The molecular ion peak was observed at m/e 266 
which appeared to be of a compound which had undergone loss 
of one molecule of water. The melting point behaviour of 
this compound indicated some thermal rearrangement. The 
compound after melting at 128° gave the following analysis. 
Molecular formula (^1^E1A^202' IR (KBr) 1600 cm"1 (CO) and 
absence of OH peak; PMR (DMSO-dg) 3.8 (s, ?H, 0CH-), 5-.4~ 
1 
( s , 2H, NCH2Ph), 7 .5 (m, 8H, a romat ic p r o t o n s ) and 9.2 6 
( s , 1H, NCKPh); M+ 266. This r ea r ranged p roduc t was 
a s s igned t h e fo l lowing s t r u c t u r e ( 1 ^ ) . 
14 






Six th compound obta ined from column (0 .5 % MeOH: 
CHC1,), m.p, 161° appeared to be a compound with c leaved 
i s o i n d o l e r i n g . I t gave t h e fo l lowing a n a l y s i s . Molecular 
formula C ^ g H - j ^ C y IR (KBr) 3200 (OH), 1630 cm""1 (NHCO); 
PMR (DMS0-d6) 3.7 ( s , 3H, OGH ) , 3 .9 ( s , 2H, NCg2Ph), 4 , 1 
( s , 2H, Ar-CHpOH) and around 7.2 6 (m, 8H, a romat ic p r o t o n s ) 
The compound on a c y l a t i o n wi th a c e t i c anhydr ide i n p y r i d i n e 
showed M+ a t m/e 370; IR peaks a t 1680 (NHGOCEj and 1715 
cm*"1 (0CQCH-) and PMR (CDC1-) 2.05 ( s , 3H, NHC0CH-), 2 .15 
( s , 3H, OCOCH^), 3 .8 ( s , 3H, OCHj , 4 .8 (bh , 2H, NCg2), 
5.18 ( s , 2H, 0CH2), aroun 
and 8.85 6 ( s , 1H, NHCO). 
r d 7 .2 (m, 8H, a roma t i c p r o t o n s ) 
Based on t h e above a n a l y s i s , t h e compound was 










The seventh compound obtained from the column (1% 
MeOHsCHCl^) was found to be identical in all respects with 
the compound 2-(p_-metho:xybenzyl)phthalaz-l-one (14). 
The mechanism of lithium aluminium hydride reduct-
ion thus appears to follow the course shown in Fig. 8. 
3,3,3 Synthesis of N-(substituted benzylidinejamino-
It2,t3,fr4,-tetrahydroiso.quinoline (5_) 
Compounds of the type £ were made by reacting 2T-
amino-1,2,3»4~tetrahydroisoquinoline (20) with respective 
araldehydes. Isochroman (17) was converted to o_-(p-bromo-
ethyl)benzylbromide (18) by treating it with 40$ HBr-HOAc. 
Condensation of 18 with t-butyl-carbazate in DMF and tri-
ethylamine afforded lJ~(t-butyloxycarbonyl)amino-l,2,3»4-
tetrahydroisoquinoline (19). Hydrolysis and decarboxylat-
ion of 19 with cone. HC1 yielded N-amino-l,2,3,4-tetrahydro-
isoquinoline (20). Attempts to prepare 2jD directly from 18 
by treating it with hydrazine hydrate/sulphate proved 
futile. Condensation of 20. with araldehydes in glacial 
acetic acid gave the desired compounds of type £. 
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'^\(^mEoECl i i i 
20 
NNHC02CMe5 
Reagen t s ; 
i 40 % HBr-HOAq 
i NHgNHCOgCMe^, Et^N 
iii cone. HC1 
iv R-CgH^CHO, AcOH 
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3.4 BIOLOGICAL ACTIVITY 
The compounds listed in tables 1, 3 and 5 were 
tested in mice and rats for their antiimplantation activity 
by method described in chapter 2. Compounds 2±, 2J?, 2J5, 
28 and ^8 showed antiimplantation activity at 25 mg/kg/day 
in mice, but the activity could not be reproduced in rats 
at the same dose level. In view of this low order of 
activity, these compounds were not tested for their PG— 
metabolism inhibition activity. 
These compounds were also submitted for general 
biological screening in the Pharmacology Division of this 
Institute. None of these compounds showed any noteworthy 
activity. The approximate LDj-~ for most of these compounds 
was found to be 1000 mg/kg ( i.p. ). 
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3.5 E X P E R I M E N T A L 
The melting points were determined in a sulphuric 
acid bath and are uncorrected. The IB. spectra were taken 
on Perkin-Elmer 177 and 577 instruments. The NMB. spectra 
were recorded on Varian A60D and Perkin-Elmer R-32 spectro-
photometers using TMS as internal standard and the chemical 
shift values are expressed in 6 and J values in Hz. The 
mass spectra were run on Hitachi RMTJ-6B instrument fitted 
with a direct inlet system. The homogenity of the com-




A solution of N-amino-dihydroisoindol-l,3-dione 
(10) and substituted araldehyde in equimolar quantities 
in glacial acetic acid was heated under reflux for 20 min. 
The reaction mixture .was cooled and diluted with water. 
The solid thus separated was collected through filteration, 
washed with water and dried. 
The compounds of the type J. which were prepared by 
the above method are listed in Table 1 and their spectral 
data are reported in Table 2. 
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N-(Substituted benzylidine )aniino-dihydroisoindoles (4_) 
70 Condensation of N-amino-dihydroisoindole (8) with 
substituted araldehyde in glacial acetic acid as described 
for 2 afforded the desired N-(substituted benzylidine)amino-
dihydroisoindole of type 4_. 
The compounds of the type 4, along with their 




de J (20_) was condensed with substituted araldehydes in 
glacial acetic acid as described for 2. ^ ° yield the 
desired compounds of the type £. 
The compounds of the type £ are listed in Table 5 
and their spectral data are described in Table 6. 
N-(t-Butyloxycarbonyl)amino-dihydroisoindole (2) 
a,a'-I)ibromo-o-xylene (6_, 1.98 g) and t_-butyl 
carbazate (0.99 g) were dissolved in DMP (5 ml). To it 
triethylamine (2.08 ml) was gradually added at 50-60 so 
as to complete the addition in 10 min. The reaction 
mixture was allowed to stand at room temperature for 3 hr, 
diluted with water (14 ml) and again allowed to stand for 
1 hr. Solid thus separated out was collected through 
filteration and washed with water. Crystallised with 
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minimum amount of nitromethane. Yield 0.6 g (40%), m.p.; 
116° (lit.70 m.p. 115-117.5°). 
N~Amino-dih.ydroisoind.ole hydrochloride (8) 
N-(t-Butylaxycarbonyl)amino-dihydroisoindole (2, 
0.6 g) was added'to cone. HC1 (0.8 ml) over a period of 
10 min at 40°. The reaction mixture was allowed to stand 
for 1 hr and then concentrated under pressure to dryness. 
The residue was taken in absolute ethanol and crystallised 
with dry ether. Yield 0.3 g (69%), m.p. 203° (lit.70 m.p. 
203-205°). 
N-Amino-dihydroisoindol-1,3-dione (10) 
Phthalimide (6 g) was dissolved in ethanol (40 ml) 
and hydrazine hydrate (2.2 ml) was added to it. The 
reaction mixture was stirred for 3 min and then quickly 
refluxed for 5 min, water (25 ml) was added at once 
followed tay another addition of 100 ml of water. Solid 
thus separated was collected through filteration and dried. 
Yield 3.5 g (53%), m.p. 203° (lit.71 m.p. 205°). 
lithium aluminium hydride reduction of N-(p_-methoxy-
benzylidine)amino-dihydroisoindol-l,3-dione72 
A solution of N-(p_-methoxybenzylidine)amino-
dihydroisoindol-1,3-dione (2 g) in dry THF (100 ml) was 
gradually added to a stirred suspension of LiAlH, (1.5 g) 
in dry THP (50 ml) at 0°. The reaction mixture was stirred 
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at the same temperature for 2 h r , decomposed by careful 
addi t ion of a l k a l i , f i l t e r e d through hyflo superoel and 
the f i l t r a t e was extracted with e the r . The organic l aye r 
was washed with water to n e u t r a l , dried over anhyd. sodium 
sulphate and concentrated under reduced p res su re . The 
o i l y ' m a t e r i a l thus obtained was chromatographed over s i l i c a 
gel e lu t ing with increas ing amounts of benzene in hexane. 
The products obtained in the increas ing order of p o l a r i t y 
are described below and have been charac ter ized on the 
bas i s of t h e i r elemental ana lys i s , mass, IR and PMR data , 
as described in the t e x t . 
: N-(p_-Methoxybenzylidine)amino-dihydroisoindole 
75 fo Hexane;benzene; y ie ld 2.5 f0 , m.p. 189-90°. 
IR (IGBr)i 2950, 2900, 1610 and 1590. 
;PMR (CDC1,): 3.7 ( s , 3H, OCHj, 4.6 ( s , 4H, 2NCH2Ph), 
6.8 (d, 2H, ArH, J = 10.25) , 7.2 (m, 5H,ArCfpT, 
isoindole aromatic protons) and 7.45 (d, 2H, 
ArH, J = 10 .25) . 
Analysis Pound: 0, 75.95; H, 6.55; N, 10.77 
C16Hl6N2° Requires: G, 76.19; _fl, 6.34; IT, 11.11 J?. 
N-(£-Methoxybenzylidine)amino-dihydroisoindol-l-one (12) 
15% HexaneJbenzene; y ie ld 1 .4$ , m.p. 128°, 
M+ m/e 266, 132 and 121. • - - - • - - - ~> 
j 
IR (KBr)s, 3310, 1640 and 1600. 
1 
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PMR (CDClJ: 3.72 (s, 3H, OCEU), 5.3 (s, 2H, NCH_2Ph), 
7.5 (m, 8H, aromatic protons) and 8.1 (s, 
1H, ArCHN). 
N-(E-Methoxybenzyl )amino- l -hydroxydihydro iso indol -3-one (1^) 
0.5%• MeOH:CHCl5; Yie ld 3 .4$ ; m,p . 128° (240°) 
M+ m/e 266 (M-HgO). 
IR (EBr) : 3200, 1670 and 1600. 
PMR (CDCl,): 3.7 ( s , 3H, 0CH-), 4 .1 ( s , 2H, NCHgPh), 4 ,5 
(bh, 2H, m and OH), 5.52 ( s , 1H, CHOH) and 
7.2 (m, 8H, a romat ic p r o t o n s ) . 
2-(p_-Methoxy)benzyl-phthalaz-l--one (14_) 
1.0# MeOHzCHCl-; Yie ld 3 . 3 $ . ; m..p. 240° 
M+ m/e 266. 
IR (KBr): 1600 and 1580.. 
PMR (DMS0-d6): 3 .8 ( s , 3H, 0CH-), 5.4 ( s , 2H, NCHgPh), 
7.5 (m> 8H, a romat ic p ro tons ) and 9.2 ( s , 1H, 
NCHPh). 
N- (p_-Methoxy) benzyl -N'-[o-(hy droxymethyl) benzoyl ] -
hydrazine (1^ _) 
0.5#MeOH:CHCl_; Yield 3,1% ; m.p. 161°. 
IR (KBr); 3200, 1630 and 1600. 
PMR (EMS0-d6): 3.7 (s, 3H, OCH,), 3.9 (s, 2H, NCH2Ph), 
4.1 (s, 2H, ArCH20H) and 7.2 (m, 8H, aromatic 
protons). 
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N-(£ -Me thoxy )benzy l ,N-ace ty l -N ' -Co- ( ace toxyme thy l )benzoy l ] -
h y d r a z i n e (1(5) 
Aoyla t ion of 15_ with a c e t i c anhydr ide and 
p y r i d i n e y i e l d e d 16j Yie ld 82$ ', M+ m/e 370. 
IE (KBr)s 1715, 1680 and 1590. 
PMR (0DC1-): 2.05 ( s , 3H, NCOCEU), 2.15 ( s , 3H, OCOCH^), 
3.8 ( s , 3H, 0CH-), 4 .8 (b s , 2H, NCH2Ar), 5.18 
(s, 2H, 0CH2Ph) and 7.2 (m, 8H, aromatic 
protons). 
£-(p-Bromoethyl)benzylbromide ^ (18) 
Isochroman '•? (17, 67 g, 0.5 mol) was dissolved 
in 40$ HBr-HOAc (500 ml) and the mixture was heated at 
100 for 16 hr. Decomposed with water (375 ml) and extract-
ed with EtOAc. Organic layer was washed with sodium bi-
carbonate and then with water to neutral, dried over anhyd. 
sodium sulphate and concentrated. Distilled under reduced 
pressure. Yield 55 g (41%)} b.p. 163O/'>"'0.5 mmj m.p. 53° 
(lit.74 m.p. 53°). 
N-(t>-Butyloxycarbonyl)amino-l,2,3,4-tetrahydroisoquinoline 
_ . .. -
Condensation of o-((3-bromoethyl)benzylbromide 
(18) with t-butylcarbazate in IMF and triethylamine as 
described for 7 afforded N-(t-butyloxycarbonyl)amino-
l,2,3»4-tetrahydroisoquinoline (!£). Crystallized with 
188 
benzene:hexane; Yield 53$ i m.p. 156 . 
IR (KBr): 1700, 1600 and 1580. 
PMR (CDG13): 1.45 (s, 9H, 3CHJ, 3.0 (m, 4H, CH2Ph and 
NCH2), 4.05 (s, 2H, NCH2Ph), 6.05 (s, 1H, NH) 
and 7.0 (in, 4H, aromatic protons). 
Analysis Pound: C, 67.35; H, 7.91; N, 11.05 
G14H20W2°2 Rehires: C, 67.74; H, 8.06; N, 11.29$. 
IT- Amino--l,2,3>4-tetrahydroisoquinoline hydrochloride (20) 
Hydrolysis and decarboxylation of N-(t-
butyloxycarbonyl)amino-1,2,3,4-tetrahydroiso quinoline (19) 
with cone. HC1 as described for 8 yielded N-amino-1,2,3»4~ 
tetrahydroisoquinoline hydrochloride. Yield 43$ ; m.p. 
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I n t e r f e r e n c e wi th pos t -ovu la to r s r even t s i n t h e 
r e p r o d u c t i v e mechanism i s a p o t e n t i a l l y u s e f u l approach 
t o f e r t i l i t y c o n t r o l and i s de s igna t ed as p o s t - c o i t a l 
c o n t r a c e p t i o n , s ince c o n t r a c e p t i o n can be e f f e c t u a t e d by 
a d m i n i s t r a t i o n of the i n h i b i t o r y agen t s t o women p o s t -
c o i t a l l y . Work embodied i n the p r e s e n t t h e s i s i s r e l a t e d 
t o some a s p e c t s of t h e p o s t - c o i t a l c o n t r a c e p t i v e e f f e c t s 
of ' a t y p i c a l ' e s t r o g e n s and p r o s t a g l a n d i n (PG) m e t a b o l i c 
i n h i b i t o r s . 
Use of ' a t y p i c a l ' e s t r o g e n s which i n t e r f e r e wi th 
e s t r o g e n a c t i o n a t t h e l e v e l of g e n i n a l t r a c t and of PG 
2 
m e t a b o l i c i n h i b i t o r s which i n c r e a s e PG l e v e l s , have been 
recogn ized as p romis ing approaches t o p o s t - c o i t a l 
c o n t r a c e p t i o n . 
CHAPTER 1 
The n o n - s t e r o i d a l compounds p o s s e s s i n g ' a t y p i c a l ' 
e s t r o g e n i c a c t i v i t y i n c l u d e t r i a r y l - e t h y l e n e s , - e t h a n e s 
and compounds which i n c o r p o r a t e t h i s s t r u c t u r a l u n i t i n a 
r i g i d framework such as d i a r y l - b e n z o f u r a n s , - i n d o l e s , 
-d ihydro and t e t r a h y d r o - n a p h t h a l e n e s , - coumar ins , 
-chromenes and -chromans e t c . Many of t h e s e compounds 
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have been tested for their efficacy as post-coital 
contraceptive agents and for possible clinical appli-
cation. The first chapter of the present thesis is 
devoted to a review of 1,1,2-triarylethylene/ethane 
(TAEs) as non-steroidal estrogens. 
CHAPTER 2 
TAEs are a promising class of 'atypical' 
estrogens having a wide spread in their hormonal acti-
vities from frank estrogens at one end of the spectrum 
to estrogen antagonists with very weak estrogenicity at 
the other. On this account many of the TAE derivatives 
have found useful clinical applications. Attempts to 
develop post-coital contraceptive agent from among TAEs 
have led to some promising compounds. Amongst these, 
centchroman , 3,4-trans-2,2-dimethyl-3-phenyl-4-[p_-( (3-
pyrrolidinoethoxy)]phenyl-7-methoxychroman (i) hag shown 
considerable promise. The post-coital contraceptive 
activity of centchroman is related to its 'atypical' 
estrogenic character mediated very likely by its inter-
action with the estrogen receptor. Centchroman has weak 
in vitro receptor affinity but brings about nuclear trans-
location of cytosol receptor and their prolonged retention 
in uterine nuclei. This is presumably responsible for 
the uterotrophic activity of centchroman but the basis 
for its weak intrinsic hormonal activity is not yet known. 
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Some analogs of centchroman were designed in order 
to study the receptor binding specifici ty of th is molecule 
and the possible basis of i t s ' a typical ' ac t iv i ty . In 
addition, in order to investigate the stereospecifici ty 
of i t s action, optical resolution of dl-centchroman was 
undertaken. The optical resolution of centchroman and 
the synthesis of i t s various analogs and the resu l t s of 
the i r receptor binding and bioassay studies are discussed 
in this chapter of the thes i s . 
Resolution of dl-centchroman and determination of 
absolute configuration of optical antipodes 
Estrogen receptors display stereospecifici ty in 
•ligand binding . I t would be expected on th i s basis that 
the d- and 1-isomers of centchroman would have differences 
in receptor a f f in i t i es as well as biological potencies. 
Optical resolution of dl-centchroman was thus undertaken. 
This was achieved by preparing diastereoisomeric sa l t of 
centchroman with di-p_-toluoyl-d-tartaric acid followed by 
selective and repeated crystal l izat ions to afford d-
centchroman-di-p_-toluoyl-d-tartrate (2_). Aqueous alkaline 
hydrolysis of 2 yielded pure d-centchroman Q) (Scheme l ) . 
Similarly 1-centchroman (£) was obtained using di-p_-
to luoyl-1- tar tar ic acid monohydrate as the optically 
active acid. 
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The absolute configuration of d- and 1-isomers 
was studied by CD. Circular dichroism of the resolved 
isomers afforded mirror image spectra, an indication of 
optical purity and hence resolution. 
Optical rotatory power for 1-centchroman was 
calculated from the CD spectrum. On the basis of project-
ed 
ion of models in the aromatic quadrants the 3R> 4R 
absolute configuration was assigned to the centchroman 
isomer with negative rotatory power in the 236 nm region. 
The d-isomer was similarly assigned 3S, 4S-absolute 
configuration. 
These isomers shox^ ed marked separation between 
their receptor affinities as well as biological potencies. 
The receptor binding affinity, uterotrophic activity and 
antiimplantation activity were associated largely with 
the 1-isomer and the corresponding d-isomer was marginally 
active in these tests, thus substantiating the well known 
stereospecificity of estrogen receptor. The study also 
indicates that biological activity of centchroman is 
related to its estrogenic activity mediated through 
estrogen receptor. 
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1 2 d~di~£-toluoyl- 2 3S,4S(+) isomer 
(Centchroman) d-tartrate 




Role of 7-methoxy group 
Prom SAR of estrogens it is apparent that the 
presence of a free OH in these molecules in position 
corresponding to C--0H of E ? is essential for high receptor 
affinity and consequently for biological potency « The 
poor receptor affinity of centchroman may he due to the 
presence of OMe group in this position in this molecule. 
It is in fact possible that the activity of centchroman 
may result from its in vivo demethylation to the free 
phenolic compound and a methoxy group modulates its 
availability. In order to establish validity of this 
presumption 7-hydroxy analog of centchroman was synthesis-
ed and its in vivo, in vitro receptor interaction and bio-
logical activity studied. 
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Synthesis of the 7-hydroxy analog of centchroman 
was achieved by dealkylat ion of 1 . Thus r eac t ion of 1 
in diethylene glycol and KOH in the presence of hydrazine 
hydrate at 250 for 30 min furnished, besides the desired 
7-hydroxy analog of centchroman (j5), 3 t4 - t rans -2 . t 2-
dimethyl~3-phenyl-4-(2.-hydroxy)phenyl-7-methoxychroman (7) 
and 3,4-trans-2y2-dimethyl--5'-phenyl~4-(p-hydroxy)phenyl^7-
hydroxychroman ( 8 ) . Although t h i s reac t ion could not be 
achieved in a se l ec t ive manner, the var ious compounds 
r e s u l t i n g from t h i s react ion were eas i ly resolved by 
column chromatography and were character ized on the bas is 
of PMR spec t ra . About 30$ of the s t a r t i n g ma te r i a l was 
recovered unchanged. Increase in react ion time only 
f a c i l i t a t e d the formation of 7 and 8. 
3,4-trans-2,2-dimethyl-3-phenyl-4-[p_-( (3-pyrroli-
dinoethoxy)]phenyl-7-hydroxychroman (£) showed 22 fold 
increase in receptor binding and 16 fold inc rease in 
1 
> 
6 R = H, R± = CH2CH2N 
W 7 R = Me, R± = H 
8 R = Rx = H 
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u te ro t rop ico potency as compared to the parent 1 . However, 
there was no change in the ant i implanta t ion a c t i v i t y of 6. 
Role of the basic ether side chain 
The p_-t~aminoalkoxyphenyl residue i s responsible 
for some of the a c t i v i t i e s c h a r a c t e r i s t i c to TAEs . This 
residue apparently assoc ia tes /b inds with the receptor and 
thus modulates the a c t i v i t y J0f the parent molecules. In 
order to study the receptor binding s p e c i f i c i t y of t h i s 
bas ic ether side chain residue in TAEs and to e s t ab l i sh 
a cor re la t ion between the propensi ty of i t s receptor 
i n t e r a c t i o n and b io logica l a c t i v i t y , some homologs of 
centchroman were synthesised.. 
For the synthesis of centchroman analogs with 
var iab le length of the side chain and nature of s u b s t i -
t u t i o n at n i t rogen atom, 5»4-ois-2,2~dime.thyl-g-phenyl-4-
(p-hydroxy)phenyl-7-methoxychroman (9) was reac ted with 
benzyl chloride in acetone (Scheme 2) to afford the 
benzylated product 10 and subsequently isomerized with 
n-bu ty l - l i th ium to y ie ld the corresponding trans-chroman 
(11) . Debenzylation followed by a lky la t ion of the 
product 12_ with NjN'-diethylaminoethyl ch lor ide , N,N'-
dimethylaminoethyl chloride and N,N'-diethylaminopropyl 
chloride gave the desired a lkyla ted compounds 1J5, 2A aiL^ 
15 r e spec t ive ly . 
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Compounds 12, and 1£ had binding affinities close 
to that of centchroman and eventually their antiimplanta-
tion activities were also comparable. Compound 14» 
however, displayed a poor binding affinity and antiimplan-
tation activity as compared to 1, thus indicating the 
binding specificity of a pyrrolidinoethoxy side chain. 
o/\ 
9 R = H 
10 R = CH2Ph 
^ 
MeO 
11 R = CH2Ph 
12 R = H 





Effect of position of side chain 
In order to establish a correlation between the 
position of the basic ether side chain and receptor binding 
and biological activity of centchroman and TAE estrogens, 
some positional isomers of centchroman in which the side 
chain is transposed to p_, or m positions of C.-phenyl 




Friedie-Grafts reaction of m-hydroxybenzoic acid 
with m~methoxyphenol in stannic chloride (Scheme 3) gave 
2,3'-dihydroxy-4-methoxybenzophenone (16.)» Condensation 
of 1£ with phenylacetic acid and subsequent reaction of 
coumarin 17. with excess of MeMgl gave chromene 18. Alky-
lation of 18 with 3-pyrrolidinoethyl chloride gave alkyla-
ted chromene 1£. 'Catalytic hydrogenation of 18 gave 3>4-
.cjus-chroman (20.). Alkylation of 20 with 3-pyrrolidinoethyl 
chloride and subsequent isomerization of alkylated chroman 
21 with n-butyl-lithium gave the title compound 22.. The 
cis. and trans geometry was established on the basis of 
coupling constant values for C~ and C. proton signals in 
the PMR. spectra of 20. and 22 respectively. 
Synthesis of 3.4-trans-2.2-dimethyl-5-phenyl-4-ro-(3-
pyrrolidinoethoxy)]phenyl-7~methoxychroman (43) 
Reaction of salicylic acid with m-methoxyphenol 
(Scheme 4) gave 2,2'~dihydroxy~4-methoxybenzophenone (23)« 
In order to avoid the formation of isomeric coumarins at 
the next step reaction of p_-benzyloxybenzoic acid with m-
methoxyphenol was attempted to obtain benzophenone 2J5 with 
2'-hydroxy protected. The reaction led to the debenzylated 
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isomeric coumarins 2,5. and 28 which could not be purified.-
Attempted purification of free phenols £4 and 2J7 and the 
corresponding p_-nitrobenzoyl esters (2j5 and 29) also proved 
fruitless. At all these and subsequent stages the isomeric 
mixture was monitored by HPLO and PMR spectra in which two 
peaks appeared for OCH-, group. 
The mixture of coumarins 2£ and 28 was reacted 
with excess of MeMgl to afford cis and trans butenols 
50 and 3.1 respectively. At this stage too the butenols 
could not be purified. However, acid catalysed cycliza-
tion of isomeric butenols 3.Q, axi^- HL yielded the required 
2,2-dimethyl-3-phenyl-4-(o-hydroxy)phenyl-7-methoxy-
chromene (3J2) as the sole reaction product. The dereali-
zation of 3>4-double bond appears to be involved in the 
exclusive formation of 3.2. 
Chromene .^2. was acylated with acetic anhydride and 
pyridine to give 3_3„ and alkylated with Mel and p-pyrroli-
dine ethyl chloride to afford alkylated compounds 3_4_ aii^ 
5J5 respectively. 
To establish the identity of £2, whether it is one 
which corresponds to coumarin 25_ or ,28 a similar sequence 
of reactions was followed starting from .benzophenone 23 
derivative with 2'-hydroxy protected.. 
Thus reaction of p_-anisic acid and m-methoxyphenol 
(Scheme 5) gave 2-hydroxy-2' ,4-dimethoxybenzophenone (5_6) 
M e C r ^ / ^ O H 
MeO 
MeO 






41 R = H 
Scheme 6 
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which on condensation with phenylacetic acid gave coumarin 
22. Grignard reaction of 3J7 wi'bh MeMgl gave a mixture of 
cis- and trans-butenols 38 and 3J£ respectively. Purifica-
tion of 3_8 and 3_£ was made and they were identified on the 
basis of their mass fragmentation pattern. However, both 
these compounds cyclized to give the same chromene 40. 
The chromenes 3_4_ and 4_Q_ were identical in all respects 
and thus the identity of hydroxychromene 3_2. was established 
conclusively as 2,2-dimethyl~3-phenyl-4-(o-hydroxy)phenyl-
7-methoxychromene. 
Catalytic hydrogenation of 2£ (Scheme 6) and 
subsequent alkylation of the product 41 gave 3.4-cis 
alkylated chroman {&2) which on base catalysed isomeriza-
tion yielded the desired 3.4- trans -chroman (4J>). cis 
and trans Geometry was established as usual on the basis 
of coupling constant value for C~ and C, protons. 
Synthesis of 3»4-trans-2,2-dimethyl-3-fp-(g-pyrrolidino-
ethoxy)]phenyl-4-phenyl-7-methoxychroman (150) 
Benzoylation of m-methoxyphenol followed by Pries 
rearrangement of the product (Scheme 7) gave 2-hydroxy-4-
methoxybenzophenone (44). Condensation of 4J; with p_-
hydroxyphenylacetic acid and subsequent Grignard reaction 
of the coumarin 4_£ yielded chromene 4jo. Alkylation of 46 






Cata ly t i c hydrogenation of 4J> and subsequent a lky la t ion 
of the ois-chroman 4.8 gave c is a lkylated chroman 4j? which 
upon base catalysed isomerizat ion gave the des i red 3 ,4-
t rans-2 ,2-d imethyl -5- [2- (P-pyrro l id inoethoxy)]phenyl -4-
phenyl-7-methoxychroman (5<D). The cis. and t r ans geometry 
was in fe r red on the bas is of coupling constant values for 
C, and C, protons in the PMR spectra of 4.8 and 52. 
r e spec t i ve ly . 
These pos i t i ona l isomers of centchroman displayed 
only marginal binding a f f in i ty and ant i implanta t ion a c t i -
v i t y as compared to 1. However, £0. showed a marked 
increase in u te ro t roph ic potency as compared to centchroman. 
3-(p_-Hydroxy)phenyl-4-aryl-7-methoxy-chromenes and 
-chromans 
Possible metabolic hydroxylation of 3-phenyl 
residue in centchroman can result in its conversion to the 
hexesterol type of moiety and in modulation of its activity. 
In order to study the hormonal properties of such a poten-
tial metabolite of centchroman, 3-(p_-hydroxy)phenyl analog 
of centchroman and its ethers were synthesised-
Synthesis of 3»4-trans-212-dimethyl-3-(p-hydroxy)phenyl-4-
[^-(p-pyrrolidinoethoxy) ]phenyl-7-methoxychroman (%9) 
2,4'-Dihydroxy-4-methoxybenzophenone (£1) was 
condensed with p_-benzyloxyphenylacetic acid (Scheme 8) to 
OH 
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yield the corresponding coumarin 5_2. £2. was then reacted 
with excess of MeMgl and the product dimethylchromene 5J5 
was alkylated with p-pyrrolidinoethyl chloride to afford 
the alkylated chromene £6. Debenzylation of %6 by 
hydrogen gave £7. Hydrogenation of 5JL at 800 psi '.-
hydrogen pressure and 60° gave the cis chroman £8 which 
upon base catalysed isomerization gave the desired trans-
chroman £9. As usual the cis and trans geometry was 
established on the basis of coupling constant value for 
C* and 0. protons. 
Synthesis of 3»4-trans-3-[p.-(P-pyrrolidinoethoxy) ]phenyl-
4-phenyl-7-methoxychroman (67) 
Reduction of 3-(p_-acetoxy)phenyl-4-phenyi~ 
7-methoxycoumarin (£2) with Ni-Al alloy in IN NaOH at SO-
BS0 for 30 min or in 5N NaOH at -95-100° for 5 hr (Scheme 9) 
gave exclusively the erythrp propionic acid (62_). The 
erythro configuration was assigned on the basis of its 
reluctance towards cyclization and earlier work carried 
•7 
out in this laboratory . When propionic acid (62) was 
refluxed in benzene and acetic anhydride, it gave a mixture 
°f Sis ^ ^ trans acetoxy-dihydrocoumarins (6£). However, 
the configurational assignment is only tentative and needs 
further evidences which are in progress* 
LiAlH, reduction of j62 in tetrahydrofuran and 












with excess of p_-toluene sulphonyl chloride in pyridine to 
afford ditosylate 6£. Instead of the formation of tri-
tosylate, a ditosylate propyl chloride 6£ was obtained and 
characterized on the basis of mass fragmentation and PMR 
spectra, Cyclization of 6£ with ethanolic alkali afforded 
trans-hydroxychroman (66). the trans geometry was establi-
shed on the basis of coupling constant value for C, and 0. 
protons. Alkylation of 66, with |3-pyrrolidinoethyl chloride 
gave the desired title compound 67» 
Synthesis of 3,4-trans-2t2-dimethyl~5-(p-hydroxy)phenyl-
4-phenyl-7-methoxychroman (71) 
Benzoylation of resorcinol followed by Pries 
rearrangement of the product afforded 2,4-dihydroxybenzo-
phenone (68). Condensation of 68 with p_-hydroxyphenyl-
acetic acid (Scheme 10) followed by Grignard reaction of 
the product diacetoxycoumarin (69) gave dihydroxychromene 
(70_). Demethylation of ,4_6 also afforded 70, in low yields* 
To get the title compound, however, 48 was isomerized with 
n-butyl-lithium. 
Incorporation of a hydroxy function in C,-phenyl 
results in increased uterotrophic potency. Thus 71 was 
found to be more potent uterotrophic substance than 1. 
However, results of the biological screening of most of 
















A relatively recent discovery in the field of 
fertility control is the introduction of prostaglandins 
(PGs) which have emerged as very powerful luteolytic 
agents. It has also been established that elevated levels 
of prostaglandins E? and F? in amniotic fluid exert 
frequent and strong contraction on the uterus and thus 
lead to the expulsion of foetus. An alternative approach 
to elevate the PG- levels in blood appeared to be through 
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inhibition of PG metabolism. Recently lerner ejt al have 
reported substituted phenyl-triazolo[5,l-oc]isoindoles (1) 
and isoquinoline as new classes of antifertility compounds 
which seem to act by inhibiting PG-metabolism. 
Based on structures 1 and 2 it appeared of interest 
to study compounds of types j5.-Ji £° r "their post-coital 
contraceptive activity, mediated through their expected 
PG-metabolism inhibition effect. 
2 4 1 
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Synthesis of N-(substituted benzylidine)amino-dihydro~ 
isoindoles (±) 
N-Amino-dihydroisoindole appeared to be a suitable 
intermediate for the preparation of compounds of type 4_. 
Condensation of hydrazine hydrate/sulphate with a,oc!-
dibromo-,o-xylene (6.) at different temperatures always led 
to disubstituted hydrazine. Similar attempts to make mono 
addition product of araldehydes with hydrazine yielded 
diaddition products. However, N-aminodihydroisoindole (8) 
was finally made by reacting t,-butylcarbazate with £ 
followed by hydrolysis and decarboxylation. Condensation 
of 8 with substituted araldehydes in glacial acetic acid 
gave the required compounds of type 4. 
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Because of the difficulty in the preparation of 8, 
an alternative approach through corresponding phthalimides 
and their subsequent conversion to compounds of type 4. was 
investigated. 
Synthesis of N-(substituted benzylidine)amino-dihydro-
isoindol~l,3-diones (£) 
N-Amino-dihydroisoindol-1,3-dione (10) was prepared 
by the reaction of phthalimide and hydrazine hydrate. An 
increase in reaction time resulted in the formation of 
rearranged product, phthalaz-l,4-dione (11). However, 10. 
and 11 on condensation with substituted araldehydes gave 
the same Schiff's bases of type £. 
0 
• > 




Stereochemistry of N- (p_-methoxybenzy l i dine) amino -
d ihydroisoindol- l ,3-dione and N-(3,4 ,5- t r imethoxybenzyl i -
dine)amino-dihydroisoindol- l ,3-dione was es tab l i shed on 
the basis of PMR studies using sh i f t reagent Bu(fod) , . I t 
has been observed tha t whereas N-(p_-methoxybenzylidine) 
amino-dihydroisoindol-l ,3-dione ex i s t s i n a n t i form the 
corresponding N-(3,4>5-trimethoxybenzylidine)amino-dihydro-
i so indo l - l , 3 -d ione i s having a predominantly syn configu-
r a t i o n . This discrepancy probably a r i ses out of e l ec t ron ic 
and s t e r i c influence of the aromatic r ing containing three 
OMe groups over the s t a b i l i t y of the intermediate hydroxy 
compound and mode of dehydration. 
A s imi la r study with l\l-(2,4-dimethoxybenzylidine) 
amino-dihydroisoindol- l ,3-dione could not be carr ied out 
because of i t s poor s o l u b i l i t y in the required so lven t s . 
For the conversion of compounds of type 2 to the 
corresponding 4 , LiAlEL reduction was carr ied out . Trea t -
ment of N-(p_~methoxybenzylidine)amino-dihydroisoinol-l,3-
dione with LiAlH, in tetrahydrofuran at room temperature 
gave an extremely complex mixture from which the required 
compound could be i so la t ed only in t r a c e s . However, a t 0 ° , 
a mixture of seven products was obtained. Pu r i f i ca t i on was 
made by column chromatography and the compounds have been 
character ized on the basis of spec t r a l data and elemental 
ana ly s i s . Along with these compounds a t a r r y mate r i a l 
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obtained in major amount could not be charac ter ized . 
The compounds in the inc reas ing order of polarity-
a re , the required N-(p_-methoxybenzylidine)amino-dihydro-





which was also formed by the rearrangement of 1^. and N-(p_-
methoxybenzyl)-N*-[o-hydroxymethyl)benzoyl]hydrazine (1£) . 
A poss ib le mechanism of the formation of these compounds 
has been proposed. 
Synthesis of N- (subs t i tu ted benzyl id ine)amino- l ,2 ,3 ,4-
te t ra l iydroisoquinol ine (5.) 
Compounds of the type £ were made by the conden-
sa t ion of N-amino-1,2,3,4- te trahydroisoquinol ine (20.) with 
respec t ive araldehydes. Conversion of isochroman 1/7 to 
the dibromo compound 18 followed by condensation with t -
butylcarbazate gave N-(t_-butyloxycarbonyl)amino-l,2,3,4-
te t rahydroisoquinol ine (1£) . Hydrolysis and decarboxyla-
t i o n of 19. afforded 20 which on condensation with a r a lde -
hydes gave the desired compounds of type 5.. 
Various compounds prepared were t e s t ed for t h e i r 
ant i implanta t ion a c t i v i t y . None of these compounds was 
found to be s i gn i f i can t ly a c t i v e . Some of these compounds 
did show a c t i v i t y a t 25 mg/kg/day in mice, but the same 
order o f ' a c t i v i t y could not be observed in r a t s . 
0 V ' 
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